Sentence,class,file
http://dx.doi.org/10.1016/j.ajem.2011.08.003 .,OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2007 ;21(6):603-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2011 ;30(3):222-6. http://dx.doi.org/10.1097/ INF.0b013e3181f86398 .,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
J Med Case  Rep. 2014 ;8(1):282. http://dx.doi.org/10.1186/1752- 1947-8-282 .,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2010 ;20(4):511- 26. http://dx.doi.org/10.1016/j.nic.2010.07.004 .,OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2012 ;126(1):43- 6. http://dx.doi.org/10.1017/S0022215111002568 .,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
1936 ;227(5874 ):701-3.  http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2013 ;31(1):1-6. http://dx.doi.org/10.3109/15513815.2 011.618868 .,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
2015 ;5(3):11-20. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/48/b6/autopsy-05-04019.PMC4757916.pdf
"2015;5(4):27-33.   http://dx.doi.org/10.4322/acr.2015.027 ABSTRACT Firstly described by Rudolf Virchow in the 19th century, congenital generalized lymphangiectasia is a rare entity characterized  by dilation of lymphatic vessels, and was recently classified in primary or secondary lymphangiectasia.",Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2014 ;15(3):275-80. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2013 ;84(4):303-14. http://dx.doi.org/10.1111/ cge.12173 .,Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2012 ;31(2):74-86. http://dx.doi.org/10.3109/15513815.,Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
1959 ;12(1):62-9. http://dx.doi.org/10.1136/ jcp.12.1.62 .,Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2004 ;54(7):532-6. http://dx.doi.org/10.1111/ j.1440-1827.2004.01651.x .,Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2004 ;38(4):308-13. http://dx.doi.org/10.1002/ppul.20100 .,Non-OADS,/arxiv_data1/oa_pdf/7b/36/autopsy-05-04027.PMC4757917.pdf
2015;5(4):35-43. http://dx.doi.org/10.4322/acr.2015.028 ABSTRACT Streptococcus agalactiae  is a well-known pathogen during pregnancy and in neonates.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2014 ;14(1):323. http://dx.doi.org/10.1186/1471- 2334-14-323 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2011 ;364(21):2016 -25. http://dx.doi.org/10.1056/ NEJMoa1005384 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2005 ;42(3):117- 8. http://dx.doi.org/10.1007/s00592-005-0189-8 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2001 ;33(4):556-61. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2007 ;37(12):796-801. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
http://dx.doi.org/10.1016/j.vaccine.2013.01.009 .,OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2015 ;30(3):158-62. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2011 ;53(2):114-23. http://dx.doi.org/10.1093/cid/cir325 .,OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
1997 ;34(2):151-3. http://dx.doi.org/10.1016/S0163- 4453(97)92528-7 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
1997 ;25(5):1180 - 7. http://dx.doi.org/10.1086/516094 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
1991 ;266(8):1112 -4. http://dx.doi.org/10.1001/ jama.1991.03470080082034 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2004 ;23(3):168- 73. http://dx.doi.org/10.1007/s10096-003-1098-9 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2011 ;11(1):149. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2013 ;17(6):e379 -84. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2008 ;27(9):762-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2014 ;15(3):250-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2007 ;28(1):63-8.  http://dx.doi.org/10.1097/01.paf.0000248775.34108.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2007 ;45(11):3850 -2. http://dx.doi.org/10.1128/ JCM.01358-07 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
1998 ;15(11):597-600. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
2013 ;3(1):58-63. http://dx.doi.org/10.4103/2229- 5151.109423 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
http://dx.doi.org/10.1136/ hrt.2004.055046 .,Non-OADS,/arxiv_data1/oa_pdf/7e/0e/autopsy-05-04035.PMC4757918.pdf
"2015;5(4):45-51. http://dx.doi.org/10.4322/acr.2015.022 ABSTRACT Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficiency of the lysosomal acid  alpha-glucosidase (GAA) enzyme described in 1932 by the Dutch pathologist Joannes Cassianus Pompe.",Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2013 ;71(5):284- 9. http://dx.doi.org/10.1590/0004-282X20130022 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
"2008 ;71(23, Suppl 2 ):S4- 11. http://dx.doi.org/10.1212/WNL.0b013e31818da91e .",Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2014 ;6:177. http://dx.doi.org/10.3389/ fnagi.2014.00177 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
1998 ;79(1):69-72. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2006 ;8(5):267-88. http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2005 ;128(Pt  3):671-7. http://dx.doi.org/10.1093/brain/awh384 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2006 ;2(4):318-20. http://dx.doi.org/10.4161/auto.2984 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2000 ;287(1):136- 43. http://dx.doi.org/10.1006/abio.2000.4838 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
1994 ;203(3):1535 -41. http://dx.doi.org/10.1006/ bbrc.1994.2360 .,Non-OADS,/arxiv_data1/oa_pdf/15/75/autopsy-05-04045.PMC4757919.pdf
2015;5(4):53-63. http://dx.doi.org/10.4322/acr.2015.030 ABSTRACT  We present the case of a patient who underwent cardiac transplantation with the diagnosis of idiopathic dilated  cardiomyopathy.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2013 ;50(5):290- 7. http://dx.doi.org/10.1136/jmedgenet-2013-101532 .,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2007 ;28(1):15-21. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
1977 ;63(1):86- 108. http://dx.doi.org/10.1016/0002-9343(77)90121-8 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
1978 ;58(6):1204 - 11. http://dx.doi.org/10.1161/01.CIR.58.6.1204 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2003 ;41(2):322-9. http://dx.doi.org/10.1016/S0735- 1097(02)02715-8 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2006 ;25(4):479-82. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2014 ;41(2):203-7. http://dx.doi.org/10.14503/THIJ-12- 3086 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2003 ;26(7):1498 - 503. http://dx.doi.org/10.1046/j.1460-9592.2003.t01-1- 00217.x .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2013 ;46(6):524-7.  http://dx.doi.org/10.1016/j.jelectrocard.2013.08.007 .,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2014 ;7(2):230- 6. http://dx.doi.org/10.1161/CIRCEP.113.000932 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2012 ;9(4):223-33. http://dx.doi.org/10.1038/ nrcardio.2011.173 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2012 ;21(4):229-39. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2015 ;36(14):837-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
1997 ;30(6):1512 -20. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2015 ;25(3):191-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2005 ;14(1):37-41. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
1995 ;76(5):414-8. http://dx.doi.org/10.1016/S0002- 9149(99)80116-7 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2012 ;76(1):189- 94. http://dx.doi.org/10.1253/circj.CJ-11-0747 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2011 ;97(21):1744 - 52. http://dx.doi.org/10.1136/hrt.2011.227967 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2010 ;3(4):314-22.  http://dx.doi.org/10.1161/CIRCGENETICS.110.937805 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2014 ;104(2):280-9. http://dx.doi.org/10.1093/cvr/ cvu212 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2006 ;116(7):2012 -21.  http://dx.doi.org/10.1172/JCI27751 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2009 ;104(9):1076 -84.  http://dx.doi.org/10.1161/CIRCRESAHA.109.196899 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2011 ;109(12):1342 -53. http://dx.doi.org/10.1161/ CIRCRESAHA.111.255075 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2013 ;25(1):93- 100. http://dx.doi.org/10.1016/j.cellsig.2012.09.025 .,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2004 ;13(1):26-32. http://dx.doi.org/10.1016/S1054- 8807(03)00107-8 .,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
http://dx.doi.org/10.1126/ scitranslmed.3008008 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2009 ;360(11):1075 -84. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2011 ;4(5):743-52. http://dx.doi.org/10.1161/ CIRCEP.111.964890 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2012 ; 1818 (8): 2020 - 9. http://dx.doi.org/10.1016/j.bbamem.2011.07.039 .,OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
1996 ;335(18):1378 -86. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2014 ;93(5):211- 35. http://dx.doi.org/10.1097/MD.0000000000000038 .,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2005 ;24(11):1988 -90. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
2007 ;26(7):714-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/eb/autopsy-05-04053.PMC4757920.pdf
"2015;5(4):65-70. http://dx.doi.org/10.4322/acr.2015.026 ABSTRACT Lymphangioma is a rare, benign lesion derived from a malformation of the lymphatic system, which is more frequently  found in the head, neck, and axilla.",Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1964 ;108(6):790-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
2003 ;38(8):1255 -7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1966 ;41(216):204-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1991 ;26(11):1309 -13. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1998 ;85(3):395-7. http://dx.doi.org/10.1046/j.1365- 2168.1998.00628.x .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1995 ;25(7):525-7. http://dx.doi.org/10.1007/ BF02015784 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1990 ;20(7):560-1. http://dx.doi.org/10.1007/ BF02011393 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1973 ;178(1):13-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1954 ;140(2):185-93.  http://dx.doi.org/10.1097/00000658-195408000-00006 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
2000 ;55(2):283.  http://dx.doi.org/10.1016/S0090-4295(99)00402-1 .,OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
2014 ;20(26):8745 -50. http://dx.doi.org/10.3748/wjg.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1968 ;115(6):861- 3. http://dx.doi.org/10.1016/0002-9610(68)90536-9 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1992 ;27(2):220-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1993 ;23(4):305-6. http://dx.doi.org/10.1007/ BF02010922 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
1985 ;120(11):1266 -9. http://dx.doi.org/10.1001/ archsurg.1985.01390350048010 .,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
2006 ;10(5):746-51. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/33/autopsy-05-04065.PMC4757921.pdf
"2015;5(4):71-76. http://dx.doi.org/10.4322/acr.2015.023 ABSTRACT A ganglion cyst (GC) is a mucinous or gelatinous-filled benign tumor overlying a joint or tendon sheath, which commonly  arises in the dorsal and volar wrist side but may occur anywhere in the body.",Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2004 ;12(4):335-7. http://dx.doi.org/10.1007/s00167- 003-0476-2 .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2004 ;12(2):123-9. http://dx.doi.org/10.1007/ s00167-003-0372-9 .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2000 ;10(2):230-41. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
1999 ;15(8):867-70. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2005 ;13(1):44- 7. http://dx.doi.org/10.1007/s00167-004-0519-3 .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
1997 ;168(1):123- 7. http://dx.doi.org/10.2214/ajr.168.1.8976934 .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
1999 ;15(4):373- 8. http://dx.doi.org/10.1016/S0749-8063(99)70054-X .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
http://dx.doi.org/10.1016/S0749-8063(03)00386-4 .,OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2001 ;11(5):834-40. http://dx.doi.org/10.1007/ s003300000713 .,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
1994 ;10(5):574-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
2014 ;42(2):292-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/41/autopsy-05-04071.PMC4757922.pdf
Availability and implementation : http://CRISPR-ERA.stanford.edu.,OADS,/arxiv_data1/oa_pdf/9a/9f/btv423.PMC4757951.pdf
"3676 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/9f/btv423.PMC4757951.pdf
"This is an open access article licensed under the terms of the (https://creativecommons.org/licenses/by/4.0/legalcode), which p ermits unrestricted, non- commercial use, distribution and reproduction in a ny medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/30/TODENTJ-9-393.PMC4758051.pdf
"Further study is needed to define the inflammatory response,  alterations in phagocytic function, and upregulation of receptors important in bacterial and viral  This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/ed/41/nihms756425.PMC4758189.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/93/d4/nihms-758585.PMC4758192.pdf
"See http://creativecommons.org/licenses/by-nc/2.0/de/ 2Corresponding author: University of South Carolina, U.S.A. robin648@email.sc.edu.",Non-OADS,/arxiv_data1/oa_pdf/6c/d4/nihms750151.PMC4758219.pdf
"2015. https://usa.ipums.org/usa/chapter4/chapter4.shtml Leonard SH, Beemer JK, Anderton DL.",Non-OADS,/arxiv_data1/oa_pdf/6c/d4/nihms750151.PMC4758219.pdf
http://www.raconline.org.,Non-OADS,/arxiv_data1/oa_pdf/c7/8b/10.1177_2333392815613056.PMC4758220.pdf
http://www.chqpr.org/downloads/HowtoCrea- teAccountableCareOrganizati ons.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/8b/10.1177_2333392815613056.PMC4758220.pdf
"http://www.oliverwyman.com/c ontent/dam/oliver-wyman/glo- bal/en/files/archive/2012/ OW_ENG_HLS_PUBL_The_ACO_ Surprise.pdf.%20Publish ed%20November%2026,%202012.",Non-OADS,/arxiv_data1/oa_pdf/c7/8b/10.1177_2333392815613056.PMC4758220.pdf
http://medicaleconomics.moder- nmedicine.com/medical-economics/news/modernmedicine/mod- ern-medicine-feature-articles/acos-can-accommodate-various-?,Non-OADS,/arxiv_data1/oa_pdf/c7/8b/10.1177_2333392815613056.PMC4758220.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/8f/omw003.PMC4758225.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0d/06/omw002.PMC4758227.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/85/omw001.PMC4758228.pdf
"March 2015 .http://www.who.int/features/fact ﬁles/dementia/en/ (26 June 2015, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/2e/85/omw001.PMC4758228.pdf
"http://www.aaos.org/ news/aaosnow/jan10/managing4.asp (11 August 2015, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/2e/85/omw001.PMC4758228.pdf
"http://www.nhfd.co.uk/20/hipfractureR.nsf/vwcontent/2010 ReportDownload/$File/NHFD2010Report.pdf?openelement (28 January 2016, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/2e/85/omw001.PMC4758228.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/35/0a/evv231.PMC4758234.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/35/0a/evv231.PMC4758234.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f5/cf/evv233.PMC4758235.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1c/6e/evv239.PMC4758237.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d2/40/evv241.PMC4758238.pdf
"Protein-coding gene sequences were anno- tated using existing Coleopter a mitochondrial genomes as ref- erence in Geneious ( http://www.geneious.com/ , last accessed December 17, 2015).",OADS,/arxiv_data1/oa_pdf/d2/40/evv241.PMC4758238.pdf
"2009 ) under default parameters on the server http://mafft.cbrc.jp/ alignment/software/ , last accessed December 17, 2015.",Non-OADS,/arxiv_data1/oa_pdf/d2/40/evv241.PMC4758238.pdf
"2010 ;https://www.phylo.org/ , last accessed December 17, 2015) under the GTRCAT model of nucleotidesubstitution, which approximates a GTR + /C0model with a re- duced computational cost ( Stamatakis 2006 ).",OADS,/arxiv_data1/oa_pdf/d2/40/evv241.PMC4758238.pdf
Available from: http://mesquiteproject.org .Timmermans et al.,OADS,/arxiv_data1/oa_pdf/d2/40/evv241.PMC4758238.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5e/c3/evv242.PMC4758239.pdf
Low quality read ends ( <Q20) were trimmed with FastX 0.0.13 ( http://hannonlab.cshl.,Non-OADS,/arxiv_data1/oa_pdf/5e/c3/evv242.PMC4758239.pdf
"The KO identiﬁers were mapped against KEGG path- ways to reconstruct pathways ( http://www.genome.jp/ kegg/mapper.html , last accessed April 30, 2015).",OADS,/arxiv_data1/oa_pdf/5e/c3/evv242.PMC4758239.pdf
Available from: http://www.R-project.org/ .,Non-OADS,/arxiv_data1/oa_pdf/5e/c3/evv242.PMC4758239.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0f/c1/evv244.PMC4758241.pdf
"All software tools were installed using Homebrew (http://brew.sh , last accessed December 17, 2015).",OADS,/arxiv_data1/oa_pdf/0f/c1/evv244.PMC4758241.pdf
"2013 ), and are available from DNAnexus ( http://sra.dnanexus.com/studies/SRP014489 last accessed 17 Dec 2015).",OADS,/arxiv_data1/oa_pdf/0f/c1/evv244.PMC4758241.pdf
Available from: http://www.repeatmasker.org .,Non-OADS,/arxiv_data1/oa_pdf/0f/c1/evv244.PMC4758241.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f2/96/evv245.PMC4758242.pdf
"XP-EHH values of each SNP in the Debao compared with the YL and theMG were calculated by the xpehh program ( http://hgdp.uchi- cago.edu/Software/ , last accessed December 16, 2015).",OADS,/arxiv_data1/oa_pdf/f2/96/evv245.PMC4758242.pdf
Gene ontology (GO) enrichment analysiswas performed on g: Proﬁler ( http://biit.cs.ut.ee/gproﬁler ).,OADS,/arxiv_data1/oa_pdf/f2/96/evv245.PMC4758242.pdf
The STRING database was queried for the protein–protein interac-tion ( http://string-db.org/ )(Szklarczyk et al.,OADS,/arxiv_data1/oa_pdf/f2/96/evv245.PMC4758242.pdf
Supplementary Material Supplementary ﬁgures S1–S9 andtables S1–S6 are available atGenome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/f2/96/evv245.PMC4758242.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5b/57/evv247.PMC4758243.pdf
"ThespaCBA-srtC nucleotide sequences were retrieved from GenBank ( http://www.ncbi.nlm.nih.gov , last accessed December 17, 2015) by per forming BLAST searches (Altschul et al.",OADS,/arxiv_data1/oa_pdf/5b/57/evv247.PMC4758243.pdf
"Our comparative analyses indicate the highest similarity of the plasmidic L. caseiTable 2 Primers for QPCR Ampliﬁcations Gene or Encoded Protein 50–30DNA Sequence of Forward/Reverse Primera Primers to quantify the plasmidic or chromosomal spaC expression level Plasmidic spaC GGTGGCGAATCGGGT/CCATCGAAGTTGTGCGGTATCGCT Chromosomal spaC CGGCAATAAAACCACTGG/ATTTTTAAGTTCTGCGGTATAGCC Primers to quantify Lactobacillus rhamnosus LOCK 0900, L. rhamnosus LOCK 0908 and Lactobacillus casei LOCK 0919 in mice feces Primers for L. casei LOCK 0900-speciﬁc genes Phage anti-repressor protein GGGCTGCTCTACAAAGATG/AGTTGATGGATGCCAGTTACDNA repair protein RecT CCAGTAACGCCCTCAATTC/CCCTTGTATCACCATGTTCAG Primers for L. rhamnosus LOCK 0908-speciﬁc genes DNA helicase YeeB GGCACGAGTCTATCAACATC/CCTTTCGGACACCTTGATTAGYeeC-like protein GCGAAGAAGTTGAGCTTAATG/CCATACAGAGATGAGGCAAG Primers for L. rhamnosus LOCK 0919-speciﬁc genes Ornithine cyclodeaminase GAAGATCGTATCCGTTTACCC/CTGTTCGAAGCTGAGTAAGGPhospholipase A2 family enzyme GTATGGGAATTATTGCGGTAAAG/CGTTGACGAAATTCCTGATTAC Primers for reference genes RNA polymerase asubunit GATATCGTCGCTGATCCTG/GTCAGCTGCCACATACC Translation elongation factor Tu GACCTTGGATCTTGGTGAAG/TGGATTGAACCTGGCTTTG aAll primers were designed on the basis of the L. rhamnosus LOCK 0900 ,L .r h a m n o s u s LOCK 0908, and L. casei LOCK 0919 genome nucleotide sequences, which are available from NCBI ( http://www.ncbi.nlm.nih.gov/genome , last accessed December 17, 2015) with the respective accession numbers CP005484, CP005485, CP005486 (chro- mosomes) and CP005487 (plasmid).",Non-OADS,/arxiv_data1/oa_pdf/5b/57/evv247.PMC4758243.pdf
Available from:http://dx.doi.org/10.1038/cmi.2015.09 .,OADS,/arxiv_data1/oa_pdf/5b/57/evv247.PMC4758243.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a3/9e/evv248.PMC4758244.pdf
"Accepted: December 2, 2015 Data deposition: All data used in this study are provided in the supplementary materials , except for the genotype data, which is available from Dryad under the accession http://dx.doi.org/10.5061/dryad.f8j71 .",Non-OADS,/arxiv_data1/oa_pdf/c4/8c/evv250.PMC4758246.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/8c/evv250.PMC4758246.pdf
"Lep- MAP2 software is publicly available together with its sourceand documentation at http://sourceforge.net/projects/ lepmap2/ (last accessed December 22, 2015).Construction of Ultradense Linkage Maps with Lep-MAP2 GBE Genome Biol.",OADS,/arxiv_data1/oa_pdf/c4/8c/evv250.PMC4758246.pdf
"Adapters and barcodes were eliminated from reads and quality was checked using FastQC (Andrews S. FastQC, http://www.bioinforma tics.bbsrc.ac.uk/ projects/fastqc/ , last accessed December 22, 2015).",OADS,/arxiv_data1/oa_pdf/c4/8c/evv250.PMC4758246.pdf
Supplementary Material Supplementary ﬁles S1 and S2 and tables S1–S5 are availableatGenome Biology and Evolution online (http://www.gbe.,OADS,/arxiv_data1/oa_pdf/c4/8c/evv250.PMC4758246.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"aethiopica , following quality control of the Illumina reads with PRINSEQ ( Schmieder and Edwards 2011 )a n dFASTQC (Andrews, http://www.bioinformatics.babraham.",Non-OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"ac.uk/projects/fastqc/ , last accessed December 27, 2015), adaptors were removed when necessary, using fastx-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/ , last accessed December 27, 2015), and sequences were trimmed at both ends using PRINSEQ to remove polyA/T tails greater than 5 nt and all bases with a quality score less than 20, stopping at the ﬁrst base with a quality greater than 20.",Non-OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"hamiltonii were performed on the CLC Genomics Workbench 7 ( http://www.clcbio.com , last accessed December 27, 2015) using different word and bubble sizes, of which the automatic ones provided the best results, and improved with SSPACE ( Boetzer et al.",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"Reads were then de novo assembled with Geneious R7 (Biomatters, http://www.geneious.com/ , last accessed December 27, 2015), using the highest stringency to allow the separation of similar sequences mapping to thesame region.",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"2008 ;ftp://ftp.ncbi.nlm.nih.gov/blast/ex- ecutables/blast+/2.2.29/ , last accessed December 27, 2015).",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
We used a script ( http://seqanswers.com/forums/showthread.,Non-OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"2004 ;http://dogma.ccbb.utexas.edu/ html/cite.html , last accessed December 27, 2015) at the lowest possible stringency (threshold of 25% identity, gapped and nongapped alignment), and amino acid or nucle- otide sequences of all gene and rRNA fragments identiﬁed were aligned with the corresponding genes of Cucumis ,m a n - ually compared for identity and searched for frameshifts and stop-codons (for protein-coding genes).",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"For the plastomes, the results of DOGMA were reﬁned using ORF Finder online (Tatusov and Tatusov; http://www.ncbi.nlm.nih.gov/gorf/ orﬁg.cgi , last accessed December 27, 2015) as well as manual BLASTn, tBLASTx, and BLASTp against Genbank.",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"Inaddition, the two plastomes were searched for tRNAs using tRNAscan-SE 1.21 ( Lowe and Eddy 1997 ) at low stringency (Cove score 15), and secondary structure of the candidatetRNAs was investigated usin g the online program RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi , last accessed December 27, 2015).",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"2014 ;https://www.bioinfodata.org/Blast4OneKP/ ,l a s t accessed December 27, 2015) recovered a hit for each of them.",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
2014 ;https://www.bioinfodata.,OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"When we blasted the rrn16 ofPilostyles against GenBank (BLASTn at http://blast.ncbi.nlm.nih.gov/Blast.cgi , last accessed April 2015), Fabales were not among the ﬁrst hits, but insteadother sequences of Pilostyles ,t h e n Balanophora (a holopara- site belonging to Santalales), and then Plasmodium (a nonphotosynthetic ap icomplexan).",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"BLAST searches (BLASTn at http://blast.ncbi.nlm.nih.gov/ Blast.cgi , last accessed April 2015) of the non-coding regions of the plastome of P. aethiopica revealed a 509 bp-long low-complexity region (12% GC) matching an FIG.3 .—Map of the plastid genomes of P. aethiopica andP.",OADS,/arxiv_data1/oa_pdf/64/2d/evv251.PMC4758247.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/a4/evv252.PMC4758248.pdf
Supplementary Material Supplementary ﬁgure S1 and table S1 are available at Genome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/bd/a4/evv252.PMC4758248.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/12/evv253.PMC4758249.pdf
Supplementary Material Supplementary ﬁgures S1–S3 and tables S1–S9 are available atGenome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/72/12/evv253.PMC4758249.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/05/evv254.PMC4758250.pdf
The A. ferrivorans CF27 genome (accession number CCCS020000000) was retrieved fromthe MicroScope website ( https://www.genoscope.cns.fr/agc/ microscope/ )(Vallenet et al.,OADS,/arxiv_data1/oa_pdf/9a/05/evv254.PMC4758250.pdf
"Structural Organization of tRNA Array Units The organization of tRNA between tRNA array units was com-pared as follows: 1) Each tRNA array unit was ﬁrst converted into an amino acid (aa) sequence, in which each tRNA gene was turned into the corresponding aa isotype; 2) then, incre-mental patterns (incremental path of 1) of 20 amino acids(corresponding to the tRNA genes) were extracted fromeach aa sequence and an overall amino acid pattern database associated with tRNA array units was constituted; and 3) the fuzzpro program ( http://emboss.sourceforge.net ) was used for pattern matching analysis between each incremental patternand the pattern database, allowing 0–19 maximal patternmismatches.",OADS,/arxiv_data1/oa_pdf/9a/05/evv254.PMC4758250.pdf
"From the array structure similarities, a clusteredheatmap graphical representation was performed using the CIMminer tool ( http://discover.nci.nih.gov/cimminer/ ) with default parameters.",OADS,/arxiv_data1/oa_pdf/9a/05/evv254.PMC4758250.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ad/41/evv255.PMC4758251.pdf
Supplementary Material Supplementary movies S1–S3 andﬁgures S1–S6 are available atGenome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/ad/41/evv255.PMC4758251.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
"1990 )a t http://blast.ncbi.nlm.nih.gov/Blast.cgi ,l a s t accessed January 6, 2016.",Non-OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
gigas s e tp r o v i d e da tE n s e m b l( http://metazoa.ensembl.,OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
"californica (California sea slug, Heterobranchia, sequence available at http://genome.ucsc.edu , last accessed January 6, 2016) and Lo.",OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
"CORE SINEs have been described in a wide range of species (for a comprehensive list see SINE Base at http://sines.eimb.ru , last accessed January 6, 2016), mostly vertebrates.",OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
Supplementary Material Supplementary ﬁgures S1–S10 andtables S1–S3 are available atGenome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/3c/23/evv257.PMC4758252.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/96/61/evv258.PMC4758253.pdf
Directors of graduate and post-graduate psychology training programs were identified using two methods: (1) a state-by-state Internet search and (2) the VA TrainingDirector listserv and the VA psychology training for in-ternship and fellowships Website (http://www.psychologytraining.va.gov/programs.asp).Results .,OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
"Substantial effort has yielded accessible pain educationfor physicians and clinicians, such as the NIH PainConsortium Centers of Excellence in Pain Education(http://painconsortium.nih.gov/NIH_Pain_Programs/ CoEPES.html); however, targeted curricula are neededfor psychologists and therapists.",Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
Available at: http://iprcc.nih.gov/National_Pain_Strategy/NPS_Main.htm (accessed November 2015).,Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
Available at: http://www.apa.org/ed/graduate/specialize/taxonomy.pdf (accessedNovember 2015).,Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
Available at: https://www.apa.org/about/policy/procedures-recognition.pdf (accessedNovember 2015).,Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
"Available at http://www.bls.gov/(accessed November 8, 2015).",OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
Availableat: http://www.iasp-pain.org/Education/CurriculumDetail.aspx?ItemNumber ¼2057 (accessed November 2015).,Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
Availableat: http://www.iasp-pain.org/Education/CurriculumDetail.aspx?ItemNumber ¼2054 (accessed November 2015).,Non-OADS,/arxiv_data1/oa_pdf/a7/76/pnv095.PMC4758272.pdf
"CPS1  is a gene in 2q34 of the human chromo - some and encodes the CPS1 protein, which is the first key enzyme  in the urea cycle  (http://www.genecards.org/cgi‑bin/carddisp.",Non-OADS,/arxiv_data1/oa_pdf/4a/af/mmr-12-06-7915.PMC4758274.pdf
"CPS1‑IT1 is a 2,306‑base RNA molecule transcribed  by the CPS1 gene from 211,482,295‑211,484,600 base  pairs (http://www.genecards.org/cgi‑bin/carddisp.pl?gene=   CPS1 -IT1&keywords=CPS1 -IT1).",Non-OADS,/arxiv_data1/oa_pdf/4a/af/mmr-12-06-7915.PMC4758274.pdf
"The original  data were pre-processed using the beadarray package   in R language  (version 2.18.0; http://bioconductor.org/pack - ages/release /bioc/html/beadarray.html)  (18), and normalized  using the quantile method (19).",OADS,/arxiv_data1/oa_pdf/9f/42/mmr-12-06-7891.PMC4758287.pdf
"Multi-dimensional scaling (MDS),  which was constructed with the poltMDS (20) function in  the linear models for microarray data (Limma) (21) package    (version  3.24.15; http://www.bioconductor.org/pack - ages/release/bioc/html/limma.html)  was used to investigate  the association of the samples as a measure of quality control.",OADS,/arxiv_data1/oa_pdf/9f/42/mmr-12-06-7891.PMC4758287.pdf
"The probe sets, which  featured differential expression between the controls and the  AAA samples, were annotated to Ensembl gene identifiers (IDs) for ID mapping using the database for annotation, visu - alization and integrated discovery (DAVID) tool  (version  6.7;   http://david.abcc.Ncifcrf.gov/  (24,25).",OADS,/arxiv_data1/oa_pdf/9f/42/mmr-12-06-7891.PMC4758287.pdf
"Subsequently, a cluster analysis  on the resulting network was performed with the Plugin,  ClusterONE  (http://apps.cytoscape.org/apps/clusterone)  (30)  program, using a  P<0.05 as a cut -off.",OADS,/arxiv_data1/oa_pdf/9f/42/mmr-12-06-7891.PMC4758287.pdf
"Expression profile chip data were processed  using the affy package (19) in R/Bioconductor, version 2.14.1 (20)  (http://www.bioconductor.or g/).",OADS,/arxiv_data1/oa_pdf/a0/f4/mmr-12-06-7851.PMC4758289.pdf
"Data were subjected to back - ground correction, normalization, probe summary and log2  logarithmic transformation using the robust multi -array average  (RMA Express; version 1.0; http://rmaexpress.bmbolstad.com )  method  (21).",OADS,/arxiv_data1/oa_pdf/a0/f4/mmr-12-06-7851.PMC4758289.pdf
"Based on the rat TFs database TRANSFAC  version 6.0 ( http://www.gene -regulation.co m) (29), TFs were  annotated  among DEGs.",OADS,/arxiv_data1/oa_pdf/a0/f4/mmr-12-06-7851.PMC4758289.pdf
Available at: http://www.mathworks.com/ matlabcentral/ﬁleexchange/20057-b-spline-grid–image-and- point-based-registration.,Non-OADS,/arxiv_data1/oa_pdf/ea/37/i1552-5783-57-2-467.PMC4758295.pdf
"Manual counts wereperformed with the aid of ImageJ software (http://imagej.nih.gov/ij/; provided in the public domain by the NationalInstitutes of Health, Bethesda, MD, USA).",OADS,/arxiv_data1/oa_pdf/0d/30/i1552-5783-57-2-453.PMC4758298.pdf
Available at: https://www.nasa.gov/pdf/579501main_hrp_bed_rest_experiment_information_package.pdf.,Non-OADS,/arxiv_data1/oa_pdf/66/ed/i1552-5783-57-2-495.PMC4758300.pdf
Available at:http://nspires.nasaprs.com/external/solicitations/summary.do?method ¼init&solId ¼{FDCEA984-F985E984-982DA983- 984F984F-981496823C981496825B}&path ¼closedPast.,OADS,/arxiv_data1/oa_pdf/66/ed/i1552-5783-57-2-495.PMC4758300.pdf
"34 Though PLGA microparticles or nanoparticles have been an active research topic for sustained delivery of Dex through the vitreous route,35–37to date the only FDA-approved PLGA delivery device is Ozurdex, developed by Allergan, Inc. (available in the public domain at http://www.drugs.com/ history/ozurdex.html).",Non-OADS,/arxiv_data1/oa_pdf/2b/ed/i1552-5783-57-2-557.PMC4758302.pdf
"The present study was approved by the  Experimental Animal Care and Use Committee of Mitsubishi  Tanabe Pharma Corporation (Saitama, Japan), which was regu - lated by the Management and Ethics of Animal law (Ministry of  the Environment; http://www.env.go.jp /nature /dobutsu /aigo/1_ law/).",Non-OADS,/arxiv_data1/oa_pdf/80/b0/mmr-12-06-8010.PMC4758322.pdf
"This is an Open Access article distributed under the terms of the CreativeCommons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fb/59/ofv183.PMC4758327.pdf
"Brieﬂy, transplant-eligible patients aged 18 –70 years with previously untreated, measurable MM and without grade ≥2 peripheral neuropathy or neuropathic pain [National Cancer Institute Common Terminology Criteria for Adverse Events version3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)] were randomised [1:1, strati-ﬁed by International Staging System (ISS) disease stage (Gre-ippet al, 2005)] to receive initial treatment with four 21-day cycles of VTD or VTDC.",Non-OADS,/arxiv_data1/oa_pdf/39/39/BJH-171-344.PMC4758383.pdf
Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/8918275.,OADS,/arxiv_data1/oa_pdf/b9/d1/BIMJ-58-89.PMC4758384.pdf
"Retrieved July 12, 2013, from http://www.emea.europa.",Non-OADS,/arxiv_data1/oa_pdf/b9/d1/BIMJ-58-89.PMC4758384.pdf
"Retrieved from http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Victor, N., Sch ¨afer, H. and Nowak, H. (1991).",OADS,/arxiv_data1/oa_pdf/b9/d1/BIMJ-58-89.PMC4758384.pdf
"Understanding oral and writ- ten communication, 2011. http://www.learn.geekin-terview.com/career/communication-skills/under-standing-oral-written-communication.html (accesed7 March 2014).",Non-OADS,/arxiv_data1/oa_pdf/9b/21/IJCP-69-1257.PMC4758389.pdf
J Electronic Publ 2002; 8 : DOI: http://dx.doi.org/10.3998/3336451.,Non-OADS,/arxiv_data1/oa_pdf/9b/21/IJCP-69-1257.PMC4758389.pdf
"List of Mouse Strains Strain name Abbreviation Source Reference RRID P3-IRES-tauGFP P3 http://jaxmice.jax.org/strain/006684 Feinstein and Mombaerts, 2004MGI_3693375 M71-IRES-tauGFP M71 http://jaxmice.jax.org/strain/006676 Bozza et al., 2002, Feinstein et al., 2004MGI_3051336 mOR37C-IRES-tauGFP mOR37C http://jaxmice.jax.org/strain/006641 Strotmann et al., 2000 MGI_2385951 S50-IRES-tauGFP S50 http://jaxmice.jax.org/strain/006712 Bozza et al., 2009 MGI_3722364 MOR23-IRES-tauGFP MOR23 http://jaxmice.jax.org/strain/006643 Vassalli et al., 2002 MGI_3051333M72-IRES-tauGFP M72 http://jaxmice.jax.org/strain/006678 Potter et al., 2001 MGI_3692202 M50-IRES-GFP-IRES-taulacZ M50 http://jaxmice.jax.org/strain/006686 Feinstein and Mombaerts, 2004 MGI_3693438 mI7-IRES-tauGFP mI7 http://jaxmice.jax.org/strain/006664 Bozza et al., 2002 MGI_3692194 P2-IRES-tauGFP P2 http://jaxmice.jax.org/strain/006669 Feinstein and Mombaerts, 2004 MGI_3692295 SR1-IRES-tauGFP SR1 http://jaxmice.jax.org/strain/006711 Fuss et al., 2013 MGI_3722372MOR256-17-IRES-tauGFP MOR256-17 http://jaxmice.jax.org/strain/007762 Khan et al., 2011 MGI_3718690 b2AR!M71-IRES-tauGFP http://jaxmice.jax.org/strain/006734 Omura et al., 2014 MGI_3722388 RFP!M71iM71iGFP http://jaxmice.jax.org/strain/006689 Feinstein et al., 2004 MGI_3047225 M71-IRES-tauYFP http://jaxmice.jax.org/strain/006746 MGI_3712831 M71-IRES-tauRFP2 http://jaxmice.jax.org/strain/006679 Li et al., 2004 MGI_3692987 Each strain is listed with its original strain name, the abbreviation used in the figures, the weblink at The Jackson Laboratory from which these strains are publicly available, the reference publication, and the RRID number.",Non-OADS,/arxiv_data1/oa_pdf/e4/d4/CNE-524-199.PMC4758392.pdf
"Microsoft Excel, Fiji V1.48u (http://fiji.sc, RRID:S- ciRes_000137), and MatLab v. 7.12 (http://www.math- works.com/products/matlab/, RRID:nlx_153890).",OADS,/arxiv_data1/oa_pdf/e4/d4/CNE-524-199.PMC4758392.pdf
"Forstatistical analyses and graphs, GraphPad Prism 5 (http://www.graphpad.com/, RRID:rid_000081) was used.",OADS,/arxiv_data1/oa_pdf/e4/d4/CNE-524-199.PMC4758392.pdf
"National Diabetes Statistics Report: Esti-mates of diabetes and its burden in the UnitedStates, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14.htm (accessed 8 August 2014).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"40 Boehringer Ingelheim Pharmaceuticals Inc. Jardi- ance (empagliﬂozin) tablets, for oral use [pre-scribing information] August 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204 629s000lbl.pdf (accessed 5 March 2015).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"Farxiga (dapagli- ﬂozin) tablets, for oral use [prescribing informa-tion] August 2014. http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page=1 (accessed 5March 2015).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"43 Janssen Pharmaceuticals Inc. Invokana (canagliﬂo- zin) tablets, for oral use [prescribing information]May 2014. http://www.invokanahcp.com/prescrib-ing-information.pdf (accessed 2 March 2015).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"Xigduo XR (dapagliﬂozin and metformin HCl extended-release) tablets, for oral use [prescribing informa- tion] October 2014. http://www.accessdata.fda.",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"47 Janssen Pharmaceuticals Inc. Invokamet (canagli- ﬂozin and metformin hydrochloride) tablets, fororal use [prescribing information] August 2014.http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204353s000lbl.pdf (accessed 3 March 2015).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"NDA204042, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed 10 April 2014).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"Invokana (canagliﬂozin), 2013.http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2013/204042Orig1s000SumR.pdf (accessed 29 October 2014).",Non-OADS,/arxiv_data1/oa_pdf/d6/15/IJCP-69-1071.PMC4758393.pdf
"Surv., Reston, Va. [Available at http://dx.doi.org/10.3133/sir20145131.]",Non-OADS,/arxiv_data1/oa_pdf/64/1f/WRCR-51-5839.PMC4758395.pdf
"Surv., Reston, Va. [Available at http://dx.doi.org/10.3133/ds868.]",Non-OADS,/arxiv_data1/oa_pdf/64/1f/WRCR-51-5839.PMC4758395.pdf
"Assoc., 12 pp., Pittsburg, Pa. [Available at SSRN: http://ssrn.com/abstract 52124696 or http://dx.doi.org/10.2139/ssrn.",Non-OADS,/arxiv_data1/oa_pdf/64/1f/WRCR-51-5839.PMC4758395.pdf
"of Energy, Washington, D. C. [Available at http://www.eia.gov/forecasts/aeo/pdf/0383(2015).pdf, accessed 27 May 2015.]",OADS,/arxiv_data1/oa_pdf/64/1f/WRCR-51-5839.PMC4758395.pdf
"Everyunique MLST allele was assigned an allelic type (AT)number at each locus and compared to the existing ATsin MLST database (http://mlst.mycologylab.org) on seven loci ( CAP59 ,GPD1 , IGS1, LAC1 ,PLB1 ,SOD1 and URA5 ) (Meyer et al.",OADS,/arxiv_data1/oa_pdf/31/41/MEC-24-3559.PMC4758399.pdf
Evolutionary descent of the Botswana Cng isolates was analysed by EBURST (http://eburst.mlst.net/) (Feil et al.,OADS,/arxiv_data1/oa_pdf/31/41/MEC-24-3559.PMC4758399.pdf
"Seven of the eight loci wereused in the analysis of AT, and all the sequences weretrimmed into the same lengths as the sequences in the MLST database (http://mlst.mycologylab.org).",OADS,/arxiv_data1/oa_pdf/31/41/MEC-24-3559.PMC4758399.pdf
"Of 118 STs identi- ﬁed in this study, only nine have been previouslydescribed in MLST Database (http://mlst.mycology- lab.org), and only ﬁve (three VNI STs and two VNII STs) were found to be the same or very similar to the strains isolated outside Africa.",Non-OADS,/arxiv_data1/oa_pdf/31/41/MEC-24-3559.PMC4758399.pdf
All of theallele type and sequence type information have beensubmitted to Fungal MLST Database (http://mlst.myco- logylab.org).,OADS,/arxiv_data1/oa_pdf/31/41/MEC-24-3559.PMC4758399.pdf
Available fromURL: http://www.azpicentral.com/symlin/pi_symlin.pdf#page =1.,Non-OADS,/arxiv_data1/oa_pdf/33/dc/DOM-17-904.PMC4758401.pdf
Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfig-ures2015/index.,Non-OADS,/arxiv_data1/oa_pdf/a9/56/CNCR-121-3403.PMC4758404.pdf
Available at: http://www.nccn.org/pro-fessionals/physician_gls/f_guidelines.asp.,Non-OADS,/arxiv_data1/oa_pdf/a9/56/CNCR-121-3403.PMC4758404.pdf
"One goal of the Radiative Forcing Model Intercomparison Project (RFMIP,http://www.wcrp-climate.org/modelling-wgcm-mip-catalogue/mo delling-wgcm-mips/418-wgcm-rfmip) PINCUSETAL.",Non-OADS,/arxiv_data1/oa_pdf/63/b2/GRL-42-5485.PMC4758412.pdf
"Then GFP was visualized in leaf epidermal cells using a Carl Zeiss LSM510 Meta confocal laser scanningmicroscope (Carl Zeiss AG, http://www.zeiss.com/).",OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
"The tissues were sliced into 8-mm sections with a microtome (Leica RM2155; Leica, http://www.leica.- com).",Non-OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
"RT-qPCR and RACE analysis For RT-qPCR analysis, total RNA was extracted from varioussamples using TRIzol reagent (Invitrogen, http://www.lifetechno- logies.com) and was puriﬁed using the RNeasy Micro Kit (Qia- gen, http://www.qiagen.com).",OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
"The expression levels of PAY1 and other genes were analyzed using a CFX96 Real-Time System (Bio-Rad, http://www.bio-rad.com)and rice Ubiquitin gene as an internal control.",OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
"After 20 h incubation in 2 ml of scintillation liquid, the radioactivity of each section was counted by a liquid scintillation counter (1450 MicroBeta TriLux;Perkin-Elmer, http://www.perkinelmer.com).",Non-OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
"After extraction and puriﬁcation, the sam- ples were subjected to LC-MS analysis using a liquid scintillationcounter (1450 MicroBeta TriLux, http://www.perkinelmer.com).",Non-OADS,/arxiv_data1/oa_pdf/8c/3e/TPJ-83-528.PMC4758413.pdf
http://www.strobe-statement.org/ [accessed 26 March 2015].,Non-OADS,/arxiv_data1/oa_pdf/ba/90/BJS-102-1213.PMC4758415.pdf
[Available at http://www.hydrol-earth-syst-sci.net/14/159/2010/hess-14-159-2010.pdf.],Non-OADS,/arxiv_data1/oa_pdf/0c/f8/WRCR-51-5145.PMC4758416.pdf
More information on the analytical methods are provided at the laboratory website at http://www.labstat.com/.,Non-OADS,/arxiv_data1/oa_pdf/ea/45/BIMJ-57-914.PMC4758417.pdf
[Available at http://www.nea.fr.],Non-OADS,/arxiv_data1/oa_pdf/1d/7d/JGRA-120-5284.PMC4758620.pdf
Weacknowledge the Fermi mission for the use of their data speci ﬁcally the GBM instrument (http://heasarc.gsfc.nasa.gov/FTP/fermi/data/gbm).,OADS,/arxiv_data1/oa_pdf/02/43/JGRA-120-4922.PMC4758627.pdf
Sea Surface Salinity from Naval Research Laboratory 1/128Global HYCOM Hindcast (http://www7320.nrlssc.navy.mil/GLBhy- com1–12/navo/nbrazlsss/nowcast/sss2011050618 _2011050600_909_nbrazlsss.001.gif).,OADS,/arxiv_data1/oa_pdf/76/fc/JGRC-120-4129.PMC4758629.pdf
"SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501055/DC1Data collection: The MyShake application Classifier analysis: Detecting earthquakes on a phone Network detection algorithmEstimate waring time for Katmandu, NepalFig.",Non-OADS,/arxiv_data1/oa_pdf/fd/ef/1501055.PMC4758737.pdf
15. http://earthquake.usgs.gov/earthquakes/eventpage/nc72282711#impact_dyfi16.,OADS,/arxiv_data1/oa_pdf/fd/ef/1501055.PMC4758737.pdf
Shake Alert; http://myshake.berkeley.edu/.30.,Non-OADS,/arxiv_data1/oa_pdf/fd/ef/1501055.PMC4758737.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501162/DC1General information Synthetic proceduresEnantioselective sensing experimentsQuantitative ee and concentration analysisEe and concentration analysis of hydrob enzoin 25 obtained by asymmetric Sharpless dihydroxylation MS analysis of the in situ complex formationAnalysis of the sensing mechanism with the stereodynamic Ti complexCrystallographyScheme S1.,Non-OADS,/arxiv_data1/oa_pdf/33/95/1501162.PMC4758738.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1500323/DC1 Supplementary DiscussionFig.,Non-OADS,/arxiv_data1/oa_pdf/0e/2b/1500323.PMC4758739.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501280/DC1Note S1.,Non-OADS,/arxiv_data1/oa_pdf/ca/f6/1501280.PMC4758740.pdf
"Further, we posted a request for “gray”literature and un- published data sets on the “EvolDir ”mailing list (http://evol.mcmaster.",Non-OADS,/arxiv_data1/oa_pdf/b6/9c/1500983.PMC4758741.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1500983/DC1 Fig.,Non-OADS,/arxiv_data1/oa_pdf/b6/9c/1500983.PMC4758741.pdf
Data and materials availability: All data needed to evaluate the conclusions in the paper are available from the Dryad Digital Repository(http://dx.doi.org/10.5061/dryad.780d6) and/or the Supplementary Materials.,OADS,/arxiv_data1/oa_pdf/b6/9c/1500983.PMC4758741.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501272/DC1Section I.,Non-OADS,/arxiv_data1/oa_pdf/e6/fd/1501272.PMC4758742.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501244/DC1 Fig.,Non-OADS,/arxiv_data1/oa_pdf/c4/ba/1501244.PMC4758743.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501010/DC1Table S1.,Non-OADS,/arxiv_data1/oa_pdf/73/56/1501010.PMC4758744.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1501061/DC1 Fig.,Non-OADS,/arxiv_data1/oa_pdf/51/45/1501061.PMC4758746.pdf
"Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.Additional data related to this paper may be requested from the authors and/or http://qiita.ucsd.edu/study/description/10333.Submitted 7 August 2015 Accepted 29 November 2015Published 12 February 201610.1126/sciadv.1501061 Citation: J. F. Ruiz-Calderon, H. Cavallin, S. J.",Non-OADS,/arxiv_data1/oa_pdf/51/45/1501061.PMC4758746.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/2/e1500827/DC1Fig.,Non-OADS,/arxiv_data1/oa_pdf/c1/5c/1500827.PMC4758747.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseAugust 2014 |  90  | e51766 | Page 1 of 7Video Article Real-time Imaging of Endothelial Cell-cell Junctions During Neutrophil Transmigration Under Physiological Flow Jeffrey Kroon*1, Anna E. Daniel*1, Mark Hoogenboezem1, Jaap D. van Buul1 1Department of Molecular Cell Biology, Sanquin Research and Landsteiner Laboratory, AMC at University of Amsterdam *These authors contributed equally Correspondence to: Jaap D. van Buul at j.vanbuul@sanquin.nl URL: http://www.jove.com/video/51766 DOI: doi:10.3791/51766 Keywords: Immunology, Issue 90, Leukocytes, Human Umbilical Vein Endothelial Cells (HUVECs), transmigration, VE-cadherin, PECAM-1, endothelium, transcellular, paracellular Date Published: 8/14/2014 Citation: Kroon, J., Daniel, A.E., Hoogenboezem, M., van Buul, J.D.",Non-OADS,/arxiv_data1/oa_pdf/2b/d0/jove-90-51766.PMC4758758.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51766/ Introduction Efficient and tightly controlled leukocyte transendothelial migration (TEM) is of key importance in physiological processes such as immune surveillance and acute inflammation.,Non-OADS,/arxiv_data1/oa_pdf/2b/d0/jove-90-51766.PMC4758758.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseAugust 2014 |  90  | e51860 | Page 1 of 8Video Article Isolation of Murine Valve Endothelial Cells Lindsey J. Miller1,2, Joy Lincoln2,3 1Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University 2Center for Cardiovascular and Pulmonary Research, The Heart Center, The Research Institute at Nationwide Children's Hospital 3Department of Pediatrics, The Ohio State University Correspondence to: Joy Lincoln at Joy.Lincoln@nationwidechildrens.org URL: http://www.jove.com/video/51860 DOI: doi:10.3791/51860 Keywords: Cellular Biology, Issue 90, Heart valve, Valve Endothelial Cells (VEC), Fluorescence Activated Cell Sorting (FACS), Mouse, Embryo, Adult, GFP.",Non-OADS,/arxiv_data1/oa_pdf/c0/af/jove-90-51860.PMC4758760.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51860/ Introduction The mature valve is composed of three stratified layers of specialized extracellular matrix (ECM) interspersed with valve interstitial cells (VICs) and encapsulated by a single layer of heart valve endothelial cells (VECs)1.,Non-OADS,/arxiv_data1/oa_pdf/c0/af/jove-90-51860.PMC4758760.pdf
"Z. Huang1, Emily Groves1, Nicholas W. Morrell1, Amer A. Rana1 1Department of Medicine, University of Cambridge 2Papworth Hospital Correspondence to: Mark L. Ormiston at mlo32@medschl.cam.ac.uk , Amer A. Rana at ar332@cam.ac.uk URL: http://www.jove.com/video/53384 DOI: doi:10.3791/53384 Keywords: Cellular Biology, Issue 106, Blood outgrowth endothelial cell (BOEC), endothelial progenitor cell (EPC), induced pluripotent stem cells (iPSCs) Date Published: 12/23/2015 Citation: Ormiston, M.L., Toshner, M.R., Kiskin, F.N., Huang, C.J.Z., Groves, E., Morrell, N.W., Rana, A.A. Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood.",Non-OADS,/arxiv_data1/oa_pdf/92/81/jove-106-53384.PMC4758763.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/53384/ Introduction Until recently, the post-natal generation of new blood vessels was believed to occur exclusively through a process known as angiogenesis, defined as the sprouting of new vessels from the endothelial cells of pre-existing vessels.1 This process contrasts from the vasculogenesis, or the de novo  formation of blood vessels from endothelial progenitors, which was thought to occur exclusively during embryogenesis.2 However, more recent studies have identified and isolated circulating endothelial progenitor cells (EPCs) in the peripheral blood of adults.",Non-OADS,/arxiv_data1/oa_pdf/92/81/jove-106-53384.PMC4758763.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bc/5d/amep-7-057.PMC4758781.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2016:7 57–61Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  57OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S9140 1Portfolio as a tool to evaluate clinical  competences of traumatology in medical students Fernando santonja- Medina1,2 M Paz garcía-sanz3 Francisco Martínez- Martínez1,2 David Bó1,2,4 Joaquín garcía-Estañ5 1Faculty of Medicine, Department of  Traumatology, 2Faculty of Medicine,   University hospital Virgen de la  Arrixaca, 3Faculty of Medicine,   Department of Education, 4Faculty of  Medicine, University hospital Morales  Meseguer, 5Faculty of Medicine,   Department of Physiology, University  of Murcia, Murcia, spain correspondence: Joaquín garcía-Estañ   Facultad de Medicina, Departamento   de Fisiología, Universidad de Murcia,   30100 Murcia, spain   Tel +34 868 88 4880   Fax +34 868 88 4150   Email jgestan@um.e sAbstract:  This article investigates whether a reflexive portfolio is instrumental in determining  the level of acquisition of clinical competences in traumatology, a subject in the 5th year of the  degree of medicine.",Non-OADS,/arxiv_data1/oa_pdf/bc/5d/amep-7-057.PMC4758781.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/bc/5d/amep-7-057.PMC4758781.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/bc/5d/amep-7-057.PMC4758781.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/bf/66/tcrm-12-177.PMC4758782.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 177–182submit your manuscript | www.dovepress.co m Dove press  177 http: //dx.doi.org/10.2147/TCRM.S9734 2Dove press Case seRiesopen access to scientific and medical research Open access Full T ext article intravitreal ketorolac for the treatment of chronic  cystoid macular edema after cataract surgery Miltiadis K Tsilimbaris Chrysanthi Tsika George D Kymionis Department of Ophthalmology,   University of Crete, Heraklion,   GreecePurpose:  To report two cases of chronic postoperative cystoid macular edema, resistant to  topical therapy, treated with consecutive intravitreal injections of ketorolac tromethamine.",Non-OADS,/arxiv_data1/oa_pdf/bf/66/tcrm-12-177.PMC4758782.pdf
"It has  a safe intravitreal toxicity profile11–13 and in the past we were able to demonstrate a  favorable effect after a single injection of ketorolac in patients with chronic postop - erative CME; however, edema regression was observed usually some days after the  injection.14 Hereby, we present two cases of chronic CME after complicated cataract surgery  both patients were treated with consecutive daily intravitreal injections of ketorolac Correspondence: Miltiadis K Tsilimbaris Department of Ophthalmology,  University of Crete Medical school,  PO Box 2208, 71003 Heraklion, Greece Tel +30 281 039 2351 Fax +30 281 054 2094 email tsilimb@med.uoc.g r Journal name: Therapeutics and Clinical Risk Management Article Designation: Case series Y ear: 2016 Volume: 12 Running head verso: Tsilimbaris et al Running head recto: Intravitreal ketorolac for postoperative CME DOI: http://dx.doi.org/10.2147/TCRM.S97342",Non-OADS,/arxiv_data1/oa_pdf/bf/66/tcrm-12-177.PMC4758782.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/bf/66/tcrm-12-177.PMC4758782.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bf/66/tcrm-12-177.PMC4758782.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 745–754OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  745Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9437 4effects of electromagnetic radiation exposure on  bone mineral density, thyroid, and oxidative stress  index in electrical workers halil Kunt1,* i.hsan Şentürk2,* Yücel Gönül3,* Mehmet Korkmaz4 ahmet ahsen5 Ömer hazman6 ahmet Bal7 abdurrahman genç8 ahmet songur3 1Department of science education,   Faculty of Education, Dumlupınar  University, Kütahya, 2Department  of Orthopedics and Traumatology,   3Department of anatomy, Faculty of  Medicine, afyon Kocatepe University,   afyonkarahisar, 4Department of  radiology, Faculty of Medicine,   Dumlupınar University, Kütahya,   5Department of nephrology, Faculty  of Medicine, 6Department of  Biochemistry, Faculty of science and  arts, 7Department of general surgery,   8Department of Physiology, Faculty of  Medicine, afyon Kocatepe University,   afyonkarahisar, T urkey *These authors contributed equally  to this workBackground:  In the literature, some articles report that the incidence of numerous diseases  increases among the individuals who live around high-voltage electric transmission lines  (HVETL) or are exposed vocationally.",Non-OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
"The electromagnetic balance of the human body is disrupted by  these magnetic fields.2Correspondence: Yücel Gönül Department of anatomy, Faculty of  Medicine, afyon Kocatepe University,  Ali Çetinkaya Kampusü-I.zmir Karayolu  8.km, 03200-Afyonkarahisar, Turkey Tel +90 505 571 5259 Fax +90 272 246 3300 email yucel94@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Kunt et al Running head recto: Effects of electromagnetic radiation exposure on electrical workers DOI: http://dx.doi.org/10.2147/OTT.S94374",Non-OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
"Available from: http://www.bioinitiative.or g. Accessed December 21,  2015.",OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c3/21/ott-9-745.PMC4758783.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e0/01/ott-9-755.PMC4758784.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 755–760OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  755Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9594 4association of polymorphisms hO gg1 rs1052133  and hMUTY h rs3219472 with risk of nasopharyngeal  carcinoma in a chinese population Ying Xie2 Yuan Wu3 Xunzhao Zhou3 Mengwei Yao3 sisi ning3 Zhengbo Wei1 1Department of head and neck  Tumor surgery, affiliated Tumor  hospital of guangxi Medical  University, 2guangxi Key laboratory  for high-incidence Tumor Prevention  and Treatment, experimental center  of Medical science of guangxi Medical  University,3graduate school of  guangxi Medical University, nanning,   People’s republic of chinaAbstract:  This case–control study investigates the possible relationships between the  single-nucleotide polymorphisms rs1052133 in the human 8-oxoguanine DNA glycosylase 1   (hOGG1 ) gene and rs3219472 in the human MutY glycosylase homologue (hMUTYH)  gene and  the risk of nasopharyngeal carcinoma (NPC).",Non-OADS,/arxiv_data1/oa_pdf/e0/01/ott-9-755.PMC4758784.pdf
"This lesion causes mutagenic transver - sion of G:C to T:A in several tumor suppressor genes and oncogenes, which can lead  to carcinogenesis.4,5 7,8-Dihydro-8-oxoguanine lesions are recognized and repaired  effectively by the base excision repair (BER) pathway, in which 8-oxoguanine DNA  glycosylase 1 and MutY glycosylase homologue (MUTYH) are the main enzymes.6 Single-nucleotide polymorphisms (SNPs) in key genes in the BER pathway, includ - ing the gene encoding human 8-oxoguanine DNA glycosylase 1 (hOGG1), have been correspondence: Zhengbo Wei Department of head and neck Tumor  Surgery, Affiliated Tumor Hospital of  guangxi Medical University, 71 hedi  road, 530021 nanning, People’s  republic of china Tel +86 77 1534 3612 Fax +86 77 1530 3297 email wzhbo1973@aliyun.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xie et al Running head recto: hOGG1  rs1052133 and hMUTYH  rs3219472 polymorphisms DOI: http://dx.doi.org/10.2147/OTT.S95944",Non-OADS,/arxiv_data1/oa_pdf/e0/01/ott-9-755.PMC4758784.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/e0/01/ott-9-755.PMC4758784.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/01/ott-9-755.PMC4758784.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a2/0c/dddt-10-619.PMC4758785.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 619–630Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  619Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S9874 0Protective effect of fucoidan from Fucus vesiculosus  on liver fibrosis via the TGF- β1/Smad pathway- mediated inhibition of extracellular matrix and  autophagy Jingjing li1 Kan chen1 sainan li1 Jiao Feng1 T ong liu1 Fan Wang1 rong Zhang1,2 shizan Xu1,2 Yuqing Zhou1,3 shunfeng Zhou1,3 Yujing Xia1 Jie lu1 Yingqun Zhou1 chuanyong guo1 1Department of gastroenterology,   shanghai T enth People’s hospital,   T ongji University school of Medicine,   shanghai, 2The First clinical  Medical college of nanjing Medical  University, nanjing, 3Department of  gastroenterology, The First affiliated  hospital of soochow University,   Suzhou, People’s Republic of ChinaAbstract:  Liver fibrosis is a dynamic reversible pathological process in the development of  chronic liver disease to cirrhosis.",Non-OADS,/arxiv_data1/oa_pdf/a2/0c/dddt-10-619.PMC4758785.pdf
"When stimulated by various cytokines, the ECM evolves to liver fibrosis due to  synthesis of its components, including collagen I, fibronectin, laminin (LN), and  hyaluronic acid, or reduced degradation induced by an imbalance between matrix correspondence: Yingqun Zhou; chuanyong guo Department of gastroenterology,  shanghai Tenth People’s hospital, Tongji  University school of Medicine, shanghai  200072, People’s Republic of China Tel +86 21 6630 2535 Fax +86 21 6630 3983 email yqzh02@163.co m;  guochuanyong@hotmail.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Li et al Running head recto: The action of fucoidan in liver fibrosis DOI: http://dx.doi.org/10.2147/DDDT.S98740",Non-OADS,/arxiv_data1/oa_pdf/a2/0c/dddt-10-619.PMC4758785.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/a2/0c/dddt-10-619.PMC4758785.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a2/0c/dddt-10-619.PMC4758785.pdf
"dovepress.com/terms.ph p and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
"For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Journal of Pain Research 2016:9 67–79Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  67Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S9923 1The topical 5% lidocaine medicated plaster in  localized neuropathic pain: a reappraisal of the  clinical evidence Oscar A de León- Casasola1,2 victor Mayoral3 1Department of Anesthesiology,   Division of Pain Medicine, Roswell  Park Cancer institute, 2University  at Buffalo, School of Medicine and  Biomedical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
"Available from:  http://conference.painweek.org/media/mediafile_attachments/04/724- painweek2014acceptedabstracts.pd f. Accessed September 21, 2015.",Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
"Available from: http://www.fda.gov/down - loads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm384691.pd f. Accessed September 21, 2015.",Non-OADS,/arxiv_data1/oa_pdf/cc/22/jpr-9-067.PMC4758786.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/72/64/tcrm-12-167.PMC4758787.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 167–175Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  167ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S9986 9Optimal medical therapy for secondary prevention  after an acute coronary syndrome: 18-month  follow-up results at a tertiary teaching hospital in  south Korea hee Ja Byeon1,* Y oung-Mo Yang2,* eun Joo Choi2 1Department of Pharmacy, Chosun  University hospital, 2Department  of Pharmacy, College of Pharmacy,   Chosun University, gwangju, south  Korea *These authors contributed equally  to this workBackground:  Acute coronary syndrome (ACS) is a fatal cardiovascular disease caused by  atherosclerotic plaque erosion or rupture and formation of coronary thrombus.",Non-OADS,/arxiv_data1/oa_pdf/72/64/tcrm-12-167.PMC4758787.pdf
"Keywords:  acute coronary syndrome, secondary prevention, guideline adherence, patient  discharge, electronic medical record, cardiovascular disease Introduction Acute coronary syndrome (ACS) is a serious cardiovascular disease, which is usually  caused by atherosclerotic plaque erosion or rupture and subsequent coronary thrombus  formation due to platelet activation.1,2 ACS is classified into three different types:  unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI),  and ST-segment elevation MI (STEMI).3 UA is referred to as the presence of isch - emic symptoms without an increase in biomarkers and shows a transient change in Correspondence: eun Joo Choi Department of Pharmacy, College of  Pharmacy, Chosun University, 309  Pilmun-daero, Dong-gu, gwangju 61452,  south Korea Tel +82 62 230 6382 Fax +82 62 222 5414 email ejchoi@chosun.ac.k rJournal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Byeon et al Running head recto: Optimal medical therapy for secondary prevention after ACS DOI: http://dx.doi.org/10.2147/TCRM.S99869",Non-OADS,/arxiv_data1/oa_pdf/72/64/tcrm-12-167.PMC4758787.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/72/64/tcrm-12-167.PMC4758787.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/64/tcrm-12-167.PMC4758787.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 761–772OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  761Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9766 4Expression profile analysis of long noncoding RNA  in HER-2 -enriched subtype breast cancer by next- generation sequencing and bioinformatics Fan Yang shixu lyu siyang Dong Yehuan liu Xiaohua Zhang Ouchen Wang Department of Surgical Oncology, The  First Affiliated Hospital of Wenzhou  Medical University, Wenzhou, Zhejiang,   People’s Republic of ChinaBackground:  Human epidermal growth factor receptor 2 ( HER-2 )-enriched subtype breast  cancer is associated with a more aggressive phenotype and shorter survival time.",Non-OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
"HER-2 -enriched  subtype breast cancer is associated with a more aggressive phenotype and shorter  survival time.4,5 Although HER-2 -targeted agents such as trastuzumab have dramati - cally improved prognosis of patients with HER-2  overexpression, resistance to such  agents remained a severe problem.6 Hence, the underlying molecular mechanisms of the correspondence: Xiaohua Zhang;  Ouchen Wang Department of Surgical Oncology, The  First Affiliated Hospital of Wenzhou  Medical University, Wenzhou 325000,  Zhejiang, People’s Republic of China Tel +86 577 5557 9462;  +86 577 5557 8527 email xiaohuazhang2015@sina.co m;  wmuoncologist@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Y ang et al Running head recto: LncRNAs expression profile in HER-2 -enriched subtype breast cancer DOI: http://dx.doi.org/10.2147/OTT.S97664",Non-OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
gO analysis and pathway analysis GO analysis was carried out to facilitate elucidating the  biological implications of unique genes in the significant or  representative profiles of the differently expressed genes in the  experiment.10 We downloaded the GO annotations from Gene  Ontology ( http://www.geneontology.org /).,OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/21/d6/ott-9-761.PMC4758788.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Advances in Medical Education and Practice 2016:7 87–89Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  87ExPErt O PiniO nopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/AMEP .S9678 1A proposal for health care management  and leadership education within the UK  undergraduate medical curriculum Cecilia Mafe Effie Menyah Munachi nkere imperial College School of Medicine,   imperial College London, London, UK Correspondence: Cecilia Mafe   Faculty of Medicine, imperial College  London, Exhibition road, London SW7  2AZ, UK   tel +44 20 758 95111   Email Mafececilia@gmail.co mAbstract:  Health care management and leadership education is an important gap in the under - graduate medical curriculum.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Available  from: http://www.ons.gov.uk/ons/rel/psa/expenditure-on-healthcare-in- the-uk/2013/info-healthcare-spending-in-the-uk–2013.htm l. Accessed  September 19, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
Available from:  https://www.england.nhs.uk/wp-content/uploads/2014/10/5yfv-web.,Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
Available from: http://webarchive.nationalarchives.gov.,Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"uk/20150407084003/http://www.midstaffspublicinquiry.com/repor t.  Accessed December 21, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Available from: http://hee.nhs.uk/ wp-content/blogs.dir/321/files/2013/11/HEE-Mandate.pd f. Accessed  September 13, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Available from: http://m.hsj.co.uk/5084097.articl e.  Accessed September 13, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Available from: http://www.pulsetoday.co.uk/ mckinsey-nhs-managers-least-clinically-qualified-in-developed- world/11044881.fullarticl e. Accessed December 16, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"Avail - able from: http://www.leadershipacademy.nhs.uk/wp-content/ uploads/2012/11/ NHSLeadership -Leadership-Framework-Medical- Leadership- Competency -Framework-3rd-ed.pd f. Accessed December  16, 2015.",Non-OADS,/arxiv_data1/oa_pdf/6b/53/amep-7-087.PMC4758789.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 141–148Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  141ExpErt OpInIO nopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/CIA.S9623 2recommendations for managing cutaneous  disorders associated with advancing age philippe Humbert1 Brigitte Dréno2 Jean Krutmann3 thomas Anton Luger4 raoul triller5 Sylvie Meaume6 Sophie Seité7 1research and Studies Centre on  the Integument (CE rt), Clinical  Investigation Centre (CIC Bt506),   Department of Dermatology,   Besançon University Hospital,   University of Franche-Comté,   Besançon, France; 2Department  of Dermato-Cancerology, nantes  University Hospital, nantes, France;   3IUF-Leibniz research Institute for  Environmental Medicine, Heinrich- Heine-University, Düsseldorf,   Germany; 4Department of  Dermatology, University of Münster,   Münster, Germany; 5International  Centre of Dermatology, Hertford  British Hospital, Levallois, France;   6Geriatric Service, Wounds and  Healing, rothschild Hôspital,   paris, France; 7La roche- posay  Dermatological Laboratories,   Asnières, FranceAbstract:  The increasingly aged population worldwide means more people are living with  chronic diseases, reduced autonomy, and taking various medications.",Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
"The physical and chemical barrier function declines, and cutaneous permeability Correspondence: Sophie Seite La roche-posay Dermatological  Laboratories, 110 Avenue Henri  Barbusse, 92602 Asnières Cedex, France tel +33 1 46 88 65 44 Fax +33 1 46 88 66 88 Email sophie.seite@loreal.co m Journal name: Clinical Interventions in Aging Article Designation: Expert Opinion Y ear: 2016 Volume: 11 Running head verso: Humbert et al Running head recto: Managing skin disorders in the elderly DOI: http://dx.doi.org/10.2147/CIA.S96232",Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
Available from: http://ec.europa.eu/ health/ageing/policy/index_en.ht m. Accessed: December 2014.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
Available from: http://www.wounds-uk.com/best-practice- statements /.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/cia-11-141.PMC4758790.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/fa/7b/rmhp-9-013.PMC4758791.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/fa/7b/rmhp-9-013.PMC4758791.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Risk Management and Healthcare Policy 2016:9 13–20Risk Management and Healthcare Policy Dove press submit your manuscript | www.dovepress.co m Dove press  13ORiginal ReseaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/RMHP .S9831 1Hand hygiene knowledge and practice among  university students: evidence from Private  Universities of Bangladesh Marufa sultana1 Rashidul alam Mahumud1 abdur Razzaque sarker1 sarder Mahmud Hossain2 1Health economics and Financing  Research group, centre for  equity and Health system (ceHs),   international centre for Diarrhoeal  Disease Research, Bangladesh,   2Department of Public Health,   northern University Bangladesh,   Dhaka, Bangladesh correspondence: Marufa sultana   international centre for Diarrhoeal  Disease Research, 68 shaheed Tajuddin  ahmed sharani, Mohakhali, Dhaka 1212,  Bangladesh   T el +880 2 982 7001 10 ext 2524   Fax +880 2 881 1568   email marufa@icddrb.or gAbstract:  Hand hygiene has achieved the reputation of being a convenient means of preventing  communicable diseases.",Non-OADS,/arxiv_data1/oa_pdf/fa/7b/rmhp-9-013.PMC4758791.pdf
"Risk Management and Healthcare Policy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/risk-management-and-healthcare-policy-journa lRisk Management and Healthcare Policy is an international, peer- reviewed, open access journal focusing on all aspects of public health,  policy, and preventative measures to promote good health and improve  morbidity and mortality in the population.",Non-OADS,/arxiv_data1/oa_pdf/fa/7b/rmhp-9-013.PMC4758791.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fa/7b/rmhp-9-013.PMC4758791.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/45/6d/ccide-8-015.PMC4758792.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical, Cosmetic and Investigational Dentistry 2016:8 15–27Clinical, Cosmetic and Investigational Dentistry Dove press submit your manuscript | www.dovepress.co m Dove press  15OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CCIDE.S9434 3Influence of core design, production technique,  and material selection on fracture behavior of  yttria-stabilized tetragonal zirconia polycrystal  fixed dental prostheses produced using different  multilayer techniques: split-file, over-pressing, and  manually built-up veneers Deyar Jallal Hadi Mahmood Ewa H Linderoth Ann Wennerberg Per Vult Von steyern Department of Prosthetic Dentistry,   Faculty of Odontology, Malmö  University, Malmö, Sweden Correspondence: Deyar Jallal hadi  Mahmood   Department of Prosthetic Dentistry,   Faculty of Odontology, Malmö University,  SE-205 06 Malmö, Sweden   Tel +46 40 73 994 2854   email deyar.mahmood@mah.s eAim:  To investigate and compare the fracture strength and fracture mode in eleven groups of  currently, the most commonly used multilayer three-unit all-ceramic yttria-stabilized tetragonal  zirconia polycrystal (Y -TZP) fixed dental prostheses (FDPs) with respect to the choice of core  material, veneering material area, manufacturing technique, design of connectors, and radii of  curvature of FDP cores.",Non-OADS,/arxiv_data1/oa_pdf/45/6d/ccide-8-015.PMC4758792.pdf
"This paper and the abstract of this paper were presented  at the Swedental and Annual Dental Congress, November  13, 2015 in Götenborg, Sweden ( http://invitepeople.com/ public/seminars/3909?lang=e n).",Non-OADS,/arxiv_data1/oa_pdf/45/6d/ccide-8-015.PMC4758792.pdf
"Clinical, Cosmetic and Investigational Dentistry Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-cosmetic-and-investigational-dentistry-journa lClinical, Cosmetic and Investigational Dentistry is an international,  peer-reviewed, open access, online journal focusing on the latest clini - cal and experimental research in dentistry with specific emphasis on  cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/45/6d/ccide-8-015.PMC4758792.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/45/6d/ccide-8-015.PMC4758792.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/69/76/idr-9-035.PMC4758793.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Infection and Drug Resistance 2016:9 35–42Infection and Drug Resistance Dove press submit your manuscript | www.dovepress.co m Dove press  35REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IDR.S95372Methicillin-resistant Staphylococcus aureus  multiple  sites surveillance: a systemic review of the literature John Chipolombwe1 Mili Estee Török2 Nontombi Mbelle3 Peter Nyasulu4,5 1Department of Internal Medicine,   Mzuzu Central Hospital, Ministry of  Health, Mzuzu, Malawi; 2Department  of Medicine, University of Cambridge,   Cambridge, UK; 3Department of  Medical Microbiology, University  of Pretoria, Pretoria, South Africa;   4School of Public Health, Faculty of  Health Sciences, University of the  Witwatersrand, 5Department of Public  Health, School of Health Sciences,   Monash University, Johannesburg,   South Africa Correspondence: Peter Nyasulu   Department of Public Health, School   of Health Sciences, Monash University,   144 Peter Road, Rumsuig,   Johannesburg, South Africa   Tel +27 78 518 5225   Email peter.nyasulu@monash.ed uPurpose:  The objective of this study was to evaluate the optimal number of sampling sites for  detection of methicillin-resistant Staphylococcus aureus  (MRSA) colonization.",Non-OADS,/arxiv_data1/oa_pdf/69/76/idr-9-035.PMC4758793.pdf
"Infection and Drug Resistance Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/infection-and-drug-resistance-journa lInfection and Drug Resistance is an international, peer-reviewed open- access journal that focuses on the optimal treatment of infection (bacte - rial, fungal and viral) and the development and institution of preventive  strategies to minimize the development and spread of resistance.",Non-OADS,/arxiv_data1/oa_pdf/69/76/idr-9-035.PMC4758793.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/69/76/idr-9-035.PMC4758793.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/16/11/opth-10-305.PMC4758794.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 305–306Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  305Letteropen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/OPTH.S10368 3Partial posterior vitreous detachment as a  classification criterion of epiretinal membrane Abdullah Kaya Department of Ophthalmology,   Anıttepe Military Dispansary,   Ankara, T urkeyDear editor I read with great interest the article “Relationship between variations in posterior   vitreous detachment and visual prognosis in idiopathic epiretinal membranes”  by Ota et al.1 The authors have compared visual prognosis of epiretinal membrane  (ERM) patients according to type of vitreous detachment.",Non-OADS,/arxiv_data1/oa_pdf/16/11/opth-10-305.PMC4758794.pdf
"Çankaya, Ankara 06280, Turkey tel +90 530 140 9305 email abdullahkayamd@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Letter Y ear: 2016 Volume: 10 Running head verso: Kaya Running head recto: Partial posterior vitreous detachment as a classification DOI: http://dx.doi.org/10.2147/OPTH.S103683",Non-OADS,/arxiv_data1/oa_pdf/16/11/opth-10-305.PMC4758794.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/16/11/opth-10-305.PMC4758794.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/16/11/opth-10-305.PMC4758794.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6d/bb/tcrm-12-183.PMC4758795.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 183–187Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  183ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S9189 8low-back pain at the emergency department: still  not being managed?",Non-OADS,/arxiv_data1/oa_pdf/6d/bb/tcrm-12-183.PMC4758795.pdf
"Most cases of LBP do not have a clear cause, but are believed to be the result of mus - culoskeletal problems, such as sprains or muscle strains.5 In most episodes of LBP,  a specific underlying cause is not identified or even sought.6 In chronic patients, of Correspondence: luca Miceli Department of anesthesia and intensive  Care, academic hospital of Udine,  University of Udine, Piazzale santa Maria  della Misericordia number 10, Udine  33100, italy Tel +39 347 450 7997 Fax +39 0432 559 502 email miceli.luca@aoud.sanita.fvg.i t Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Rizzardo et al Running head recto: Low-back pain in the ED DOI: http://dx.doi.org/10.2147/TCRM.S91898",Non-OADS,/arxiv_data1/oa_pdf/6d/bb/tcrm-12-183.PMC4758795.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/6d/bb/tcrm-12-183.PMC4758795.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/6d/bb/tcrm-12-183.PMC4758795.pdf
The full terms of this license are available at https://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
"com/terms.ph p and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
"For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Journal of Pain Research 2016:9 81–85Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  81ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JPR.S9685 6Video abstract Point your Smar tPhone at the code abo ve.",Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
"Or use: http://youtu.be/YECGLRkuAs 4A urinary test procedure for identification of  cannabidiol in patients undergoing medical therapy  with marijuana Paul T Wertlake Michael D henson Pacific T oxicology laboratories,   chatsworth, ca, Usa correspondence: Paul T Wertlake   Pacific Toxicology Laboratories,   9348 De soto avenue, chatsworth,   ca 91311, Usa   email pwertlake@verizon.ne tAbstract:  Marijuana is classified by the Drug Enforcement Agency (DEA) as Schedule I,  drugs having no accepted medical value.",Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
"Available from:  http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugS afetyInformationforPatientsandProviders /UCM311290.pd f. Accessed  January 17, 2016.",Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/03/15/jpr-9-081.PMC4758796.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2016:7 73–80Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  73OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S9561 4Using consensus methods to develop a country- specific Master of Public Health curriculum for  the Republic of Maldives Monica C Robotin1,2 Muthau shaheem3 Aishath s ismail3 1Faculty of Medicine, School of Public  Health, University of Sydney, 2cancer  Programs Division, cancer council  new south Wales, sydney, Australia;   3Faculty of Health Sciences, Maldives  national University, Male, Maldives Correspondence: Monica C Robotin   Faculty of Medicine, School of Public  Health, University of Sydney,   room 324 Edward Ford Building A27,  camperdown, nsW 2006,   new south Wales, Australia   Email monica.robotin@sydney.edu.a uBackground:  Over the last four decades, the health status of Maldivian people improved consider - ably, as reflected in child and maternal mortality indicators and the eradication or control of many  communicable diseases.",Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
Or use: http://youtu.be/0YC3EjsRzR c,Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
"http://mdm.sagepub.com / An update on the MPH program will be presented in  poster format at the Population Health Congress (Hobart,  September 6–9, 2015).",Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
Available from: http://www.worldbank.org/projects/ P128268/maldives-clean-energy-climate-mitigation-project?lang =en.,Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/41/96/amep-7-073.PMC4758797.pdf
"The database of Genotypes and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap) accession number for the raw data from the ASD-affected families is phs0000267.v4.",OADS,/arxiv_data1/oa_pdf/ee/c9/mp2014150a.PMC4759095.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Association between CNVs and ASD phenotypes AK Merikangas et al 1372 Molecular Psychiatry (2015), 1366 –1372 © 2015 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/ee/c9/mp2014150a.PMC4759095.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Calcium-dependent intracellular signal pathways in bipolar disorder A Hayashi et al 940 Molecular Psychiatry (2015), 931 –940 © 2015 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/9d/50/mp2014104a.PMC4759096.pdf
"This variant is present with a minor allele frequencyaround 1% (G 4A) but the Exome Aggregation Consortium browser (http://exac.broadinstitute.org/) revealed that the variantis largely restricted to Latino populations and virtually non- existent in Asian, African or European populations.",Non-OADS,/arxiv_data1/oa_pdf/45/24/mp2015131a.PMC4759097.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Novel genetic modi ﬁers of Alzheimer ‘s age at onset MA Lalli et al 1300 Molecular Psychiatry (2015), 1294 –1300 © 2015 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/45/24/mp2015131a.PMC4759097.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Chronic GSM treatment effects are predicted by A β-PET M Brendel et al 1187 © 2015 Macmillan Publishers Limited Molecular Psychiatry (2015), 1179 –1187",Non-OADS,/arxiv_data1/oa_pdf/03/7e/mp201574a.PMC4759098.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)APOE ,BDNF and A βin preclinical AD YY Lim et al 1328 Molecular Psychiatry (2015), 1322 –1328 © 2015 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/44/2e/mp2014123a.PMC4759101.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)p75NTR ectodomain is protective against A β X-Q Yao et al 1310 Molecular Psychiatry (2015), 1301 –1310 © 2015 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/e9/33/mp201549a.PMC4759103.pdf
"For linkage, the location of each gene was obtainedthrough GeneCards (http://www.genecards.org), and the sexaveraged cM location of the start of the gene was then obtainedthrough http://compgen.rutgers.edu/mapinterpolator.",OADS,/arxiv_data1/oa_pdf/8b/59/mp2015112a.PMC4759104.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Understanding and predicting suicidality AB Niculescu et al 1285 © 2015 Macmillan Publishers Limited Molecular Psychiatry (2015), 1266 –1285",Non-OADS,/arxiv_data1/oa_pdf/8b/59/mp2015112a.PMC4759104.pdf
"We con ﬁrmed that the maximum beat runs of VT could be suppressed to only couplets of PVCs by a left stellate ganglion blockade using lidocaine as the local anesthesic, under the same dose of the ISPContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.07.002 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/a7/49/main.PMC4759116.pdf
Experimental evidence shows that atContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.08.005 1880-4276/ &2015 Japanese Heart Rhythm Society.,OADS,/arxiv_data1/oa_pdf/6b/45/main.PMC4759117.pdf
Quanti ﬁcation of myocardial T1 The Look-Locker images were analyzed utilizing an open source software program (MRMap version 1.3 [ http://mrmap.sourceforge.,OADS,/arxiv_data1/oa_pdf/6b/45/main.PMC4759117.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.joa.2015.08.005 .,OADS,/arxiv_data1/oa_pdf/6b/45/main.PMC4759117.pdf
"To avoid these complications, monitoring esophageal tem- perature is recommended during RF applications to the LA posteriorContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.07.003 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/a0/22/main.PMC4759118.pdf
Am J Cardiol 1985;56:3D –9D.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.09.005 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/51/b8/main.PMC4759119.pdf
"WCD pro ﬁles were set as follows: VT rate threshold,Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.08.003 1880-4276/ &2015 Japanese Heart Rhythm Society.",OADS,/arxiv_data1/oa_pdf/7f/25/main.PMC4759120.pdf
( http://jhrs.or.jp/pdf/ statement201505_01.pdf ) [in Japanese].J.,Non-OADS,/arxiv_data1/oa_pdf/7f/25/main.PMC4759120.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/52/f7/main.PMC4759121.pdf
"As a result, the patient not only met the diagnostic criteria for BrS but also met theContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.007 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/52/f7/main.PMC4759121.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/52/f7/main.PMC4759121.pdf
Ventricular dyssynchrony caused byContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.07.004 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/2a/38/main.PMC4759122.pdf
"Subjects The subjects were 70 patients with non-valvular atrial ﬁbrilla- tion, of whom 36 received rivaroxaban once daily and 34 receivedContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.08.001 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/10/c1/main.PMC4759124.pdf
http://dx.doi.org/10.1371/journal.pone.0113641 eCollection 2014.,Non-OADS,/arxiv_data1/oa_pdf/10/c1/main.PMC4759124.pdf
〈http://www.bayer-hv.jp/hv/ ﬁles/pdf.php/140311_XAR-14_gaiyo_201403.pdf?,Non-OADS,/arxiv_data1/oa_pdf/10/c1/main.PMC4759124.pdf
RxList: 〈http://www.rxlist.com/script/main/hp.asp 〉.K.,Non-OADS,/arxiv_data1/oa_pdf/10/c1/main.PMC4759124.pdf
"aCleveland Clinic, Cleveland, Ohio bCentre Hospitalier Universitaire Trousseau, Tours, France cWaikato Hospital, Hamilton, New Zealand dDepartment of Medicine, Cardiology Division, McMaster University-Population Health Research Institute, Hamilton, Canada eDuke University Medical Center, Durham, North Carolina fGrupo HM Hospitales, Universidad CEU San Pablo, Madrid, Spain gCentro Privado De Cardiologia, Tucuman, Argentina hJohns Hopkins University, Baltimore, Maryland iServicio de Arritmias, Instituto de Cardiologia Infantil, Montevideo, Uruguay jClinica y Maternidad Suizo ArgentinaContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.12.001 1880-4276/ &2016 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/48/19/main.PMC4759125.pdf
"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Abbreviations: aCRT, adaptive cardiac resynchronization therapy; AF, atrial ﬁbrillation; ATP, antitachycardia pacing; CI, con ﬁdence interval; CL, cycle length; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy –deﬁbrillator; DT, de ﬁbrillation testing; EEG, electroencephalography; EGM, electrogram; HF, heart failure; HR, hazard ratio; ICD, implantable cardioverter-de ﬁbrillator; LV, left ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MVP, managed ventricular pacing; NCDR, National Cardiovascular Data Registry; NYHA, New York Heart Association; OR, odds ratio; PEA, peak endocardial accelera tion; PVC, premature ventricular contraction; RCT, randomized clinical trial; RV, right ventricle; SCD, sudden cardiac death; S-ICD, subcutaneous implantable cardio verter-de ﬁbrillator; SVT, supraventricular tachycardia; TIA, transient ischemic attack; VF, ventricular ﬁbrillation; VT, ventricular tachycardia (Heart Rhythm 2015;0:1 –37) ☆Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Paci ﬁc Heart Rhythm Society (APHRS), and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electro ﬁsiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.",Non-OADS,/arxiv_data1/oa_pdf/48/19/main.PMC4759125.pdf
"E-mail addr ess: ese- nerth@hrsonline.org 1547-5271/$-see front matter B 2016 ‘Heart Rhythm Society, European Heart Rhythm Association, a registered branch of the European Society of Cardiology, the Asia Paciﬁc Heart Rhythm Society, and the Sociedad Latinoamericana de Estimulación Cardíaca y Electro ﬁsiología (SOLAECE) http://dx.doi.org/10.1016/j.hrthm.2015.11.018 Journal of Arrhythmia 32 (2016) 1 –28",Non-OADS,/arxiv_data1/oa_pdf/48/19/main.PMC4759125.pdf
"published online ( http://www.hrsonline.org/appendix-b ), contains the writing committee ’s translations speci ﬁc to each manufacturer and is intended to best approximate the recommended behaviors for each available ICD model.",Non-OADS,/arxiv_data1/oa_pdf/48/19/main.PMC4759125.pdf
2011; 〈http://www.medtronic.com/wcm/groups/ mdtcom_sg/@mdt/documents/documents/ ﬁdelis-phys-ltr-2011-04.pdf 〉.,OADS,/arxiv_data1/oa_pdf/48/19/main.PMC4759125.pdf
"In the frequency domain there was signi ﬁcant lowering in the LF region in the last 5 min before onset, while the HF wasContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.08.006 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/79/c6/main.PMC4759127.pdf
The PAF prediction challenge data base [online]; 2001 〈http://www.physionet.org/physiobank/database/afdb 〉.,OADS,/arxiv_data1/oa_pdf/79/c6/main.PMC4759127.pdf
[16] 〈http://www.physionet.org/physiotools/ 〉.,Non-OADS,/arxiv_data1/oa_pdf/79/c6/main.PMC4759127.pdf
"To view a copy of this license, visit  http://creativecommons.org/licenses/by-nc-nd/4.0/",Non-OADS,/arxiv_data1/oa_pdf/37/5c/ajg2015386a.PMC4759150.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/The stressed neuromatrix N Sousa 312 Molecular Psychiatry (2016), 302 –312 © 2016 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/3c/9f/mp2015196a.PMC4759204.pdf
"Psychiatry, 2008, 13(8), 772-785. http://dx.doi.org/10.1038/ sj.mp.4002088 [2] Sullivan, P.F.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 2000, 157(10), 1552-1562. http://dx.doi.org/10.1176/ appi.ajp.157.10.1552 [3] McGuffin, P .",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gen. Psychiatry, 2003, 60(5), 497-502. http://dx.doi.org/10.1001/ archpsyc.60.5.497 [4] McGuffin, P.; Katz, R. The genetics of depression and manic-depressive disorder.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 1989, 155, 294-304. http://dx.doi.org/10.1001/jama.289.23.3095 [5] Kessler, R.C.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"JAMA, 2003, 289(23), 3095-3105. http://dx.doi.org/10.1001/jama.289.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuropsychopharmacology, 2011, 36(2), 375-389. http://dx.doi.org/10.1038/npp.2010.192 [9] Fournier, J.C.; DeRubeis, R.J.; Hollon, S.D.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"JAMA, 2010, 303(1), 47-53. http://dx.doi.org/10.1001/jama.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Ther., 2014, 351(2), 448-456. http://dx.doi.org/ 10.1124/jpet.114.216804 [11] Furey, M.L.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gen. Psychiatry, 2006, 63(10), 1121-1129. http://dx.doi.org/10.1001/archpsyc.63.10.1121 [12] Drevets, W.C.; Furey, M.L.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Arch Gen Psychiatry, 2006, 63(7), 741-747. http://dx.doi.org/10.1001/ archpsyc.63.7.741 [14] Gibbons, A.S.; Scarr, E.; McLean, C.; Sundram, S.; Dean, B.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Disord., 2009, 116(3), 184-191. http://dx.doi.org/10.1016/j.jad.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Genet., 2004, 13(17), 1903-1911. http://dx.doi.org/10.1093/hmg/ddh194 [16] Janowsky, D.S.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Lancet, 1972, 2(7778), 632-635. http://dx.doi.org/10.1016/ S0140-6736(72)93021-8 [17] Dale, H.H.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychopharmacology (Berl), 2010, 212(1), 1-12. http://dx.doi.org/10.1007/s00213-010-1932-6 [19] Lewis, A.S.; Picciotto, M.R.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychopharmacology (Berl), 2013, 229(3), 477-485. http://dx.doi.org/10.1007/s00213-013-3126-5 [20] Bonner, T.I.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Science, 1987, 237(4814), 527-532. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Toxicol., 1990, 30, 633-673. http://dx.doi.org/10.1146/annurev.pa.30.040190.003221 [22] Felder, C.C.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Drug Targets, 2010, 9(2), 241-256. http://dx.doi.org/10.2174/187152710791012062 [24] Akins, P.T.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neurochem., 1990, 54(1), 266-273. http://dx.doi.org/10.1111/j.1471-4159.1990.tb13310.x [25] Berridge, M.J.; Irvine, R.F.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Nature, 1989, 341(6239), 197-205. http://dx.doi.org/ 10.1038/341197a0 [26] Meier, M.; King, G.L.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Med., 2000, 5(3), 173-185. http://dx.doi.org/10.1177/1358836X0000500307 [27] Litosch, I.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Commun., 2012, 417(3), 956-960. http://dx.doi.org/10.1016/j.bbrc.2011.12.037 [28] Strassheim, D.; Williams, C.L.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Chem., 2000, 275(50), 39767-39772. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Ther., 1993, 58(3), 319-379. http://dx.doi.org/10.1016/0163-7258(93)90027-B [30] Dittman, A.H.; Weber, J.P.; Hinds, T.R.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Biochemistry, 1994, 33(4), 943-951. http://dx.doi.org/10.1021/bi00170a013 [31] Hille, B. Modulation of ion-channel function by G-protein-coupled receptors.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Trends Neurosci., 1994, 17(12), 531-536. http://dx.doi.org/10.1016/0166-2236(94)90157-0 [32] Herlitze, S.; Garcia, D.E.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 2013, 47, 7-12. http://dx.doi.org/10.1016/j.pnpbp.2013.08.001 [34] Dean, B.; Crook, J.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Nature, 2013, 504(7478), 101-106. http://dx.doi.org/10.1038/nature12735 [36] Oki, T.; Takagi, Y .",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Brain Res., 2005, 133(1), 6-11. http://dx.doi.org/ 10.1016/j.molbrainres.2004.09.012 [37] Porter, A.C.; Bymaster, F.P.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Brain Res., 2002, 944(1-2), 82-89. http://dx.doi.org/10.1016/S0006-8993(02) 02721-X [38] Lai, M.K.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neurology, 2001, 57(5), 805-811. http://dx.doi.org/10.1212/WNL.57.5.805 [39] Dean, B.; Crook, J.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 2000, 5(2), 203-207. http://dx.doi.org/10.1038/sj.mp.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neurosci., 2002, 22(5), 1709-1717. http://dx.doi.org/10.1016/0304-3940(90)90064-G [42] Vilaro, M.T.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 1950, 13(1), 47-62. http://dx.doi.org/10.1136/jnnp.13.1.47 [45] Gershon, S.; Shaw, F.H.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Lancet, 1961, 1(7191), 1 3 7 1-1374. http://dx.doi.org/10.1016/S0140-6736(61)92004-9 [46] Joubert, J.; Joubert, P.H.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gen. Psychiatry, 1978, 35(1), 119-122. http://dx.doi.org/10.1001/archpsyc.1978.01770250121012 [48] Janowsky, D.S.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Lancet, 1972, 1(7762), 1236-1237. http://dx.doi.org/10.1016/S0140-6736(72)90956-7 [49] Fibiger, H.C.; Lytle, L.D.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychol., 1970, 72(3), 384-389. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry Res., 1999, 89(1), 1-20. http://dx.doi.org/10.1016/S0165-1781(99)00085-2 [51] Riemann, D.; Hohagen, F.; Bahro, M.; Lis, S.; Stadmuller, G.; Gann, H.; Berger, M. Cholinergic neurotransmission, REM sleep and depression.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Res., 1994, 38 Suppl 1, 15-25. http://dx.doi.org/10.1016/0022-3999(94)90132-5 [52] Gillin, J.C.; Sutton, L.; Ruiz, C.; Kelsoe, J.; Dupont, R.M.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gen. Psychiatry, 1991, 48(3), 264-270. http://dx.doi.org/10.1001/archpsyc.1991.01810270076011 [53] Riemann, D.; Hohagen, F.; Krieger, S.; Gann, H.; Muller, W.E.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Res., 1994, 28(3), 195-210. http://dx.doi.org/10.1016/0022-3956(94)90006-X [54] Sagales, T.; Erill, S.; Domino, E.F.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 1989, 25(4), 403-412. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 1991, 30(2), 157-169. http://dx.doi.org/10.1016/0006-3223(91)90170-Q [57] Daws, L.C.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Rev., 1993, 17(1), 51-68. http://dx.doi.org/10.1016/S0149-7634(05)80230-1 [59] Overstreet, D.H.; Russell, R.W.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychopharmacology (Berl), 1979, 65(1), 1 5-20. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Behav., 1982, 17(5), 885-891. http://dx.doi.org/10.1016/0091-3057(82) 90466-X [62] Overstreet, D.H.; Janowsky, D.S.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 1986, 21(7), 657-664. http://dx.doi.org/10.1016/0006-3223(86)90127-7 [63] Vaugeois, J.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"http://dx.doi.org/10.1016/ S0014-2999(96)00800-X [64] El Yacoubi, M.; Bouali, S.; Popa, D.; Naudon, L.; Leroux-Nicollet, I.; Hamon, M.; Costentin, J.; Adrien, J.; Vaugeois,  J.M.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"U. S. A., 2003, 100(10), 6227-6232. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuro- pharmacology, 1983, 22(10), 1215-1222. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuropsychopharmacology, 2006, 31(8), 1637-1646. http://dx.doi.org/10.1038/sj.npp.1300948 [67] Comings, D.E.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Genet., 2005, 14(16), 2421-2434. http://dx.doi.org/10.1093/hmg/ ddi244 [69] Cohen-Woods, S.; Gaysina, D.; Craddock, N.; Farmer, A.; Gray, J.; Gunasinghe, C.; Hoda, F.; Jones, L.; Knight, J.; Korszun, A.; Owen, M.J.; Sterne, A.; Craig, I.W.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Genet., 2009, 18(8), 1504-1509. http://dx.doi.org/10.1093/hmg/ddp051 [70] Shi, J.; Hattori, E.; Zou, H.; Badner, J.A.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Genet., 2007, 144B(6), 715-723. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Chem., 2012, 12(21), 2375-2392. http://dx.doi.org/10.2174/156802612805289935 [72] Carson, R.E.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Blood Flow Metab., 1998, 18(10), 1130-1142. http://dx.doi.org/10.1097/00004647-199810000-00010 [73] Cannon, D.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gene, 2001, 271(1), 87-92. http://dx.doi.org/10.1016/S0378-1119(01) 00494-2 [75] Krejci, A.; Bruce, A.W.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neurochem., 2004, 91(1), 88-98. http://dx.doi.org/10.1111/j.1471-4159.2004.02694.x [76] Dean, B.; McLeod, M.; Keriakous, D.; McKenzie, J.; Scarr, E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 2002, 7(10), 1083-1091. http://dx.doi.org/10.1038/sj.mp.4001199 [77] Zavitsanou, K.; Katsifis, A.; Yu, Y.; Huang, X.F.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Bull., 2005, 65(5), 397-403. http://dx.doi.org/10.1016/j.brainresbull.2005.02.007 [78] Zavitsanou, K.; Katsifis, A.; Mattner, F .",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"http://dx.doi.org/10.1038/sj.npp.1300367 [79] Messer, W.S., Jr.; Miller, M.D.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Lett., 1988, 89(3), 367-372. http://dx.doi.org/10.1016/0304-3940(88) 90554-X [80] Seeger, T.; Fedorova, I.; Zheng, F.; Miyakawa, T.; Koustova, E.; Gomeza, J.; Basile, A.S.; Alzheimer, C.; Wess, J. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neurosci., 2004, 24(45), 10117-10127. http://dx.doi.org/10.1523/JNEUROSCI.3581-04.2004 [81] Tzavara, E.T.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 2003, 8(7), 673-679. http://dx.doi.org/ 10.1038/sj.mp.4001270 [82] Austin, M.P.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 2001, 178, 200-206. http://dx.doi.org/10.1192/ bjp.178.3.200 [83] Burdick, K.E.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry Res., 2005, 136(1), 43-50. http://dx.doi.org/10.1016/j.psychres.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 2005, 186, 32-40. http://dx.doi.org/10.1192/bjp.186.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Bipolar Disord., 2005, 7(3), 216-235. http://dx.doi.org/10.1111/j.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuroscience, 2001, 104(3), 791-798. http://dx.doi.org/10.1016/S0306-4522(01)00133-6 [87] Mayberg, H.S.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry Res., 2006, 148(1), 23-31. http://dx.doi.org/10.1016/j.pscychresns.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Pharmacol., 1988, 158(1-2), 11-19. http://dx.doi.org/10.1016/ 0014-2999(88)90247-6 [91] Kasper, S.; Moises, H.W.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Pharmacopsychiatria, 1981, 14(6), 195-198. http://dx.doi.org/10.1055/s-2007-1019597 [92] Beckmann, H.; Moises, H.W.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Nervenkr., 1982, 231(3), 213-220. http://dx.doi.org/10.1007/ BF00343291 [93] Gillin, J.C.; Lauriello, J.; Kelsoe, J.R.; Rapaport, M.; Golshan, S.; Kenny, W.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry Res., 1995, 58(2), 99-105. http://dx.doi.org/10.1016/0165-1781(95)02700-7 [94] Newhouse, P.A.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Gen. Psychiatry, 1988, 45(10), 906-912. http://dx.doi.org/10.1001/ archpsyc.1988.01800340028004 [95] Montgomery, S.A.; Asberg, M. A new depression scale designed to be sensitive to change.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 1979, 134, 382-389. http://dx.doi.org/10.1192/bjp.134.4.382 [96] Hamilton, M. The assessment of anxiety states by rating.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychol., 1959, 32(1), 50-55. http://dx.doi.org/10.1111/j.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Disord., 1988, 14(1), 61-68. http://dx.doi.org/10.1016/0165-0327(88)90072-9 [98] Young, R.C.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"J. Psychiatry, 1978, 133, 429-435. http://dx.doi.org/10.1192/bjp.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuropsychopharmacology, 2010, 35(12), 2479-2488. http://dx.doi.org/10.1038/npp.2010.131 [100] Chau, D.; Rada, P.V.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Sci., 1999, 877, 769-774. http://dx.doi.org/10.1111/ j.1749-6632.1999.tb09320.x [101] Thomas, R.L.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Ther., 2009, 331(3), 1086-1095. http://dx.doi.org/10.1124/jpet.109.160242 [102] Wess, J .",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Pharmacol., 2014, 86(1), 116-123. http://dx.doi.org/ 10.1124/mol.114.091785 [104] May, L.T.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Ther., 2005, 312(1), 382-390. http://dx.doi.org/ 10.1124/jpet.104.073767 [105] Sheikh, J.I.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychiatry, 2007, 22(4), 356-360. http://dx.doi.org/10.1002/gps.1681 [107] Rada, P.; Colasante, C.; Skirzewski, M.; Hernandez, L.; Hoebel, B. Behavioral depression in the swim test causes a biphasic, long-lasting change in accumbens acetylcholine release, with partial compensation by acetylcholinesterase and muscarinic-1 receptors.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Neuroscience, 2006, 141(1), 67-76. http://dx.doi.org/ 10.1016/j.neuroscience.2006.03.043 [108] Gillman, P.K.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Pharmacol., 2007, 151(6), 737-748. http://dx.doi.org/10.1038/sj.bjp.0707253 [109] Mavissakalian, M.; Perel, J.; Guo, S. Specific side effects of long-term imipramine management of panic disorder.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Psychopharmacol., 2002, 22(2), 155-161. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Life Sci., 1993, 52(5-6), 441-448. http://dx.doi.org/10.1016/0024-3205(93) 90300-R [114] Stockwell, J.; Abdi, N.; Lu, X.; Maheshwari, O.; Taghibiglou, C. Novel central nervous system drug delivery systems.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Drug Des., 2014, 83(5), 507-520. http://dx.doi.org/10.1111/cbdd.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Ther., 2004, 104(1), 29-45. http://dx.doi.org/10.1016/j.pharmthera.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"NeuroRx., 2005, 2(1), 3-14. http://dx.doi.org/ 10.1602/neurorx.2.1.3 [117] Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S.P.",OADS,/arxiv_data1/oa_pdf/a1/7b/CN-13-739.PMC4759313.pdf
"Bull., 2010, 36, 359-369. http://dx.doi.org/10.1093/schbul/sbn094 [3] Blanchard, J.J.; Cohen, A .S .",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2006, 32, 238-245. http://dx.doi.org/10.1093/schbul/sbj013 [4] Barch, D.M.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2010, 36, 919-934. http://dx.doi.org/10.1093/ schbul/sbq068 [5] Germans, M.K.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Diff., 2000, 28, 659-672. http://dx.doi.org/10.1016/S0191-8869(99)00129-4 [6] Meehl, P.E.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2010, 36, 143-150. http://dx.doi.org/10.1093/schbul/sbn061 [9] Kring, A.M.; Moran, E.K.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2008, 34, 819-834. http://dx.doi.org/10.1093/schbul/sbn071 [10] Herbener, E.S.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Res., 2008, 98, 239-246. http://dx.doi.org/10.1016/j.schres.2007.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 2006, 115, 496-508. http://dx.doi.org/10.1037/0021-843X.115.3.496 [13] Gard, D.E.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Res., 2007, 93, 253-260. http://dx.doi.org/10.1016/j.schres.2007.03.008 [14] Strauss, G.P.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 2012, 169, 364-373. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 1976, 85, 374-382. http://dx.doi.org/10.1037/0021-843X.85.4.374 [16] Bleuler, E. Dementia Praecox or the Group of Schizophrenias.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 2000, 25, 54-67. http://dx.doi.org/10.1006/ceps.1999.1020 [18] Barch, D.M.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 2008, 117, 776-787. http://dx.doi.org/10.1037/a0013944 [19] Dickerson, F.B.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Res., 2005, 75, 405-416. http://dx.doi.org/10.1016/j.schres.2004.08.026 [20] Medalia, A.; Saperstein, A.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2010, 36, 949-956. http://dx.doi.org/10.1093/ schbul/sbp160 [22] Andreasen, N.C.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry Res., 1989, 30, 119-123. http://dx.doi.org/10.1016/0165-1781(89)90153-4 [24] Marin, R.S.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry Res., 1991, 38, 143-162. http://dx.doi.org/10.1016/0165-1781(91)90040-V [25] Fervaha, G.; Foussias, G.; Agid, O.; Remington, G. Neural substrates underlying effort computation in schizophrenia.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Rev., 2013, 37, 2649-2665. http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 2013, 170, 165-172. http://dx.doi.org/10.1176/appi.ajp.2012.12010109 [27] Chapman, L.J.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 1976, 85, 374-382. http://dx.doi.org/10.1037/0021-843X.85.4.374 [28] Llerena, K.; Park, S.G.; McCarthy, J.M.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry, 2013, 54, 568-574. http://dx.doi.org/10.1016/j.comppsych.2012.12.001 [29] Horan, W.P.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2006, 32, 259-273. http://dx.doi.org/10.1093/schbul/sbj009 [30] Treadway, M.T.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
http://dx.doi.org/10.1371/journal.pone.,Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Rev., 2011, 35, 537-555. http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 1994, 151, 1453-1462. http://dx.doi.org/10.1176/ajp.151.10.1453 [33] Sayers, S.L.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Assess., 1996, 8, 269-280. http://dx.doi.org/ 10.1037/1040-3590.8.3.269 [34] Berridge, K.C.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Trends Neurosci., 2003, 26, 507-513. http://dx.doi.org/10.1016/S0166-2236(03)00233-9 [35] Pecina, S.; Berridge, K.C.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2005, 25, 11777-11786. http://dx.doi.org/ 10.1523/JNEUROSCI.2329-05.2005",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2005, 25, 8637-8649. http://dx.doi.org/10.1523/ JNEUROSCI.1902-05.2005 [37] Mahler, S.V.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuro- psychopharmacology, 2007, 32, 2267-2278. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Rev., 2002, 26, 321-352. http://dx.doi.org/10.1023/A:1022823221146 [39] van Wingerden, M., Vinck, M.; Lankelma, J.; Pennartz, C.M.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2010, 30, 7078-7087. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuroimage, 2005, 25, 607-615. http://dx.doi.org/10.1016/j.neuroimage.2004.12.055 [42] Gradin, V.B.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Brain, 2011, 134, 1751-1764. http://dx.doi.org/10.1093/brain/awr059 [43] Herbener, E.S.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2008, 34, 875-887. http://dx.doi.org/10.1093/schbul/sbn081 [44] Waltz, J.A.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry Res., 2012, 203, 46-53. http://dx.doi.org/10.1016/j.pscychresns.2011.09.004 [46] Pelizza, L.; Ferrari, A. Anhedonia in schizophrenia and major depression: state or trait?",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Gen. Psychiatry, 2009, 8, 22. http://dx.doi.org/10.1186/1744-859X-8-22 [47] Porter, J.H.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Behav., 1988, 31, 779-786. http://dx.doi.org/10.1016/0091-3057 (88)90383-8 [48] Kring, A .",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Sci., 2010, 19, 255-259. http://dx.doi.org/10.1177/0963721410377599 [49] Sherdell, L.; Waugh, C.E.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychol., 2012, 121, 51-60. http://dx.doi.org/10.1037/a0024945 [50] Haber, S.N.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Rev., 2002, 26, 631-664. http://dx.doi.org/10.1016/S0149-7634(02)00021-0 [52] Heimer, L. A new anatomical framework for neuropsychiatric disorders and drug abuse.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 2003, 160, 1726-1739. http://dx.doi.org/10.1176/appi.ajp.160.10.1726 [53] Chau, D.T.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry Rep., 2004, 6, 391-399. http://dx.doi.org/10.1007/s11920-004-0026-8 [54] Dowd, E.C.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Res., 2010, 44, 707-716. http://dx.doi.org/10.1016/j.jpsychires.2009.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuroimage, 2009, 46, 1148-1153. http://dx.doi.org/ 10.1016/j.neuroimage.2009.03.038 [57] Stice, E.; Spoor, S.; Ng, J.; Zald, D.H.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Behav., 2009, 97, 551-560. http://dx.doi.org/10.1016/j.physbeh.2009.03.020 [58] Kelley, A.E.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Rev., 2004, 27, 765-776. http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 2002, 159, 1642-1652. http://dx.doi.org/10.1176/appi.ajp.159.10.1642 [60] Wolf, D.H.; Satterthwaite, T.D.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuroimage, 2008, 41, 1504-1513. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2005, 6, 533-544. http://dx.doi.org/10.1038/nrn1704 [64] Choi, S.H.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry, 2014, 15, 525-533. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"J. Psychiatry, 2005, 187, 481-482. http://dx.doi.org/10.1192/bjp.187.5.481 [67] Plailly, J.; d'Amato, T.; Saoud, M.; Royet, J.P. Left temporo-limbic and orbital dysfunction in schizophrenia during odor familiarity and hedonicity judgments.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuroimage, 2006, 29, 302-313. http://dx.doi.org/10.1016/j.neuroimage.2005.06.056 [68] Rolls, E.T.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2003, 18, 695-703. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Mem., 2008, 90, 475-478. http://dx.doi.org/10.1016/j.nlm.2008.06.001 [70] Takeuchi, H.; Taki, Y.; Nouchi, R.; Sekiguchi, A.; Kotozaki, Y.; Miyauchi, C.M.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Funct., 2014, 219, 71-83. http://dx.doi.org/10.1007/s00429-012-0485-3 [71] Raichle, M.E.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"U S A, 2001, 98, 676-682. http://dx.doi.org/ 10.1073/pnas.98.2.676 [72] Dowd, E.C.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"http://dx.doi.org/10.1371/journal.pone.0035622 [73] Park, I.H.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry Res., 2009, 171, 155-165. http://dx.doi.org/10.1016/j.pscychresns.2008.03.010",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Lett., 2011, 489, 110-114. http://dx.doi.org/10.1016/j.neulet.2010.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Lett., 2014, 579, 7-11. http://dx.doi.org/ 10.1016/j.neulet.2014.07.001 [76] Buckner, R.L.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Sci., 2008, 1124, 1-38. http://dx.doi.org/10.1196/ annals.1440.011 [77] Sass, L.A.; Parnas, J. Schizophrenia, consciousness, and the self.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Bull., 2003, 29, 427-444. http://dx.doi.org/10.1093/ oxfordjournals.schbul.a007017 [78] Ostby, Y.; Walhovd, K.B.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"U.S.A., 2012, 109, 16800-16804. http://dx.doi.org/10.1073/ pnas.1210627109 [79] Wise, R.A. Dopamine, learning and motivation.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2004, 5, 1-12. http://dx.doi.org/10.1038/nrn1406 [80] Wise, R.A.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Trends Neurosci., 2009, 32, 517-524. http://dx.doi.org/10.1016/j.tins.2009.06.004 [81] O'Doherty, J.; Dayan, P.; Schultz, J.; Deichmann, R.; Friston, K.; Dolan, R.J. Dissociable roles of ventral and dorsal striatum in instrumental conditioning.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2002, 5, 97-98. http://dx.doi.org/10.1038/nn802 [83] Fiorillo, C.D.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Brain Funct., 2005, 1, 7. http://dx.doi.org/10.1186/1744-9081-1-7 [84] Preuschoff, K.; Quartz, S.R.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neurosci., 2008, 28, 2745-2752. http://dx.doi.org/10.1523/JNEUROSCI.4286-07.2008 [85] Koch, K.; Schachtzabel, C.; Wagner, G.; Schikora, J.; Schultz, C.; Reichenbach, J.R.; Sauer, H.; Schlösser, R.G.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuroimage, 2010, 50, 223-232. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Neuropsychopharmacology, 2009, 34, 1567-1577. http://dx.doi.org/10.1038/npp.2008.214 [87] Murray, G.K.; Corlett, P.R.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Psychiatry, 2008, 13, 267-276. http://dx.doi.org/10.1038/sj.mp.4002058 [88] Park, I.H.",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"Res., 2015, 161, 229-236. http://dx.doi.org/10.1016/j.schres.2014.11.005   Received: January 03, 2015 Revised: February 05, 2015 Accepted: February 25, 2015",Non-OADS,/arxiv_data1/oa_pdf/52/19/CN-13-750.PMC4759314.pdf
"http://dx.doi.org/10.1371/journal.pmed.1001547 [2] Ferrari, A.J.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Med., 2006, 354(12), 1231-1242. http://dx.doi.org/10.1056/NEJMoa052963 [4] Gaoni, Y.; Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Soc., 1964, 86(8), 1646-1647. http://dx.doi.org/10.1021/ja01062a046 [5] Moreira, F.A.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Metab., 2009, 23(1), 133-144. http://dx.doi.org/10.1016/j.beem.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Drug Discov., 2008, 7(5), 438-455. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Med., 2003, 9(1), 76-81. http://dx.doi.org/10.1038/nm803 [8] Piomelli, D.; Tarzia, G.; Duranti, A.; Tontini, A.; Mor, M.; Compton, T.R.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"CNS Drug Rev., 2006, 12(1), 21-38. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2014, 171(6), 1392-1407. http://dx.doi.org/10.1111/bph.12298 [10] Burston, J.J.; Sim-Selley, L.J.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2008, 327(2), 546-553. http://dx.doi.org/10.1124/jpet.108.141382 [11] Devane, W.A.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Nature, 1990, 346(6284), 561-564. http://dx.doi.org/10.1038/346561a0 [13] Munro, S.; Thomas, K.L.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Nature, 1993, 365(6441), 61-65. http://dx.doi.org/10.1038/365061a0 [14] Devane, W.A.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Science, 1992, 258(5090), 1946-1949. http://dx.doi.org/10.1126/science.1470919 [15] Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Commun., 1995, 215(1), 89-97. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 1995, 50(1), 83-90. http://dx.doi.org/10.1016/0006-2952(95)00109-D [17] Sugiura, T.; Kondo, S.; Sukagawa, A.; Tonegawa, T.; Nakane, S.; Yamashita, A.; Ishima, Y.; Waku, K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 1996, 240(1), 53-62. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Fatty Acids, 2002, 66(2-3), 173-192. http://dx.doi.org/10.1054/plef.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuron, 1994, 13(6), 1447http://dx.doi.org/10.1016/0896-6273(94)90430-8-1455.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuron, 2001, 29(3), 717-727. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuron, 2001, 29(3), 729-738. http://dx.doi.org/10.1016/S0896-6273(01)00247-1 [23] Wilson, R.I.; Nicoll, R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Nature, 2001, 410(6828), 588-592. http://dx.doi.org/10.1038/35069076 [24] Kano, M.; Ohno-Shosaku, T.; Hashimotodani, Y.; Uchigashima, M.; Watanabe, M. Endocannabinoid-mediated control o f  s y n a p t i c  transmission.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Rev., 2009, 89(1), 309-380. http://dx.doi.org/ 10.1152/physrev.00019.2008 [25] Sugiura, T.; Waku, K. Cannabinoid receptors and their endogenous ligands.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 2002, 132(1), 7-12. http://dx.doi.org/10.1093/ oxfordjournals.jbchem.a003200 [26] Grotenhermen, F. Pharmacology of cannabinoids.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Synapse, 2004, 53(4), 208-213. http://dx.doi.org/10.1002/syn.20050 [28] Zhang, H.Y.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Aging, 2013, 34(3), 791-804. http://dx.doi.org/10.1016/j.neurobiolaging.2012.06.011 [30] Zarruk, J.G.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Stroke, 2012, 43(1), 211-219. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2012, 166(8), 2371-2385. http://dx.doi.org/10.1111/ j.1476-5381.2012.01948.x [32] Zoppi, S.; Madrigal, J.L.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2014, 171(11), 2814-2826. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Cell Immunol., 2014, 287(1), 1-17. http://dx.doi.org/10.1016/j.cellimm.2013.11.002 [34] Schmöle, A.C.; Lundt, R.; Ternes, S.; Albayram, O.; Ulas, T.; Schultze, J.L.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Aging, 2014, 36(2), 710-719. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2000, 275(1), 605-612. http://dx.doi.org/10.1074/jbc.275.1.605 [37] Di Marzo, V.; De Petrocellis, L. Why do cannabinoid receptors have more than one endogenous ligand?",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pain, 2006, 124(1-2), 175-183. http://dx.doi.org/10.1016/j.pain.2006.04.001 [39] Zygmunt, P.M.; Ermund, A.; Movahed, P.; Andersson, D.A.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"http://dx.doi.org/ 10.1371/journal.pone.0081618 [40] Deutsch, D.G.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 1993, 46(5), 791-796. http://dx.doi.org/10.1016/0006-2952(93) 90486-G [41] Wei, B.Q.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2006, 281(48), 36569-36578. http://dx.doi.org/10.1074/jbc.M606646200 [42] Blankman, J.L.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2007, 14(12), 1347-1356. http://dx.doi.org/10.1016/j.chembiol.2007.11.006 [43] Karlsson, M.; Contreras, J.A.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 1997, 272(43), 27218-27223. http://dx.doi.org/10.1074/jbc.272.43.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2007, 152(5), 734-743. http://dx.doi.org/10.1038/sj.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2005, 517(3), 174-181. http://dx.doi.org/10.1016/ j.ejphar.2005.05.032 [46] O'Sullivan, S.E.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2007, 152(5), 576-582. http://dx.doi.org/10.1038/sj.bjp.0707423 [47] O'Sullivan, S.E.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Immunobiology, 2010, 215(8), 611-616. http://dx.doi.org/10.1016/j.imbio.2009.09.007 [48] Hungund, B.L.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2004, 9(2), 184-190. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychoneuroendocrinology, 2009, 34(8), 1257-1262. http://dx.doi.org/10.1016/j.psyneuen.2009.03.013 [50] Hill, M.N.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacopsychiatry, 2008, 41(2), 48-53. http://dx.doi.org/10.1055/s-2007-993211 [51] Ogawa, S.; Hattori, K.; Sasayama, D.; Yokota, Y.; Matsumura, R.; Matsuo, J.; Ota, M.; Hori, H.; Teraishi, T.; Yoshida, S.; Noda, T.; Ohashi, Y.; Sato, H.; Higuchi, T.; Motohashi, N.; Kunugi, H. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Rep., 2015, 5, 7796. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2013, 18(10), 1125-1135. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2013, 18(7), 813-823. http://dx.doi.org/ 10.1038/mp.2012.72 [54] Chiang, K .",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Genet., 2004, 13(18), 2113-2119. http://dx.doi.org/10.1093/hmg/ddh216 [55] Ho, W.S.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lipids Health Dis., 2012, 11, 32. http://dx.doi.org/10.1186/1476-511X-11-32 [56] Giuffrida, A.; Leweke, F.M.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsycho- pharmacology, 2004, 29(11), 2108-2114. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Res., 2013, 47(3), 401-406. http://dx.doi.org/10.1016/ j.jpsychires.2012.12.001 [58] Hiles, S.A.; Baker, A.L.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Immun., 2012, 26(7), 1180-1188. http://dx.doi.org/10.1016/ j.bbi.2012.06.001 [59] Liu, Y .",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Affect Disord., 2012, 139(3), 230-239. http://dx.doi.org/10.1016/j.jad.2011.08.003 [60] Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2010, 67(5), 446-457. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsychopharmacology, 2011, 36(12), 2452-2459. http://dx.doi.org/10.1038/npp.2011.132 [62] Ogawa, S.; Fujii, T.; Koga, N.; Hori, H.; Teraishi, T.; Hattori, K.; Noda, T.; Higuchi, T.; Motohashi, N.; Kunugi, H. Plasma L-tryptophan concentration in major depressive disorder: new data and meta-analysis.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"http://dx.doi.org/10.4088/JCP.13r08908 [63] Schwarcz, R.; Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2002, 303(1), 1-10. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Sci., 2012, 8(9), 1254-1266. http://dx.doi.org/10.7150/ijbs.4679 [66] Yang, L.; Li, F.F.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Res., 2013, 3(1), 44-51. http://dx.doi.org/10.4236/ojst.2013.31009 [68] Warner, T.D.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Dis., 1999, 6(1), 15-34. http://dx.doi.org/10.1096/fj.03-0645rev [70] Muller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Muller, B .",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2006, 11(7), 680-684. http://dx.doi.org/10.1038/sj.mp.4001805 [71] Faridhosseini, F.; Sadeghi, R.; Farid, L.; Pourgholami, M. Celecoxib: a new augmentation strategy for depressive mood episodes.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychopharmacol., 2014, 29(3), 216-223. http://dx.doi.org/10.1002/hup.2401 [72] Kurhe, Y.; Mahesh, R.; Gupta, D. Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Res., 2014, 39(7), 1395-1402. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Transm., 2014, 121(6), 671-682. http://dx.doi.org/10.1007/s00702-014-1159-5 [74] Kunugi, H.; Ida, I.; Owashi, T.; Kimura, M.; Inoue, Y.; Nakagawa, S.; Yabana, T.; Urushibara, T.; Kanai, R.; Aihara, M.; Yuuki, N.; Otsubo, T.; Oshima, A.; Kudo, K.; Inoue, T.; Kitaichi, Y.; Shirakawa, O.; Isogawa, K.; Nagayama, H.; Kamijima, K.; Nanko, S.; Kanba, S.; Higuchi, T.; Mikuni, M. Assessment of the dexamethasone/ CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Behav., 2003, 43(1), 60-66. http://dx.doi.org/10.1016/S0018-506X(02) 00016-8 [76] Sasayama, D.; Hori, H.; Iijima, Y.; Teraishi, T.; Hattori, K.; Ota, M.; Fujii, T.; Higuchi, T.; Amano, N.; Kunugi, H. Modulation of cortisol responses to the DEX/CRH test by polymorphisms of the interleukin-1beta gene in healthy adults.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Brain Funct., 2011, 7, 23. http://dx.doi.org/10.1186/1744-9081-7-23 [77] Hill, M.N.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsychopharmacology, 2009, 34(13), 2733-2745. http://dx.doi.org/10.1038/npp.2009.114 [78] Ruginsk, S.G.; Uchoa, E.T.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Physiol., 2013, 40(10), 698-705. http://dx.doi.org/10.1111/1440-1681.12155 [79] Bedse, G.; Colangeli, R.; Lavecchia, A.M.; Romano, A.; Altieri, F.; Cifani, C.; Cassano, T.; Gaetani, S. Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuro- psychopharmacol., 2014, 24(9), 1511-1523. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Behav., 2014, 117, 17-24. http://dx.doi.org/10.1016/ j.pbb.2013.11.026 [81] Kerr, D.M.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuroscience, 2012, 204, 53-63. http://dx.doi.org/10.1016/j.neuroscience.2011.09.032 [82] Hill, M.N.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"U S A, 2010, 107(20), 9406-9411. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"FEBS Lett., 2003, 536(1-3), 157-160. http://dx.doi.org/10.1016/S0014-5793(03)00048-6 [84] Aliczki, M.; Zelena, D.; Mikics, E.; Varga, Z.K.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Behav., 2013, 63(5), 752-758. http://dx.doi.org/10.1016/j.yhbeh.2013.03.017 [85] Long, J.Z.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2009, 16(7), 744-753. http://dx.doi.org/10.1016/j.chembiol.2009.05.009 [86] Wiebelhaus, J.M.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2015, 352(2), 195-207. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2014, 21(24), 2803-2821. http://dx.doi.org/10.2174/0929867321666140303143455 [88] Klimek, V.; Schenck, J.E.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2002, 52(7), 740-748. http://dx.doi.org/10.1016/S0006-3223(02)01383-5 [89] Reddy, P.L.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 1992, 31(2), 112-118. http://dx.doi.org/10.1016/0006-3223(92) 90198-9 [90] Serra, G.; Forgione, A.; D ' A q u i l a ,  P .",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"http://dx.doi.org/10.1097/00002826-199001001-00009 [91] Carpenter, L.L.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychopharmacology (Berl), 1977, 53(3), 309-314. http://dx.doi.org/10.1007/BF00492370 [95] Tanda, G.; Carboni, E.; Frau, R.; Di Chiara, G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychopharmacology (Berl), 1994, 115(1-2), 285-288. http://dx.doi.org/10.1007/BF02244785 [96] Djordjevic, J.; Djordjevic, A.; Adzic, M.; Radojcic, M.B.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsychobiology, 2012, 66(2), 112-119. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuroscience, 2013, 235, 40-50. http://dx.doi.org/10.1016/j.neuroscience.2013.01.021 [98] Chiba, S.; Numakawa, T.; Ninomiya, M.; Yoon, H.S.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychopharmacology (Berl), 2010, 211(3), 291-301. http://dx.doi.org/10.1007/s00213-010-1894-8",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2007, 562(1-2), 82-91. http://dx.doi.org/10.1016/j.ejphar.2007.01.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"http://dx.doi.org/10.1371/journal.pone.0020766 [102] Nader, J.; Rapino, C.; Gennequin, B.; Chavant, F.; Francheteau, M.; Makriyannis, A.; Duranti, A.; Maccarrone, M.; Solinas, M.; Thiriet, N. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropharmacology, 2014, 87, 214-221. http://dx.doi.org/10.1016/j.neuropharm.2014.03.014 [103] Dazzi, L.; Talani, G.; Biggio, F.; Utzeri, C.; Lallai, V.; Licheri, V.; Lutzu, S.; Mostallino, M.C.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"http://dx.doi.org/ 10.1371/journal.pone.0092224 [104] Vinod, K.Y.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry, 2007, 62(10), 1103-1110. http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Hippocampus, 2014, 25(1), 16-26. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsychopharmacology, 2014, 39(7), 1763-1776. http://dx.doi.org/10.1038/npp.2014.24 [109] Naidu, P.S.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychopharmacology (Berl), 2007, 192(1), 61-70. http://dx.doi.org/10.1007/s00213-006-0689-4 [110] Lomazzo, E.; Bindila, L.; Remmers, F.; Lerner, R.; Schwitter,  C.; Hoheisel, U.; Lutz, B.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropsychopharmacology, 2014, 40(2), 488-501. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2010, 10(8), 828-858. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2002, 179(1), 57-63. http://dx.doi.org/10.1006/taap.2001.9342 [114] Holtfrerich, A.; Hanekamp, W.; Lehr, M. (4-Phenoxyphenyl) tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2013, 63, 64-75. http://dx.doi.org/ 10.1016/j.ejmech.2013.01.050 [115] Ortar, G.; Cascio, M.G.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2008, 43(1), 62-72. http://dx.doi.org/10.1016/j.ejmech.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2013, 63, 118-132. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2008, 51(12), 3487-3498. http://dx.doi.org/10.1021/ jm701631z [118] Zvonok, N.; Pandarinathan, L.; Williams, J.; Johnston, M.; Karageorgos, I.; Janero, D.R.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2008, 15(8), 854-862. http://dx.doi.org/10.1016/j.chembiol.2008.06.008 [119] Moreno-Sanz, G.; Sasso, O.; Guijarro, A.; Oluyemi, O.; Bertorelli, R.; Reggiani, A.; Piomelli, D. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2012, 167(8), 1620-1628. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2004, 311(2), 441-448. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2010, 17(11), 1256-1266. http://dx.doi.org/10.1016/j.chembiol.2010.08.013 [124] Deutsch, D.G.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Commun., 1997, 231(1), 217-221. http://dx.doi.org/10.1006/bbrc.1997.6072 [125] Dinh, T.P.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lipids, 2002, 121(1-2), 149-158. http://dx.doi.org/10.1016/S0009-3084(02)00150-0 [126] Dinh, T.P.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"U.S.A., 2002, 99(16), 10819-10824. http://dx.doi.org/10.1073/ pnas.152334899",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2004, 67(7), 1381-1387. http://dx.doi.org/ 10.1016/j.bcp.2003.12.003 [128] Naidoo, V.; Karanian, D.A.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neurotherapeutics, 2012, 9(4), 801-813. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochemistry, 2013, 52(29), 5016-5026. http://dx.doi.org/10.1021/bi400430k [130] West, J.M.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biotechnol., 2003, 21(6), 687-691. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2013, 56(21), 8484-8496. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2006, 316(3), 1088-1097. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 2008, 9(16), 2704-2710. http://dx.doi.org/ 10.1002/cbic.200800428 [136] Minkkila, A.; Savinainen, J.R.; Kasnanen, H.; Xhaard, H.; Nevalainen, T.; Laitinen, J.T.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2009, 4(8), 1253-1259. http://dx.doi.org/10.1002/cmdc.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 2010, 399(1), 132-134. http://dx.doi.org/10.1016/ j.ab.2009.12.009 [139] Nomura, D.K.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2008, 4(6), 373-378. http://dx.doi.org/10.1038/ nchembio.86 [140] Aaltonen, N.; Savinainen, J.R.; Ribas, C.R.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2013, 20(3), 379-390. http://dx.doi.org/10.1016/j.chembiol.2013.01.012 [141] Nomura, D.K.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lett., 2008, 18(22), 5875-5878. http://dx.doi.org/10.1016/j.bmcl.2008.08.007 [142] Karbarz, M.J.; Luo, L.; Chang, L.; Tham, C.S.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Analg., 2009, 108(1), 316-329. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lett., 2008, 18(17), 4838-4843. http://dx.doi.org/10.1016/j.bmcl.2008.07.081 [144] Keith, J.M.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lett., 2012, 3(10), 823-827. http://dx.doi.org/10.1021/ml300186g [145] Chang, J.W.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2012, 19(5), 579-588. http://dx.doi.org/10.1016/j.chembiol.2012.03.009 [146] Chang, J.W.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2013, 8(7), 1590-1599. http://dx.doi.org/10.1021/cb400261h [147] Long, J.Z.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2009, 5(1), 37-44. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2010, 53(4), 1830-1842. http://dx.doi.org/10.1021/jm9016976 [149] Morera, L.; Labar, G.; Ortar, G.; Lambert, D.M.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2012, 20(21), 6260-6275. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neuropharmacology, 2015, 91, 148-156. http://dx.doi.org/10.1016/j.neuropharm.2014.12.001 [152] Moore, S.A.; Nomikos, G.G.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Soc., 2006, 128(30), 9699-9704. http://dx.doi.org/10.1021/ja062999h [154] Dickason-Chesterfield, A.K.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neurobiol., 2006, 26(4-6), 407-423. http://dx.doi.org/10.1007/s10571-006-9072-6 [155] Matuszak, N.; Muccioli, G.G.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2009, 52(23), 7410-7420. http://dx.doi.org/10.1021/jm900461w [156] De Petrocellis, L.; Melck, D.; Ueda, N.; Maurelli, S.; Kurahashi, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 1999, 57(4), 417-423. http://dx.doi.org/10.1016/S0006-2952(98) 00314-1 [159] Quistad, G.B.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2001, 173(1), 48-55. http://dx.doi.org/ 10.1006/taap.2001.9175 [160] Holtfrerich, A.; Makharadze, T.; Lehr, M. High-performance  liquid chromatography assay with fluorescence detection for  the evaluation of inhibitors against human recombinant monoacylglycerol lipase.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 2010, 399(2), 218-224. http://dx.doi.org/10.1016/j.ab.2009.12.015 [161] Niphakis, M.J.; Cognetta, A.B., 3rd; Chang, J.W.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neurosci., 2013, 4(9), 1322-1332. http://dx.doi.org/10.1021/cn400116z [162] Saario, S.M.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2005, 12(6), 649-656. http://dx.doi.org/10.1016/j.chembiol.2005.04.013 [163] King, A.R.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2009, 157(6), 974-983. http://dx.doi.org/10.1111/j.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2005, 48(6), 1849-1856. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochemistry, 2007, 46(45), 13019-13030. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Pharmacol., 2011, 667(1-3), 74-79. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Lett., 2011, 2(2), 91-96. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2011, 338(1), 114-124. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neurosci., 2012, 3(5), 418-426. http://dx.doi.org/10.1021/cn200089j [171] Ahn, K.; Johnson, D.S.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2009, 16(4), 411-420. http://dx.doi.org/10.1016/j.chembiol.2009.02.013 [172] Gattinoni, S.; De Simone, C.; Dallavalle, S.; Fezza, F.; Nannei, R.; Amadio, D.; Minetti, P.; Quattrociocchi, G.; Caprioli, A.; Borsini, F.; Cabri, W.; Penco, S.; Merlini, L.; Maccarrone, M. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2010, 5(3), 357-360. http://dx.doi.org/10.1002/cmdc.200900472 [173] Caprioli, A.; Coccurello, R.; Rapino, C.; Di Serio, S.; Di Tommaso, M.; Vertechy, M.; Vacca, V.; Battista, N.; Pavone, F.; Maccarrone, M.; Borsini, F. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Ther., 2012, 342(1), 188-195. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biol., 2005, 12(11), 1179-1187. http://dx.doi.org/10.1016/j.chembiol.2005.08.011 [175] Ramarao, M.K.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Biochem., 2005, 343(1), 143-151. http://dx.doi.org/10.1016/j.ab.2005.04.032 [176] Zhang, D.; Saraf, A.; Kolasa, T.; Bhatia, P.; Zheng, G.Z.",OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Chem., 2009, 4(9), 1505-1513. http://dx.doi.org/10.1002/cmdc.200900210 [178] Clapper, J.R.; Moreno-Sanz, G.; Russo, R.; Guijarro, A.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Sciolino, N.R.",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Neurosci., 2010, 13(10), 1265-1270. http://dx.doi.org/10.1038/nn.2632   Received: June 28, 2015 Revised: November 02, 2015 Accepted: November 04, 2015",Non-OADS,/arxiv_data1/oa_pdf/88/85/CN-13-760.PMC4759315.pdf
"Psychiatry., 2005, 186, 275-277. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Chem., 2007, 7(3), 311-340. http://dx.doi.org/10.2174/156802607779941314 [7] Yin, H.; Zhou, Y.; Zhu, M.; Hou, S.; Li, Z.; Zhong, H.; L u ,  J .",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Chem., 2010, 17(25):2746-2763. http://dx.doi.org/10.2174/092986710791859289 [9] Huber, C.; Marschallinger, J.; Tempfer, H.; Furtner, T.; Couillard-Despres, S.; Bauer, H.C.; Rivera, F.J.; Aigner, L. Inhibition of leukotriene receptors boosts neural progenitor proliferation.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurosci., 2007, 2 7(38), 10116-101127. http://dx.doi.org/10.1523/JNEUROSCI.2368-07.2007 [17] Cahill-Smith, S .",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Pharmacol., 2014, 78(3), 441-453. http://dx.doi.org/10.1111/bcp.12357 [18] James, S.J.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Organogenesis, 2008, 4(2), 68-75. http://dx.doi.org/10.4161/org.4.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Chem., 2010, 17(25), 2746-2763. http://dx.doi.org/10.2174/092986710791859289 [26] Su, L.D.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Brain Res., 1995, 685(1-2), 201-204. http://dx.doi.org/ 10.1016/0006-8993(95)00490-H [28] Singh, D.P.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Res., 2000, 6(4), 307-311. http://dx.doi.org/10.1177/09680519000060040601 [31] Clasadonte, J .",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurosci., 2006, 26(16), 4383-4393. http://dx.doi.org/10.1523/JNEUROSCI.4531-05.2006 [33] Law, M.H.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"CNS Drugs, 2005, 19(10), 805-819. http://dx.doi.org/10.2165/00023210-200519100-00001 [36] Müller, N.; Schwarz, M.J.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Rev., 2010, 6(3), 213-220. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Chem., 2 0 1 3, 9(6), 763-773. http://dx.doi.org/10.2174/1573406411309060002 [40] Müller, N.; Ulmschneider, M.; ,Scheppach, C.; Schwarz, M.J.; Ackenheil, M.; Möller, H.J.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurosci., 2005, 255(2), 149-151. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Res., 2007, 90(1-3), 179-85. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neuropsychopharmacol., 2006, 9(3), 343-348. http://dx.doi.org/10.1017/S1461145705005808 [50] Martínez-Gras, I.; Pérez-Nievas, B.G.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Science, 2002, 298 (5594), 789-791. http://dx.doi.org/10.1126/science.1074069 [60] Hsieh, H.L.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Des., 2 0 0 8 ,  14(14), 1419-1427. http://dx.doi.org/10.2174/138161208784480171 [62] Aïd, S.; Bosetti, F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neuroscience, 2006, 141(3), 1149-1146. http://dx.doi.org/10.1016/j.neuroscience.2006.05.001 [64] Cakała, M.; Malik, A .",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Disord., 2007, 23(1), 8-21. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurology, 2004, 62(1), 66-71. http://dx.doi.org/10.1212/WNL.62.1.66 [69] Thal, L.J.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neuropsychopharmacology, 2005, 30(6), 1204-1215. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Cortex, 2005, 15(8), 1250-1260. http://dx.doi.org/10.1093/cercor/bhi008 [73] García-Bueno, B.; Serrats, J.; Sawchenko, P.E.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurosci., 2005, 6(5), 351-362. http://dx.doi.org/10.1038/nrn1665 [76] Wong, C.T.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Fatty Acids, 2002, 67, 341-343. http://dx.doi.org/10.1054/plef.2002.0439 [80] Söğüt, S.; Zoroğlu, S.S.; Ozyurt, H.; Yilmaz, H.R.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Acta, 2003, 3 3 1(1-2), 111-117. http://dx.doi.org/10.1016/S0009-8981(03)00119-0 [81] Zoroglu, S.S.; Armutcu, F.; Ozen, S.; Gurel, A.; Sivasli, E.; Yetkin, O.; Meram, I.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neurosci., 2004, 254(3), 143-147. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Res., 2011, 143(1), 58-65. http://dx.doi.org/10.1007/s12011-010-8840-9 [83] Parellada, M.; Moreno, C.; Mac-Dowell, K.; Leza, J.C.; Giraldez, M.; Bailón, C.; Castro, C.; Miranda-Azpiazu, P.; Fraguas, D.; Arango, C. P l a s m a  a n t i o x i d a n t  c a p a c i t y  i s  r e d u c e d  i n  A s p e r g e r  syndrome.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Res., 2012, 46(3), 394-401. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Life Sci., 2004, 75(21), 2539-2549. http://dx.doi.org/10.1016/j.lfs.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Toxicol., 2005, 96(2), 146-148. http://dx.doi.org/10.1111/j.1742-7843.2005.pto960210.x [86] Sakuma, S .",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"F a t t y  A c i d s ,  1996, 54(3), 193-197. http://dx.doi.org/10.1016/S0952-3278(96)90016-2 [87] Ritter, A.; Goulitquer, S.; Salaün, J.P.; Tonon, T.; Correa, J.A, Potin, P. Copper stress induces biosynthesis of octadecanoid and eicosanoid oxygenated derivatives in the brown algal kelp Laminaria digitata.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"New Phytol., 2008, 180, 809-821. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Neuroscientist, 2009, 15, 3 9 2-407. http://dx.doi.org/10.1177/ 1073858409337035 [90] Lee, K.H.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Brain Res., 2 0 0 7, 1 1 7 1:1-8. http://dx.doi.org/10.1016/j.brainres.2007.07.053 [91] DiSilvestro, R.A.; Selsby, J.; Siefker, K. A pilot study of copper supplementation effects on plasma F2alpha isoprostanes and urinary collagen crosslinks in young adult women.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Redox Signal., 2009, 15, 1583-1606. http://dx.doi.org/10.1089/ars.2011.3999 [93] Vu.",OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Blood, 2007, 110(10), 3517-3525. http://dx.doi.org/10.1182/blood-2007-03-079616 [98] Yui, K.; Koshiba, M.; Nakamura, S.; Kobayashi, Y.",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Obesity, 2009, 18(1), 27-34. http://dx.doi.org/10.1038/oby.2009.208   Received: January 20, 2015 Revised: February 25, 2015 Accepted: February 25, 2015",Non-OADS,/arxiv_data1/oa_pdf/ac/87/CN-13-776.PMC4759316.pdf
"Med., 2012, 366, 733-743. http://dx.doi.org/10.1056/NEJMra1114194 [2] Marshall, C.R.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Biol., 2012, 838, 115-135. http://dx.doi.org/10.1007/978-1-61779-507-7_5 [3] Phelan, M.C.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2001, 101, 91-99. http://dx.doi.org/10.1002/1096-8628(20010615)101:2<91::AID-AJMG1340>3.0.CO;2-C [4] Bonaglia, M.C.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2001, 69, 261-268. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neuron, 1999, 23, 569-582. http://dx.doi.org/10.1016/S0896-6273(00)80809-0 [7] Lim, S.; Naisbitt, S.; Yoon, J.; Hwang, J.I-k.; Suh, P-G.; Sheng, M.; Kim, E. Characterization of the Shank family of synaptic proteins.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Chem., 1999, 41, 29510-29518. http://dx.doi.org/ 10.1074/jbc.274.41.29510 [8] Sheng, M.; Kim, E. The Shank family of scaffold proteins.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurochem., 2002, 83, 1013-1017. http://dx.doi.org/10.1046/j.1471-4159.2002.01204.x",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Cell Neurosci., 2004, 26, 182-190. http://dx.doi.org/10.1016/ j.mcn.2004.01.009 [11] Uchino, S.; Wada, H.; Honda, S.; Nakamura, Y.; Ondo, Y.; Uchiyama, T.; Tsutsumi, M.; Suzuki, E.; Hirasawa, T.; Kohsaka, S. Direct interaction of post-synaptic density-95/Dlg/ZO-1 domain-containing synaptic molecule Shank3 with GluR1 α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurochem., 2006, 97, 1203-1214. http://dx.doi.org/10.1111/ j.1471-4159.2006.03831.x [12] Durand, C.M.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2007, 39, 25-27. http://dx.doi.org/10.1038/ng1933 [13] Mössner, R.; Marshall, C.R.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2007, 81, 1289-1297. http://dx.doi.org/10.1086/522590 [14] Gauthier, J.; Spiegelman, D.; Piton, A.; Lafrenière, R.G.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Part B., 2009, 150B, 421-424. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2 0 1 1, 21, 208-211. http://dx.doi.org/10.1097/ YPG.0b013e328341e069 [16] Boccuto, L.; Lauri, M.; Sarasua, S.M.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2013, 21, 310-316. http://dx.doi.org/10.1038/ ejhg.2012.175 [17] Nemirovsky S.I.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"PLoS One, [Online] 2015, 10. http://journals.plos.org/ plosone/article?id=10.1371/journal.pone.0116358  [18] Uchino, S.; Waga, C. SHANK3 a s  a n  a u t i s m  s p e c t r u m  d isorder-associated gene.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Brain Dev., 2013, 25, 106-110. http://dx.doi.org/ 10.1016/j.braindev.2012.05.013 [19] Jiang, Y-H.; Ehlers, M.D.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neuron, 2013, 78, 8-27. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurochem., 2014, 128, 280-293. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurobiol., 2014, 74, 123-135. http://dx.doi.org/10.1002/dneu.22084 [22] Bozdagi, O.; Sakurai, T; Papapetrou, D.; Wang, X.; Dickstein, D.L.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Autism, [Online] 2010, 1, 15. http://www.molecularautism.com/ content/1/1/15 [23] Wang, X; McCoy, P.A; Rodriguiz, R.M.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"2011, 20, 3093-3108. http://dx.doi.org/10.1093/hmg/ddr212 [24] Peça, J.; Feliciano, C.; Ting, J.T.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Nature, 2011, 472, 437-442. http://dx.doi.org/10.1038/nature09965 [25] O’Kusky, J.R.; Ye, P.; D’Ercole, A.J.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Pharmacol., 2004, 490, 25-31. http://dx.doi.org/ 10.1016/j.ejphar.2004.02.042 [27] Femandez, A.M.; Torres-Alemán, I.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurosci., 2012, 13, 225-239. http://dx.doi.org/10.1038/nrn3209 [28] Pini, G.; Scusa, M.F.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Treat., [Online] 2012, 2012, Article ID 679801, 14 http://www.hindawi.com/journals/aurt/2012/679801/ [29] Khwaja, O.S.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Autism, [Online] 2013, 4, 9. http://www.molecularautism.com/content/4/1/9 [31] Shcheglovitov, A.; Shcheglovitova, O.; Yazawa, M.; Portmann, T.; Shu, R.; Sebastiano, V.; Krawisz, A.; Froechlich, W.; Bernstein, J.A.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Nature, 2013, 503, 267-271. http://dx.doi.org/10.1038/ nature12618 [32] Perea, G.; Navarrete, ; Araque, A. Tripartite synapses: astrocytes process and control synaptic information.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Trends Neurosci., 2009, 32, 421-431. http://dx.doi.org/10.1016/j.tins.2009.05.001 [33] Perea, G.; Araque, A. GLIA modulates synaptic transmission.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Rev., 2010, 63, 93-102. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Biol., 2012, 970, 307-331. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Nature, 2013, 504, 394-400. http://dx.doi.org/10.1038/nature12776 [36] Paolicelli, R.C.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Science, 2011, 333, 1456-1458. http://dx.doi.org/10.1126/science.1202529 [37] Kettenmann, H.; Kirchhoff, F.; Verkhratsky, A. Microglia: New roles for the synaptic stripper.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neuron, 2013, 77, 10-18. http://dx.doi.org/10.1016/j.neuron.2012.12.023 [38] Miyamoto, A.; Wake, H.; Moorthouse, A.J.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurosci., [Omline] 2013, 7, 70. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654203/ [39] Morgan, J.T.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Psychiatry., 2005, 17, 485-495. http://dx.doi.org/10.1080/02646830500381930 [41] Enstrom, A.M.; Lit, L.; Onore, C.E; Gregg, J.P.; Hansen, R.; Pessah, I.N.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Immun., 2009, 23, 124-133. http://dx.doi.org/10.1016/j.bbi.2008.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neuron, 2009, 64, 61-78. http://dx.doi.org/10.1016/j.neuron.2009.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurosci., 2014, 17, 400-406. http://dx.doi.org/10.1038/nn.3641 [44] Verhoeven, W.M.A.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Gent., 2012, 55, 625-629. http://dx.doi.org/10.1016/j.ejmg.2012.07.009 [46] Awadalla, P.; Gauthier, J.; Myers, R.A.; Casals, F.; Hamdan, F.F.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2010, 87, 316-324. http://dx.doi.org/10.1016/j.ajhg.2010.07.019 [47] Gauthier, J.; Champagne, N.; Lafrenière, R.G.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Neurol., 2014, 253, 126-137. http://dx.doi.org/10.1016/j.expneurol.",OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Psychiat., 2014, doi:10.1038/mp.2014.63 http://www.nature.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"com/mp/journal/vaop/ncurrent/full/mp201463a.htmlhttp://dx.doi.org/10.1038/mp.2014.63 [51] Failla, P.; Romano, C.; Alberti, A.; Vasta, A.; Buono, S.; Castiglia, L.; Luciano, D.; Benedetto, D.D.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Genet., 2007, 71, 599-601. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Nature, 2013, 503, 72-77. http://dx.doi.org/10.1038/ nature12630   Received: February 10, 2015 Revised: March 16, 2015 Accepted: March 15, 2015",Non-OADS,/arxiv_data1/oa_pdf/67/5d/CN-13-786.PMC4759317.pdf
"Interv., 2008, 8(2), 99-107. http://dx.doi.org/10.1124/mi.8.2.7 [2] Meltzer, H.Y.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2000, 45(3), 175-184.http://dx.doi.org/10.1016/S0920-9964(99)00198-X [4] Freedman, R. Schizophrenia.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Med., 2003, 349(18), 1738-1749. http://dx.doi.org/10.1056/NEJMra035458 [5] Lieberman, J.A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Biol Psychiatry, 1999, 46(6), 729-739. http://dx.doi.org/10.1016/S0006-3223(99)00147-X [6] Lewis, D.A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuron, 2000, 28(2), 325-334.http://dx.doi.org/10.1016/S0896-6273(00)00111-2 [7] Weinberger, D.R.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Gen. Psychiatry, 1987, 44(7), 660-669. http://dx.doi.org/10.1001/archpsyc.1987.01800190080012 [8] Weinberger, D.R.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychiatry, 2006, 67(6), 983-990.http://dx.doi.org/10.4088/JCP.v67n0616 [10] Lieberman, J.A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychiatry, 2001, 50(11), 884-897. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychiatry, 2005, 29(5), 846-858. http://dx.doi.org/10.1016/j.pnpbp.2005.03.010 [12] Glantz, L.A.; Gilmore, J.H.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2006, 81(1), 47-63.http://dx.doi.org/10.1016/j.schres.2005.08.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neurosci., 2005, 6(4), 312-324. http://dx.doi.org/10.1038/nrn1648 [14] Benes, F.M.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuro- psychopharmacology, 2001, 25(1), 1-27. http://dx.doi.org/10.1016/ S0893-133X(01)00225-1 [15] Lewis, D.A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Trends Neurosci., 2012, 35(1), 57-67. http://dx.doi.org/10.1016/ j.tins.2011.10.004 [16] Gonzalez-Burgos, G.; Hashimoto, T.; Lewis, D.A.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychiatry Rep., 2010, 12(4), 335-344. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Gen. Psychiatry, 2000, 57(11), 1061-1069. http://dx.doi.org/10.1001/archpsyc.57.11.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"J. Psychiatry, 2011, 168(9), 921-929. http://dx.doi.org/10.1176/appi.ajp.2011.11010052 [19] Beasley, C.L.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 1997, 24(3), 349-355.http://dx.doi.org/10.1016/ S0920-9964(96)00122-3 [20] Beasley, C.L.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychiatry, 2002, 52(7), 708-715. http://dx.doi.org/10.1016/S0006-3223(02)01360-4 [21] Olney, J.W.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 1999, 33(6), 523-533.http://dx.doi.org/10.1016/S0022-3956(99)00029-1 [22] Keefe, R.S.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2004, 68(2-3), 283-297.http://dx.doi.org/10.1016/j.schres.2003.09.011 [23] Baddeley, A.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"J. Psychiatry, 1996, 153(3), 321-330. http://dx.doi.org/10.1176/ajp.153.3.321 [25] Miller, E.K.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neurosci., 2001, 24, 167-202. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Bull., 2008, 34(5), 962-973. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Dis., 2013, 53, 36-48.http://dx.doi.org/10.1016/j.nbd.2012.11.013 [28] Lewis, D.A.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Med., 2006, 12(9), 1016-1022. http://dx.doi.org/10.1038/nm1478 [29] Genius, J.; Giegling, I.; Benninghoff, J.; Rujescu, D. Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment?",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Biotechnol., 2012, 13(8), 1549-1556. http://dx.doi.org/10.2174/138920112800784943 [30] Homayoun, H.; Moghaddam, B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neurosci., 2007, 27(43), 11496-11500. http://dx.doi.org/10.1523/JNEUROSCI.2213-07.2007 [31] Bird, J.M.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Trends Neurosci., 2008, 31(5), 234-242. http://dx.doi.org/10.1016/ j.tins.2008.02.005 [33] Kegeles, L.S.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Gen. Psychiatry, 2012, 69(5), 449-459. http://dx.doi.org/10.1001/archgenpsychiatry.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Bull., 2010, 36(6), 1066-1072. http://dx.doi.org/10.1093/schbul/ sbq106 [35] Carlsson, A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuropsychopharmacology, 1988, 1(3), 179-186. http://dx.doi.org/10.1016/0893-133X(88)90012-7 [36] Sumiyoshi, T. A possible dose-side effect relationship of antipsychotics: Relevance to cognitive function in schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Pharmacol., 2008, 1, 791-812.http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Targets, 2006, 10(4), 515-531.http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Science, 1975, 188(4194), 1217-1219.http://dx.doi.org/10.1126/ science.1145194 [39] Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Nature, 1976, 261(5562), 717-719.http://dx.doi.org/10.1038/261717a0 [40] Nikam, S.S.; Awasthi, A.K.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Brain Res., 2008, 172, 177-197.http://dx.doi.org/10.1016/S0079-6123(08) 00909-6 [42] Meltzer, H.Y.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2004, 174(1), 143-150.http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2004, 174(1), 32-38.http://dx.doi.org/10.1007/s00213-003-1709-2 [45] Harvey, P.D.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Rev., 2009, 19(3), 324-335.http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2010, 122(1-3), 1-23.http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuropsychopharmacol., 2009, 19(2), 147-151. http://dx.doi.org/10.1016/j.euroneuro.2008.10.006 [48] Ohno, Y.; Tatara, A.; Shimizu, S.; Sasa, M. Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neurosci., 2013, 7, 140. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2007, 95(1-3), 158-168.http://dx.doi.org/10.1016/j.schres.2007.06.008 [54] Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H.Y.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"J. Psychiatry, 2001, 158(10), 1722-1725. http://dx.doi.org/10.1176/appi.ajp.158.10.1722 [55] Sumiyoshi, T.; Uehara, T. Serotonin-1A Receptors and Cognitive Enhancement in Schizophrenia: Role for Brain Energy Metabolism.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"127-140. http://dx.doi.org/10.5772/36118 [56] Hagiwara, H.; Fujita, Y.; Ishima, T.; Kunitachi, S.; Shirayama, Y.; Iyo, M.; Hashimoto, K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuropsychopharmacol., 2008, 18(6), 448-454. http://dx.doi.org/10.1016/j.euroneuro.2007.11.005 [57] Nagai, T.; Murai, R.; Matsui, K.; Kamei, H.; Noda, Y.; Furukawa, H.; Nabeshima, T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2009, 202(1-3), 315-328.http://dx.doi.org/10.1007/s00213-008-1240-6 [58] Snigdha, S.; Neill, J.C.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Brain Res., 2008, 191(1), 26-31.http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Pharmacol., 2004, 493(1-3), 75-83. http://dx.doi.org/10.1016/j.ejphar.2004.04.028 [60] Horiguchi, M.; Meltzer, H.Y.The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2012, 221(2), 205-215.http://dx.doi.org/10.1007/s00213-011-2561-4 [61] Uehara, T.; Sumiyoshi, T.; Itoh, H.; Kurata, K. Lactate production and neurotransmitters; evidence from microdialysis studies.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Behav., 2008, 90(2), 273-281. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2007, 195, 297-302.http://dx.doi.org/10.1007/s00213-007-0881-1",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2006, 186(2), 218-225. http://dx.doi.org/10.1007/s00213-006-0370-y [64] Uehara, T.; Itoh, H.; Matsuoka, T.; Rujescu, D.; Genius, J.; Seo, T.; Sumiyoshi, T. Effect of transient blockade of N-methyl-D-aspartate receptors at neonatal stage on stress-induced lactate metabolism in the medial prefrontal cortex of adult rats: role of 5-HT1A receptor agonism.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Synapse, 2012, 66(5), 408-417.http://dx.doi.org/10.1002/ syn.21529 [65] Uehara, T.; Matsuoka, T.; Sumiyoshi, T. Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; Toward the therapeutics of cognitive impairment of schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neurosci., 2014, 8, 291. http://dx.doi.org/10.3389/fnbeh.2014.00291 [66] Uehara, T.; Sumiyoshi, T. Lactate metabolism as a new target for the therapeutics of schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"135-148. http://dx.doi.org/ 10.2174/9781608057580113010007 [67] Llado-Pelfort, L.; Santana, N.; Ghisi, V.; Artigas, F.; Celada, P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Cortex, 2012, 22(7), 1487-1497.http://dx.doi.org/10.1093/cercor/ bhr220 [68] Bortolozzi, A.; Masana, M.; Diaz-Mataix, L.; Cortes, R.; Scorza, M.C.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Neuropsychopharmacol., 2010, 13(10), 1299-1314. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psycho- pharmacol., 2010, 30(6), 732-734. http://dx.doi.org/10.1097/JCP.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Chem., 2014, 57(11), 4407-4426. http://dx.doi.org/10.1021/jm400533t [71] Madhavan, L.; Freed, W.J.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Ther., 2003, 304(3), 913-923. http://dx.doi.org/10.1124/jpet.102.044370 [72] McIntosh, A.M.; Owens, D.C.; Moorhead, W.J.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"J. Psychiatry, 2002, 159(12), 1983-1991. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Anat., 2010, 217(4), 324-333. http://dx.doi.org/10.1111/j.1469-7580.2010.01231.x [75] Lieberman, J.A.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Hippocampus, 2007, 17(6), 443-455. http://dx.doi.org/10.1002/hipo.20281 [77] Kimura, T.; Hong Nguyen, P.T.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Pharmacol., 2009, 157(3), 451-463. http://dx.doi.org/10.1111/j.1476-5381.2009.00141.x [78] Hirata, K.; Yamaguchi, H.; Takamura, Y.; Takagi, A.; Fukushima, T.; Iwakami, N.; Saitoh, A.; Nakagawa, M.; Yamada, T. A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Ther., 2005, 314(1), 252-259. http://dx.doi.org/10.1124/jpet.105.083543 [79] Fukushima, T.; Nakamura, A.; Iwakami, N.; Nakada, Y.; Hattori, H.; Hoki, S.; Yamaguchi, H.; Nakagawa, M.; Terashima, N.; Narita, H. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Commun., 2011, 407(4), 730-734. http://dx.doi.org/10.1016/j.bbrc.2011.03.091 [80] Fukushima, T.; Koide, M.; Ago, Y.; Baba, A.; Matsuda, T. T-817MA, a novel neurotrophic agent, improves sodium nitroprusside-induced mitochondrial dysfunction in cortical neurons.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Int., 2006, 48(2), 124-130.http://dx.doi.org/10.1016/j.neuint.2005.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Psychopharmacology (Berl), 2009, 206(4), 623-630.http://dx.doi.org/10.1007/s00213-009-1527-2 [83] Uehara, T.; Sumiyoshi, T.; Seo, T.; Matsuoka, T.; Itoh, H.; Suzuki, M.; Kurachi, M. Neonatal exposure to MK-801, an N-methyl-d-aspartate receptor antagonist, enhances methamphetamine-induced locomotion and disrupts sensorimotor gating in pre- a n d  postpubertal rats.",Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Brain Res., 2010, 1352, 223-230.http://dx.doi.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Synapse, 2014, 68(5), 202-208.http://dx.doi.org/10.1002/syn.21734 [85] Uehara, T.; Sumiyoshi, T.; Hattori, H.; Itoh, H.; Matsuoka, T.; Iwakami, N.; Suzuki, M.; Kurachi, M. T-817MA, a novel neurotrophic agent, ameliorates loss of GABAergicparvalbumin-positive neurons and sensorimotor gating deficits in rats transiently exposed to MK-801 in the neonatal period.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"Res., 2012, 46(5), 622-629.http://dx.doi.org/10.1016/j.jpsychires.2012.01.022 [86] Nakamura, T.; Matsumoto, J.; Takamura, Y.; Ishii, Y.; Sasahara, M.; Ono, T.; Nishijo, H. Correlation among parvalbumin-immuno- reactive neuron density, phase-locked gamma oscillations, and autistic/schizophrenic symptoms in PDGFR-beta knock-out mice.",OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3a/db/CN-13-793.PMC4759318.pdf
"http://dx.doi.org/ 10.1002/0471142301 [3] Gaddum, J.H.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1967, 45(4), 613-620. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1989, 339(3), 298-301. http://dx.doi.org/10.1007/BF00173581 [7] Prast, H.; Saxer, A.; Philippu, A.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1988, 337(1), 53-57. http://dx.doi.org/10.1007/BF00169476 [8] Philippu, A.; Hanesch, U.; Hagen, R.; Robinson, R.L.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1982, 321(4), 282-286. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Sci., 1996, 17(10), 3 5 6-363. http://dx.doi.org/ 10.1016/S0165-6147(96)80009-5 [11] Kouvelas, D.; Singewald, N.; Kaehler, S.T.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Lett., 2006, 393(2-3), 194-199. http://dx.doi.org/10.1016/j.neulet.2005.09.063  [12] Philippu, A.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Sci., 1980, 1, 376-378. http://dx.doi.org/10.1016/0165-6147(80)90054-1 [13] Dampney, R.A. F u n c t i o n a l  o r g a n i z a t i o n  o f  c entral pathways regulating the cardiovascular system.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Neurosci., 2006, 7(5), 335-346. http://dx.doi.org/10.1038/nrn1902 [15] Sinha, J.N.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Life Sci., 1980, 26(21), 1751-1760. http://dx.doi.org/10.1016/0024-3205(80) 90574-3 [16] Philippu, A. Ed.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1997, 356(4), 526-528. http://dx.doi.org/10.1007/ PL00005086 [18] Harada, C.; Hirai, T.; Fujii, Y.; Harusawa, S.; Kurihara, T.; Kamei, C. Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Lett., 1996, 216(1), 21-24. http://dx.doi.org/10.1016/0304-3940(96)12992-X [20] Grass, K .",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1 9 9 8, 357(2), 169-175. http://dx.doi.org/10.1007/ PL00005151 [21] Kraus, M.M.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Neuroreport, 1996, 7(13), 1665-1669. http://dx.doi.org/10.1097/00001756-199607080-00028 [23] Lapper, S.R.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Neuroscience, 1992,51(3), 533-545. http://dx.doi.org/10.1016/0306-4522(92)90293-B [24] Meredith, G.E.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Neurol., 1990, 296(2), 204-221. http://dx.doi.org/10.1002/cne.902960203 [25] Vuillet, J.; Dimova, R.; Nieoullon, A.; Kerkerian-Le Goff, L. Ultrastructural relationships between choline acetyltransferase- a n d neuropeptide Y-containing neurons in the rat striatum.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Neuroscience, 1992, 46(2), 351-360. http://dx.doi.org/10.1016/0306-4522(92) 90057-9 [26] Prast, H.; Hornick, A.; Kraus, M.M.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"http://dx.doi.org/ 10.1016/j.lfs.2015.04.021 [27] Thor, D.H.; Holloway, W.R. Social memory of the male laboratory rat.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Psychol., 1982, 96, 1000-1006. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Res., 1997, 49, 515-521. http://dx.doi.org/10.1002/ (SICI)1097-4547(19970901)49:5<515::AID-JNR1>3.0.CO;2-E [29] Dantzer, R.; Bluthe, R.M.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Psycho- pharmacology Berl., 1987, 91, 363-368. http://dx.doi.org/10.1007/ BF00518192 [30] Kraus, M.M.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Brain Res., 1989, 32(3), 265-277. http://dx.doi.org/10.1016/ S0166-4328(89)80059-2 [32] Ikarashi, Y.; Kuribara, H.; Shiobara, T.; Takahashi, A.; Ishimaru, H.; Maruyama, Y.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Behav., 2000, 65(3), 519-522. http://dx.doi.org/10.1016/ S0091-3057(99)00223-3 [33] Robinson, L.; Platt, B.; Riedel, G. Involvement of the cholinergic system in conditioning and perceptual memory.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Brain Res., 2001, 124(2), 151-159. http://dx.doi.org/10.1016/S0166-4328(01)00226-1 [35] Alvarez, E.O.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"http://dx.doi.org/10.1016/j.bbr.2008.12.010 [36] Zlomuzica, A.; Ruocco, L.A.; Sadile, A.G.; Huston, J.P.; Dere, E. Histamine H1 receptor knockout mice exhibit impaired spatial memory in the eight-arm radial maze.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Brain Res., 1996, 734(1-2), 316-318.http://dx.doi.org/10.1016/0006-8993(96)00886-4 [38] Alleva, L.; Tirelli, E.; Brabant, C. Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
http://dx.doi.org/10.1016/j.bbr.,OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1999, 360(5), 558-564. http://dx.doi.org/10.1007/s002109900097 [40] Prast, H.; Tran, M.H.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1999, 360(5), 552-557. http://dx.doi.org/10.1007/s002109900098 [41] Miyazaki, S.; Imaizumi, M.; Onodera, K. Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Life Sci., 1995, 57(23), 2137-2144. http://dx.doi.org/10.1016/0024-3205(95) 02206-X [42] Onodera, K.; Miyazaki, S.; Imaizumi, M. Cognitive involvement by negative modulation of histamine H2 receptors in passive avoidance task in mice.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Pharmacol., 1998, 20(4), 307-310. http://dx.doi.org/10.1358/mf.1998.20.4.485684 [43] Terry, A .",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Ther., 2011, 336(3), 751-766. http://dx.doi.org/10.1124/jpet.110.175422 [44] Köhler, C.A.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"http://dx.doi.org/10.1155/2011/328602 [45] Singewald, N.; Kouvelas, D.; Kaehler, S.T.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Lett., 2000, 289(1), 17-20. http://dx.doi.org/10.1016/ S0304-3940(00)01241-6 [46] Philippu, A. Interactions of histamine with other neuron systems.",OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
"Drug News Perspect., 2001, 14(9), 523-529. http://dx.doi.org/10.1358/dnp.2001.14.9.858409  [48] Philippu, A. Modulation by heteroreceptors of histamine release in the brain.",Non-OADS,/arxiv_data1/oa_pdf/39/a3/CN-13-819.PMC4759321.pdf
http://dx.doi.org/10.1136/gut.51.,Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"C o l o n. Rectum, 2007, 50, 376-388. http://dx.doi.org/10.1007/s10350-006-0763-3 [3] El-Salhy, M.; Lomholt-Beck, B.; Hausken, T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Gastroenterol., 2010, 45, 1435-1439. http://dx.doi.org/10.3109/ 00365521.2010.503965 [4] Miwa, J.; E c h i z e n ,  H .",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Digestion, 2001, 63, 188-194. http://dx.doi.org/10.1159/ 000051888 [5] EI-Salhy, M.; G u n d e r s e n ,  D .",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"S c i., 2012, 57, 873-878. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Gastroenterol., 2011, 106, 1290-1298. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2004, 141, 385-390. http://dx.doi.org/10.1038/ sj.bjp.0705624 [9] Kojima, S.; Ikeda, M.; Kamikawa, Y.",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Sci., 2009, 110, 122-126. http://dx.doi.org/10.1254/jphs.09032SC [10] Kojima, S.; Tohei, A.; Ikeda, M. Melatonin inhibits tachykinin NK2 receptor-triggered 5-HT release from guinea-pig isolated colonic mucosa.",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2011, 162, 1179-1185. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2012, 167, 1362-1368. http://dx.doi.org/10.1111/j.1476-5381.2012.02094.x [12] Portbury, A.L.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Cell Tissue Res., 1996, 286, 281-292. http://dx.doi.org/10.1007/s004410050698 [13] Goldhill, J.; A n g e l ,  I .",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 1998, 363, 161-168. http://dx.doi.org/10.1016/S0014-2999(98) 00797-3 [14] Goldhill, J.; Porquet, M.F.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 1999, 51, 1041-1048. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2004, 141, 1303-1312. http://dx.doi.org/10.1038/ sj.bjp.0705742 [16] Lordal, M.; Navalesi, G.; Theodorsson, E.; Maggi, C.A.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2001, 134, 215-223. http://dx.doi.org/10.1038/sj.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"B o w e l  D i s., 2008, 14, 1331-1340. http://dx.doi.org/10.1002/ibd.20487 [19] Liu, L.; M a r k u s ,  I .",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"http://dx.doi.org/10.1111/j.1365-2982.2011.01685.x [20] Tough, I.R.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2011, 164, 471-484. http://dx.doi.org/10.1111/j.1476-5381.2011.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Endocrinol., 2010, 316, 120-128. http://dx.doi.org/10.1016/j.mce.",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Sci., 2012, 57, 873-878. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Sci., 2013, 133, 186-195. http://dx.doi.org/10.1093/toxsci/kft033 [24] Bearcroft, C.P.",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Gut, 1998, 42, 42-46. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Gut, 2003, 52, 663-670. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Sci., 2009, 54, 1087-1093. http://dx.doi.org/10.1007/s10620-008-0463-z",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Gut, 2005, 54, 1402-1407. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Drugs, 2006, 66, 1073-1088. http://dx.doi.org/10.2165/00003495-200666080-00004 [31] Radwan, P.; Skrzydlo-radomanska, B.; Radwan-kwiatek, K.; Burak-czapiuk, B.; S t r z e m e c k a ,  J .",OADS,/arxiv_data1/oa_pdf/86/e9/CN-13-830.PMC4759322.pdf
"Pharmacol., 2015, 388, 79-86. http://dx.doi.org/10.1007/ s00210-014-1061-6 [2] Shiba, M.; Suzuki, H, ; Fujimoto, M.; Shimojo, N.; Imanaka-Yoshida, K.; Yoshida, T.; Kanamaru, K.; Matsushima, S.; Taki, W. Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Acta Neurochir Suppl., 2013, 115, 219-223. http://dx.doi.org/10.1007/978-3-7091-1192-5_40 [3] Piette, F.; Belmin, J.; Vincent, H.; Schmidt, N.; Pariel, S.; Verny, M.; Marquis, C.; Mely, J.; Hugonot-Diener, L.; Kinet, J.P.; Dubreuil, P.; Moussy, A.; Hermine, O. Masitinib a s  a n  adjunct therapy f o r  mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Ther., 2011, 3, 16. http://dx.doi.org/10.1186/alzrt75 [4] Vermersch, P.; Benrabah, R.; Schmidt, N.; Zéphir, H.; Clavelou, P.; Vongsouthi, C.; Dubreuil, P.; Moussy, A.; Hermine, O. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"http://dx.doi.org/10.1186/ar2740 [6] Humbert, M .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Allergy, 2009, 64, 1194-201. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Hematol., 2010, 85, 921-925. http://dx.doi.org/10.1002/ajh.21894 [8] Rosenberger, A.F.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Synapse, 2014, 68, 306-316. http://dx.doi.org/10.1002/ syn.21741 [10] Qi, D.; Ouyang, C.; Wang, Y.; Zhang, S.; Ma, X.; Song, Y.; Yu, H.; Tang, J.; Fu, W.; Sheng, L.; Yang, L.; Wang, M.; Zhang, W.; Miao, L.; Li, T.; Huang, X.; Dong, H. HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Brain Res., 2014, 1577, 69-76. http://dx.doi.org/10.1016/j.brainres.2014.06.031 [11] Wu, C.H.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"PLoS One, 2014, 9, 113397. http://dx.doi.org/10.1371/journal.pone.0113397 [12] Cui, X.; Chopp, M.; Zacharek, A.; Ning, R.; Ding, X.; Roberts,  C.; Chen, J. Endothelial nitric oxide synthase regulates white matter changes via the BDNF/TrkB pathway after stroke in mice.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"PLoS One, 2013, 8, 80358. http://dx.doi.org/10.1371/journal.pone.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Oncogene, 2004, 23, 991-999. http://dx.doi.org/10.1038/sj.onc.1207278 [14] Greuber, E.K.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Cancer, 2013, 13, 559-571. http://dx.doi.org/10.1038/ nrc3563 [15] Raimondi, C. Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Trans., 2014, 42, 1429-1434. http://dx.doi.org/10.1042/BST20140141 [16] Mukaiyama, H .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Chem., 2007, 15, 868-885. http://dx.doi.org/10.1016/ j.bmc.2006.10.041 [17] Lennmyr, F.; Ericsson, A.; Gerwins, P.; Akterin, S.; Ahlström, H.; Terént, A. Src family kinase-inhibitor PP2 reduces focal ischemic brain injury.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Ther., 2009, 331, 827-835. http://dx.doi.org/10.1124/jpet.109.156562 [19] Su, E.J.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Med., 2008, 14, 731-737. http://dx.doi.org/10.1038/nm1787 [20] Fredriksson, L.; Li, H.; Fieber, C.; Li, X.; Eriksson, U. Tissue plasminogen activator is a potent activator of PDGF-CC.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"EMBO J., 2004, 23, 3793-3802. http://dx.doi.org/10.1038/sj.emboj.7600397 [21] Zhuo, M.; Holtzman, D.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Invest., 2003, 112, 1533-1540. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Med., 2008, 14, 712-713. http://dx.doi.org/10.1038/nm0708-712 [24] Dubreuil, P .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"http://dx.doi.org/10.1371/journal.pone.0007258 [25] van Erp, N.P.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Rev., 2009, 35, 692-706. http://dx.doi.org/10.1016/j.ctrv.2009.08.004 [26] Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A.H.; Schellens, J.H.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Cancer Res., 2005, 657, 2577-2582. http://dx.doi.org/10.1158/0008-5472.CAN-04-2416 [27] Paniagua, R.T.; S h a r p e ,  O .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Invest., 2006 , 116, 2633-2642. http://dx.doi.org/10.1172/JCI28546.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Cancer, 2009, 45, 2333-2341. http://dx.doi.org/10.1016/j.ejca.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Biol., 2009, 8, 30. http://dx.doi.org/10.1186/jbiol134 [30] Marech, I.; Patruno, R.; Zizzo, N.; Gadaleta, C.; Introna, M.; Zito, A.F.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Hematol., 2014, 91, 98-111. http://dx.doi.org/10.1016/ j.critrevonc.2013.12.011 [31] European Medicines Agency.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
http://www.fda.gov/downloads/ AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM310554.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"J., 1998, 74, 743-744. http://dx.doi.org/10.1136/pgmj.74.878.743 [35] Ostrowski, R .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Res., 2006, 28, 399-414. http://dx.doi.org/10.1179/ 016164106X115008 [36] Kreiter, K. T .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Stroke, 2002, 33, 200-208. http://dx.doi.org/10.1161/hs0102.101080 [37] Zhan, Y .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Res., 2015, 93, 94-103. http://dx.doi.org/10.1002/jnr.23475 [38] Adzemovic, M.V.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"PLoS One, 2013, 8. http://dx.doi.org/10.1371/journal.pone.0056586 [39] Verkhratsky, A.; Olabarria, M.; Noristani, H.N.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Neurotherapeutics, 2010, 7, 399-412. http://dx.doi.org/10.1016/j.nurt.2010.05.017 [40] Heneka, M.T.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"2015, 14, 388-405. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Aging, 2012, 33, 2247-2261. http://dx.doi.org/10.1016/ j.neurobiolaging.2011.10.027 [42] Dhawan G .",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Cell, 1992, 69, 551-558. http://dx.doi.org/10.1016/0092-8674(92) 90455-L [44] Taylor, S.J.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Bioessays, 1996, 18, 9-11. http://dx.doi.org/10.1002/bies.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Science, 1992, 258, 1903-1910. http://dx.doi.org/10.1126/science.1361685 [46] Nygaard, H.B.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Ther., 2014, 6, 8. http://dx.doi.org/10.1186/alzrt238 [47] Um, J.W.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Nat Neurosci., 2012, 15, 1227-1235. http://dx.doi.org/10.1038/nn.3178 [48] Tremblay, M.A.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
[51] ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/ NCT01872598.,Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"http://dx.doi.org/10.1186/gb-2006-7-2-r11 [54] Luo, J .",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Immunol., 2011, 31, 1010-1020. http://dx.doi.org/10.1007/s10875-011-9579-6 [58] Benesová, Y.; Vasku, A.; Novotná, H.; Litzman, J.; Stourac, P.; Beránek, M.; Kadanka, Z.; Bednarík, J. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Scler., 2009, 15, 316-322. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"PLoS One, 2009, 4, 4952. http://dx.doi.org/10.1371/ journal.pone.0004952 [60] Vos, C.M.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Neuroimmunol., 2003, 138, 106-114. http://dx.doi.org/10.1016/S0165-5728(03) 00036-5 [61] Bannerman, P.; Hahn, A.; Soulika, A.; Gallo, V.; Pleasure, D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Pat., 2010, 20, 1573-1593. http://dx.doi.org/10.1517/13543776.2010.517749 [63] Anisman, H .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Immunol., 2010, 185, 4252-4260. http://dx.doi.org/10.4049/ jimmunol.1001228 [65] Proescholdt, M .",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Med., 2011, 17, 119-125. http://dx.doi.org/10.1016/j.molmed.2010.11.006 [68] Siroos, B, Harirchian, M.H.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Scler., 2013, 19, 1238-1239. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Immunol., 2009, 182, 4192-4199. http://dx.doi.org/10.4049/jimmunol.0803631 [70] Steinman, L .",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Trends Immunol., 2005, 26, 565-571. http://dx.doi.org/10.1016/j.it.2005.08.014 [71] Mena, A.C.; Pulido, E.G.",OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
"Neuroimmunol., 2009, 209, 6-15. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a1/f3/CN-13-836.PMC4759323.pdf
Available  at:  http://www.healthdata.org/ gbd/data .,OADS,/arxiv_data1/oa_pdf/20/b0/main.PMC4759480.pdf
"Rajeev  Guptaa,b aDepartment  of  Medicine,  Fortis  Escorts  Hospital, Jaipur  302017,  India bAcademic  &  Research  Development  Unit,  Rajasthan  University of  Health  Sciences,  Jaipur  302033,  India E-mail  address:  rajeevgg@gmail.com  (R.  Gupta) Available  online  18  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.07.042 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/20/b0/main.PMC4759480.pdf
"Vasim  Farooq  MBChB,  MRCP,  PhD* Institute  of  Cardiovascular  Sciences,  Manchester  Academic  Health Sciences  Centre,  University  of  Manchester  and  Manchester  Heart Centre,  Manchester  Royal  Inﬁrmary,  Central  Manchester  University Hospitals  NHS  Trust,  Manchester,  United  KingdomCarlo  Di  Mario  MD,  PhD NIHR  Cardiovascular  BRU,  Royal  Brompton  &  Hare ﬁeld  NHS Foundation  Trust  and  Imperial  College  London,  London,  United Kingdom Patrick  W.  Serruys  MD,  PhDa,b aEmeritus  Professor  of  Medicine  with  a  Chair  in  Interventional Cardiology  at  the  Erasmus  University,  Rotterdam,  The  Netherlands bInternational  Centre  for  Circulatory  Health,  NHLI,  Imperial  College, London,  United  Kingdom *Corresponding  author E-mail  address:  vasimfarooq@icloud.com  (V.  Farooq) Available  online  12  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.10.385 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/89/57/main.PMC4759481.pdf
1  –  3D  model  of  heart.Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2016.01.009 0019-4832/ #  2016  Published  by  Elsevier  B.V.  on  behalf  of  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/09/12/main.PMC4759482.pdf
"E-mail  addresses:  chandrasekar.palaniswamy@mountsinai.org ,  drpchandrasekar@gmail.com  (C.  Palaniswamy).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.034 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/6f/a8/main.PMC4759483.pdf
Khanolkar).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0240019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/80/c4/main.PMC4759484.pdf
http://www.amazon.com/ Broken-Hearts-Tangled-History-Cardiac/dp/1421408015/ ref=sr_1_1?ie=UTF8&qid=1360790266&sr=8-1&keywords= Broken+Hearts%3A+The+Tangled+History+of+Cardiac+Care .,Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
http://dx.doi.org/10.1186/2046- 2395-3-10 .Table  5  –  Disease  stage  and  impact  of  various  therapies  in  prolongation  of  life.,Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
http://www.thennt.com/nnt/statins-for-heart- disease-prevention-with-known-heart-disease/ .,Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
Available  at:  http://annals.org .,Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
http://portal.saude.,Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
"Sundeep  Mishra Professor,  Department  of  Cardiology,  AIIMS,  New  Delhi,  India E-mail  addresses:  sundeepmishraihj@gmail.com , editorihj2015@gmail.com Available  online  18  January  2016 http://dx.doi.org/10.1016/j.ihj.2016.01.003 0019-4832/ #  2016  Published  by  Elsevier  B.V.  on  behalf  of  Cardiological Society  of  India.i  n  d  i  a  n  h  e  a  r  t  j  o  u  r  n  a  l  6  8  (  2  0  1  6  )  1  9  –  2  7  27",Non-OADS,/arxiv_data1/oa_pdf/2b/07/main.PMC4759485.pdf
2013  http://www.who.int/countryfocus/ cooperation_strategy/ccsbrief_ind_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/93/f6/main.PMC4759486.pdf
2010 http://www.who.int/dietphysicalactivity/marketing-food-to- children/en/ .i  n  d  i  a  n  h  e  a  r  t  j  o  u  r  n  a  l  6  8  (  2  0  1  6  )  6  –  8  7,Non-OADS,/arxiv_data1/oa_pdf/93/f6/main.PMC4759486.pdf
2015  https://sustainabledevelopment.un.org/ post2015/transformingourworld .,Non-OADS,/arxiv_data1/oa_pdf/93/f6/main.PMC4759486.pdf
"Shanthi  Mendis Geneva,  Switzerland E-mail  address:  Prof.shanthi.mendis@gmail.comAvailable  online  12  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.12.002 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/93/f6/main.PMC4759486.pdf
E-mail  address:  sachintalwar@hotmail.com  (S.  Talwar).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0360019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/82/a5/main.PMC4759487.pdf
2012.  http://dx.doi.org/10.1093/mmcts/ mms010 .,Non-OADS,/arxiv_data1/oa_pdf/82/a5/main.PMC4759487.pdf
Monwarul  Islam).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0390019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.world-heart-federation.org/ what-we-do/applied-research/rheumatic-heart-disease/ [accessed  14.06.14].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://siteresources.worldbank.org/ EXTNWDR2013/Resources/8258024-1320950747192/ 8260293-1320956712276/8261091-1348683883703/WDR2013_bp_Jobs_Growth_and_Development.pdf [accessed 01.12.13].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.economist.com/ blogs/feastandfamine/2012/11/bangladesh  [accessed 01.12.13].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://apps.who.int/iris/bitstream/10665/ 112738/1/9789240692671_eng.pdf?ua=1  [accessed  25.10.14].,OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.du.ac.bd/DownLoads/ qlink/nhadsb.pdf  [accessed  25.10.14].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.sid.gov.bd/wp-content/uploads/ 2014/01/Socio_Economic.pdf  [accessed  25.10.14].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.bbs.gov.bd/PageReportLists.aspx?,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.sid.gov.bd/wp-content/uploads/ 2013/02/SVRS-101.pdf  [accessed  25.10.14].i  n  d  i  a  n  h  e  a  r  t  j  o  u  r  n  a  l  6  8  (  2  0  1  6  )  8  8  –  9  8 96,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
Available  at:  http://www.bbs.gov.bd/webtestapplication/ userﬁles/image/Survey%20reports/Bangladesh%20Literacy% 20Surver%202010.pdf  [accessed  01.12.13].,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
http://dx.doi.org/10.1371/journal.pone.0025326 .,Non-OADS,/arxiv_data1/oa_pdf/6c/d9/main.PMC4759488.pdf
E-mail  address:  amvora@hotmail.com  (A.  Vora).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0370019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/84/3d/main.PMC4759489.pdf
http://www.eucomed.org/medical-technology/ facts- ﬁgures .,Non-OADS,/arxiv_data1/oa_pdf/84/3d/main.PMC4759489.pdf
E-mail  address:  cardioramachandra@gmail.com.Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.038 0019-4832/ #  2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/11/1d/main.PMC4759490.pdf
E-mail  address:  manjunath.r.goroshi@gmail.com  (M.  Goroshi).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0220019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/89/d5/main.PMC4759491.pdf
E-mail  address:  bharatjsr@gmail.com  (V.  Bharat).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0230019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/54/9c/main.PMC4759492.pdf
2013.  http://www.health.qld.gov.au/legionnaires/ docs/guide-water-qual.pdf .i  n  d  i  a  n  h  e  a  r  t  j  o  u  r  n  a  l  6  8  (  2  0  1  6  )  6  3  –  6  7  67,Non-OADS,/arxiv_data1/oa_pdf/54/9c/main.PMC4759492.pdf
Goel).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0100019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/01/73/main.PMC4759493.pdf
E-mail  address:  rajeevbhardwaj_dr@yahoo.com  (R.  Bhardwaj).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.08.0220019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/94/86/main.PMC4759494.pdf
E-mail  address:  shuvananray@gmail.com  (S.  Ray).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0140019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/c3/74/main.PMC4759495.pdf
http://dx.doi.org/10.1002/ccd.22777 .,Non-OADS,/arxiv_data1/oa_pdf/c3/74/main.PMC4759495.pdf
E-mail  address:  goutamdattadn@yahoo.in  (G.  Datta).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0300019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/c6/b2/main.PMC4759496.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/06/main.PMC4759500.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.08.001 Introduction Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) is considered to be a variant of neo-vascular Age RelatedMacular Degeneration (AMD).,Non-OADS,/arxiv_data1/oa_pdf/c3/06/main.PMC4759500.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/27/09/main.PMC4759501.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.11.008 Introduction Phthiriasis palpebrarum, which usually occurs by phthiria- sis pubis infestation of the eyelids, is a rare condition usuallyassociated with poor hygiene.",Non-OADS,/arxiv_data1/oa_pdf/27/09/main.PMC4759501.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/14/e1/main.PMC4759502.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.12.004 Introduction Ichthyosis is an inherited group of skin disorders character- ized by the skin thickening and scale formation.,Non-OADS,/arxiv_data1/oa_pdf/14/e1/main.PMC4759502.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/main.PMC4759503.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.11.003 Introduction Enhanced Depth Imaging-Optical Coherence Tomogra- phy (EDI-OCT) is one of the most recent innovations for the visualization of the retina: it allows a deeper and cross- sectional analysis of the retina, choroid and scleral struc-tures.",Non-OADS,/arxiv_data1/oa_pdf/9d/fe/main.PMC4759503.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/93/00/main.PMC4759504.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.10.001 Introduction Laser-assisted subepithelial keratectomy (LASEK) was developed by Massimo Camellin1and recently it has emerged as a procedure for treating myopia that may blend thepositive aspects of photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) while eliminating some of the complications seen with both.2The conceptual advan- tages attributed to LASEK were less postoperative pain, faster visual recovery and less haze when compared to PRK.3 Peer review under responsibility of Saudi Ophthalmological Society, King Saud University Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.com www.sciencedirect.comReceived 10 April 2015; received in revised form 6 September 2015; accepted 7 October 2015; available online 16 October 2015.",Non-OADS,/arxiv_data1/oa_pdf/93/00/main.PMC4759504.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/19/32/main.PMC4759505.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.08.003 Introduction Cysticercosis is the infection of the human being by the larval form of bacon tapeworm, Taenia Solium.",Non-OADS,/arxiv_data1/oa_pdf/19/32/main.PMC4759505.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/de/e1/main.PMC4759506.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.09.002 Introduction Bilateral congenital aniridia is a rare disorder and is char- acterized by a partial or total absence of the iris associatedwith foveal hypoplasia which leads to a reduction of the visualacuity and nystagmus from an early age.,Non-OADS,/arxiv_data1/oa_pdf/de/e1/main.PMC4759506.pdf
"Asif  Hasan Professor  of  Cardiology,  Centre  of  Cardiology, JNMCH  AMU,  Aligarh,  India E-mail  address:  asif_8796@rediffmail.comAvailable  online  19  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.12.015 0019-4832/ #  2016  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/52/b2/main.PMC4759507.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/67/main.PMC4759508.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.12.002 Introduction Despite growing number of intraocular lens (IOL) power calculation formulas, there is no evidence that these formulas have good predictive accuracy in pediatrics, whose eyes are still undergoing rapid growth and refractive changes.1High anisometropia after cataract surgery in children may lead toamblyopia and disruption of binocular fusion.",Non-OADS,/arxiv_data1/oa_pdf/c3/67/main.PMC4759508.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e1/a2/main.PMC4759509.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.11.006 Introduction Juvenile xanthogranuloma (JXG) is a benign inflammatory condition of uncertain pathogenesis characterized by skin and ocular involvement – typically in the iris – in children.1 However, it can involve the cornea and the conjunctiva pre- senting as epibulbar lesions and has been also reported inolder age groups.",Non-OADS,/arxiv_data1/oa_pdf/e1/a2/main.PMC4759509.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f7/59/main.PMC4759510.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.11.001 Introduction Laser-assisted in situ keratomileusis (LASIK) is a commonly employed procedure for the correction of myopia.1Myopia is an independent risk factor for glaucoma progression.2The intraocular pressure (IOP) measurements following LASIK are known to be inaccurate.3With the IOP being the onlymodifiable risk factor, obtaining accurate IOP readings is essential in diagnosing and managing glaucoma.4It is now possible to measure corneal biomechanics in the form of cor- neal hysteresis.",Non-OADS,/arxiv_data1/oa_pdf/f7/59/main.PMC4759510.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/ba/main.PMC4759511.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.11.007 Introduction From a clinical perspective, high intraocular pressure (IOP) is a major risk factor for glaucoma,1–3and it is the only proven treatable risk factor.",Non-OADS,/arxiv_data1/oa_pdf/70/ba/main.PMC4759511.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8b/3e/main.PMC4759512.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.10.004 Introduction Diabetic macular edema is characterized by intraretinal and subretinal accumulations of fluid, resulting principallyfrom retinal vascular leakage and is the main cause of visualimpairment in diabetic patients.",Non-OADS,/arxiv_data1/oa_pdf/8b/3e/main.PMC4759512.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fc/22/main.PMC4759513.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.09.001 Introduction Rosacea is a common chronic disease with unknown pathogenesis.,Non-OADS,/arxiv_data1/oa_pdf/fc/22/main.PMC4759513.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/49/42/main.PMC4759514.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.12.001 Peer review under responsibility of Saudi Ophthalmological Society, King Saud University Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.com www.sciencedirect.comReceived 18 October 2014; received in revised form 23 November 2015; accepted 3 December 2015; available online 11 December 2015. aDepartment of Ophthalmology, Nizwa Hospital, Oman bDepartment of Paediatrics, Nizwa Hospital, Oman cDept of Health Information and Research, Directorate General of Health Sevices, Al Dakhilya Governate, Oman ⇑Corresponding author at: Dept of Ophthalmology, Nizwa Hospital, PB 1222, Nizwa 611, Oman.",Non-OADS,/arxiv_data1/oa_pdf/49/42/main.PMC4759514.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a6/f6/main.PMC4759516.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.09.003 Introduction Retinitis Pigmentosa (RP) is the most common inherited retinal dystrophy.,Non-OADS,/arxiv_data1/oa_pdf/a6/f6/main.PMC4759516.pdf
"Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.This is an open access ar ticle under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).http://dx.doi.org/10.1016/j.sjopt.2015.12.003 Guru Nanak Eye Centre affiliated to Maulana Azad Medical College and associated Hospitals, Maharaja Ranjit Singh Marg, Near Barakhamba Flyover, New Delhi 110002, India ⇑Corresponding author at: G-30, First Floor, Preet Vihar, Opposite Metro Pillar No.",Non-OADS,/arxiv_data1/oa_pdf/58/e2/main.PMC4759517.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f2/cd/main.PMC4759518.pdf
http://dx.doi.org/10.1016/j.sjopt.2015.10.003 Introduction Valsalva retinopathy usually occurs as a result of increased venous pressure secondary to performing a Valsalva manoeu- vre.,Non-OADS,/arxiv_data1/oa_pdf/f2/cd/main.PMC4759518.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ec/36/main.PMC4759519.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.08.005 Introduction Neurofibromatosis type 1 (NF-1) is an autosomal domi- nantly inherited disease characterized by café-au-lait spots, neurofibromas, axillary freckling, Lisch nodules of iris, glio-mas and various systemic vascular ischemic manifestationsmainly in the aorta, brain and kidney.",Non-OADS,/arxiv_data1/oa_pdf/ec/36/main.PMC4759519.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/35/4a/main.PMC4759520.pdf
"http://dx.doi.org/10.1016/j.sjopt.2015.08.002 Introduction Blunt ocular trauma can result in a myriad of findings including commotion retinae, choroidal ruptures, macular hole, retinal detachment, retinal and vitreous hemorrhage.1 Isolated cases of retinal vascular occlusions in otherwise healthy patients have been reported in association with ocu- lar contusion.2–6We describe an unusual case of macular infarction and traumatic optic neuropathy (TON) followingblunt ocular trauma that resulted in severe, irreversible visual loss in a young male.",Non-OADS,/arxiv_data1/oa_pdf/35/4a/main.PMC4759520.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/c9/main.PMC4759523.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.01.089 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/c9/main.PMC4759523.pdf
"Undurti  N.  DasMD,  FAMS,  FRSC UND  Life  Sciences,  2020  S  360th  St,  #  K-202, Federal  Way,  WA  98003,  USA E-mail  addresses:  undurti@lipidworld.com Available  online  12  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.07.030 0019-4832/ #  2015  Published  by  Elsevier  B.V.  on  behalf  of  Cardiological Society  of  India.i  n  d  i  a  n  h  e  a  r  t  j  o  u  r  n  a  l  6  8  (  2  0  1  6  )  1  6  –  1  8 18",Non-OADS,/arxiv_data1/oa_pdf/72/a6/main.PMC4759524.pdf
Shaﬁqur  Rahman).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.031 0019-4832/ #  2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/02/2c/main.PMC4759525.pdf
Available  at:  http://www.iedcr.org/pdf/ ﬁles/NPHC%20WEB/ UPLOAD-4/Dr.Zaman.pdf  [accessed  7.5.15].,Non-OADS,/arxiv_data1/oa_pdf/02/2c/main.PMC4759525.pdf
Available  at  http://www.who.int/chp/ steps/Part4_Section4.pdf  [accessed  15.1.14].,Non-OADS,/arxiv_data1/oa_pdf/02/2c/main.PMC4759525.pdf
http://dx.doi.org/10.4172/2165-7904.1000123 .,Non-OADS,/arxiv_data1/oa_pdf/02/2c/main.PMC4759525.pdf
2008;7:40.  http://dx.doi.org/10.1186/1476-511X-7-40 .,Non-OADS,/arxiv_data1/oa_pdf/02/2c/main.PMC4759525.pdf
"Abbreviations:  CVD,  cardiovascular  disease;  WHO,  World  Health  Organization.Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.10.3020019-4832/ # 2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/49/32/main.PMC4759526.pdf
Available  from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html .,Non-OADS,/arxiv_data1/oa_pdf/49/32/main.PMC4759526.pdf
"This is an Open Access article distributed under the terms of the CreativeCommons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/81/ofv218.PMC4759583.pdf
"This is an Open Access article distributed under the terms of the CreativeCommons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1f/43/ofw001.PMC4759584.pdf
"http://www.alzforum org/news/research-news/smooth-muscle-cells-not-peri- cytes-control-brain-blood-flow (2015, accessed 19 July2015).",Non-OADS,/arxiv_data1/oa_pdf/0b/63/10.1177_0271678X15606723.PMC4759673.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Prediction of Low-Grade Glioma Response to TMZ Mazzocco et al.,Non-OADS,/arxiv_data1/oa_pdf/f9/26/PSP4-4-728.PMC4759703.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Quantitative Herb–Drug Interaction Prediction Gufford et al.,OADS,/arxiv_data1/oa_pdf/f8/71/PSP4-4-701.PMC4759704.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Modeling and Predicting Optimal Treatment Scheduling Wilson et al.,OADS,/arxiv_data1/oa_pdf/e4/00/PSP4-4-720.PMC4759705.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Tumor Growth Inhibition Model for Multiple Myeloma Jonsson et al.,Non-OADS,/arxiv_data1/oa_pdf/6d/03/PSP4-4-711.PMC4759707.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Population PK-PD Model for Tolerance Evaluation De Buck et al.,Non-OADS,/arxiv_data1/oa_pdf/57/4c/PSP4-4-691.PMC4759708.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"2 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"Reference Cm-3 catatgaatatcctccttag (32) Rho atatctgcgccgggtctg (32) VCJ-F2 catcttcgttgtgtaggctg This study VCJ-R2 atacttaactcctcatatgaatatcctc This studyGenomic comparison of O103:H2 Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"4 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"J Clin Microbiol 2005; 43: 1552 /C163.Genomic comparison of O103:H2 Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"6 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 30246 - http://dx.doi.org/10.3402/iee.v6.30246",Non-OADS,/arxiv_data1/oa_pdf/f7/6a/IEE-6-30246.PMC4759829.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distributio n, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"2 (page number not for citation purpose)Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"No statistically significantdifferences were observed in mean pH between the twoExtracellular pH in dental biofilms grown in vivo Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"4 (page number not for citation purpose)Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"Bars /C3020mm.Extracellular pH in dental biofilms grown in vivo Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"6 (page number not for citation purpose)Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1159/000360798 6.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1177/00220345440230040401 7.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1128/AEM.02090-09 13.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/ nrmicro1556 14.,OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1371/journal.pone.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1159/000357920 16.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/AEM.02831-14 17.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
http://rsb.info.nih.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"gov/ij/Extracellular pH in dental biofilms grown in vivo Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.3 109/00016357.2011.634833 23.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1099/jmm.0.011213-0 24.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/ 10.1016/j.archoralbio.2007.05.006 25.,OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1177/0022034509351812 27.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1371/journal.pone.0025299 30.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/10.1159/000079625 32.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
doi: http://dx.doi.org/83157 40.,Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
J Vis Exp 2016; e53622:2016. doi: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"8 (page number not for citation purpose)Citation: Journal of Oral Microbiology 2016, 8: 30390 - http://dx.doi.org/10.3402/jom.v8.30390",Non-OADS,/arxiv_data1/oa_pdf/5f/2e/JOM-8-30390.PMC4759832.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"The same ratio was used for NOR extraction, before proceeding to the ﬁrst centrifugation (see Materials and Methods section for more details).Methods for analyzing urinary EVs markers Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"Molecular weights are shown.Methods for analyzing urinary EVs markers Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"Thisresult reinforced the idea that these 2 sets of transcripts were loaded in different subpopulations of uEVs.Methods for analyzing urinary EVs markers Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"Molecular weights are indicated.Methods for analyzing urinary EVs markers Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497",OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"2013;2;20677, doi: http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"2012;1:18825, doi: http://dx.doi.org/10.3402/jev.v1i0.18825 20.",Non-OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"2009;100:1603 /C17.Methods for analyzing urinary EVs markers Citation: Journal of Extracellular Vesicles 2016, 5: 29497 - http://dx.doi.org/10.3402/jev.v5.29497 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/29/61/JEV-5-29497.PMC4759834.pdf
"MATERIALS AND METHODS In this study, the number of participants was selected as 12  people based on statistics analysis by GPower Software[47,48]  GPower 3.1.0 (Franz Faul,University of Kiel, Germany) retrieved from http://www.gpower.hhu.de/.",OADS,/arxiv_data1/oa_pdf/9e/40/JMSS-5-210.PMC4759837.pdf
"Version 5.0.23, retrieved from http://www.praat.",Non-OADS,/arxiv_data1/oa_pdf/9e/40/JMSS-5-210.PMC4759837.pdf
"Version 5.0.23, retrieved from http://www.praat.org/).",Non-OADS,/arxiv_data1/oa_pdf/9e/40/JMSS-5-210.PMC4759837.pdf
Available from: http://www.praat.,Non-OADS,/arxiv_data1/oa_pdf/9e/40/JMSS-5-210.PMC4759837.pdf
Additional information about the workshop may be found  at http://seminar.mui.ac.ir/light/.,Non-OADS,/arxiv_data1/oa_pdf/32/8e/JMSS-5-259.PMC4759843.pdf
"Also, the video files of the above lectures can be  accessed at http://amt.mui.ac.ir/fa/node/214.",Non-OADS,/arxiv_data1/oa_pdf/32/8e/JMSS-5-259.PMC4759843.pdf
Available from:  http://www.en: wikipedia.org/wiki/sushruta_samhita.,Non-OADS,/arxiv_data1/oa_pdf/06/81/IJOrtho-50-3.PMC4759871.pdf
"To view please visit the journal online (http://dx.doi.org/10.1136/oemed-2015-102979) 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy 2MRC Lifecourse Epidemiology Unit, University ofSouthampton, Southampton, UK 3National Research Centre for the Working Environment,Copenhagen, Denmark Correspondence to Dr Stefania Curti, UnitàOperativa di Medicina delLavoro, Policlinico S Orsola- Malpighi, via Pelagio Palagi 9, Bologna IT-40138, Italy;stefania.curti@unibo.it Received 26 March 2015 Revised 2 October 2015 Accepted 21 October 2015 Published Online First11 November 2015 To cite: Curti S, Coggon D, Hannerz H, et al.Occup Environ Med 2016; 73: 51–55.ABSTRACT Objectives To investigate the relationship between rhegmatogenous retinal detachment (RRD) and frequentheavy lifting in a Danish working population throughnational register data.Methods A dynamic cohort of all men aged 20 – 59 years in Denmark was followed through the DanishOccupational Hospitalisation Register from 1995 to 2010for diagnosed RRD.",Non-OADS,/arxiv_data1/oa_pdf/95/7b/oemed-2015-102979.PMC4759926.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Mitry D, Charteris DG, Fleck BW, et al.",Non-OADS,/arxiv_data1/oa_pdf/95/7b/oemed-2015-102979.PMC4759926.pdf
Based  on Automated sequencing the genes were characterized  and known sequences were compared using the BLAST  facility  (http://blast.ncbi.nlm.nih.gov).,OADS,/arxiv_data1/oa_pdf/8e/ab/AJM-6-17.PMC4759968.pdf
Available from: http://www.eucast.org/fileadmin/src/media/PDFs/ EUCASTfiles/Breakpointtables/Breakpointtablev2.0120221.pdf.,OADS,/arxiv_data1/oa_pdf/8e/ab/AJM-6-17.PMC4759968.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/d5/78/JOS-4-118.PMC4759975.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/d5/78/JOS-4-118.PMC4759975.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/16/c0/JOS-4-97.PMC4759977.pdf
Available from: http://www.currentdrugdicsovery.com.,Non-OADS,/arxiv_data1/oa_pdf/26/c8/JAPTR-7-17.PMC4759980.pdf
Available from: http://www.criticalchain.co.uk/How/  CriticalChainvsCriticalPa.html.,Non-OADS,/arxiv_data1/oa_pdf/26/c8/JAPTR-7-17.PMC4759980.pdf
Available from: http://www.criticalchain.,Non-OADS,/arxiv_data1/oa_pdf/26/c8/JAPTR-7-17.PMC4759980.pdf
Available from: http://www.projectsmart.co.uk/docs/project_  management_obstacle_course.pdf.,Non-OADS,/arxiv_data1/oa_pdf/26/c8/JAPTR-7-17.PMC4759980.pdf
Available from: http://www.citeulike.org/.,Non-OADS,/arxiv_data1/oa_pdf/17/cb/JAPTR-7-27.PMC4759983.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/75/1c/SJA-10-1.PMC4760026.pdf
Available from: http://www.ama-assn.org/ama/pub/ physician-resources/medical-ethics/code-medical-ethics/opinion9045.,Non-OADS,/arxiv_data1/oa_pdf/72/ff/SJA-10-4.PMC4760040.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/53/8e/SJA-10-58.PMC4760044.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.,Non-OADS,/arxiv_data1/oa_pdf/53/8e/SJA-10-58.PMC4760044.pdf
Available from: http://www.pic.dhe.ibm.com/infocenter/spssstat/ v20r0m0/index.jsp?topic=%2Fcom.ibm.spss.statistics.cs%2Fspchart_ table.htm.,OADS,/arxiv_data1/oa_pdf/e9/ba/SJA-10-68.PMC4760047.pdf
Available from: http://www.mobihealthnews.com/13368/report-13k- iphone-consumer-health-apps-in-2012.,Non-OADS,/arxiv_data1/oa_pdf/7a/49/SJA-10-87.PMC4760050.pdf
Available from: http://www.biomedicalcentral.com/1472-6947/12/67.,Non-OADS,/arxiv_data1/oa_pdf/7a/49/SJA-10-87.PMC4760050.pdf
Available from: http://www.uhbristol.nhs.uk/ media/1529656/uhbristolmobilephonepolicy.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7a/49/SJA-10-87.PMC4760050.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/5a/2d/msv250.PMC4760074.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"Multiple Alignments, Phy logenetic Analyses, and Topology Tests Multiple alignments were obtained using MUSCLE 3.5 ( Edgar 2004 ), available on the Bioinformatics toolkit platform of the Max Planck Institute for Developmental Biology at T €ubingen (http://toolkit.tuebingen.mpg.de , last accessed November 25, 2015).",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"BoxShade ( http://www.ch.embnet.org/ software/BOX_form.html , last accessed November 25, 2015) was used to generate printouts of some multiple alignments.",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"WebLogo ( http://weblogo.berkeley.edu , last accessed November 25, 2015) was used to generate sequence logos.",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"ML analyses were performed using the online available P H Y M Ls o f t w a r e( http://www.atgc-montpellier.fr/phyml/ , last accessed November 25, 2015; Guindon and Gascuel 2003 ;Guindon et al.",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"Phylogenetic trees were visualized and rooted using FigTree 1.4 developed by AndrewRambaud ( http://tree.bio.ed.ac.uk/software/ﬁgtree/ ,l a s t accessed November 25, 2015).",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"Ancestral State Reconstructions Character matrices were constructed with Mesquite (Version3.03; http://mesquiteproject.org , last accessed November 25, 2015).",OADS,/arxiv_data1/oa_pdf/13/d5/msv260.PMC4760075.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/f8/39/msv264.PMC4760077.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
"bData from the 1000 Genomes Project ( http://www.1000genomes.org , last accessed September 10, 2015).",OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
"In each section, the upper left panel shows the worldwide distri bution of allele frequencies as provided by the HGPD Selection Browser ( http://hgdp.uchicago.edu , last accessed May 12, 2015) ( Pickrell et al.",Non-OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
2009 ); the upper right panel is a box plot of metal ( A)o rp r o t e i na b u n d a n c e( B) by SNP genotype; and the bottom panel contains the selective sweep tracks in Han Chinese (CHB) or Europ eans (CEU) as provided by the 1000 Genomes Selection Browser 1.0 ( http://hsb.upf.,Non-OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
"Effect sizes and Pvalues obtained for all SNPs tested in the eQTL analysis ( supplementary table S10 ,Supplementary Material online) were extracted from the GTEx por- tal ( http://www.gtexportal.",OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
"Genotypes and additionalsample information have been deposited at the European Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/ , last accessed June 19, 2015), under accession numberEGAS00001001292.",OADS,/arxiv_data1/oa_pdf/74/04/msv267.PMC4760079.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/f4/1a/msv270.PMC4760081.pdf
Available from: http://www.bioinformatics.babraham.,Non-OADS,/arxiv_data1/oa_pdf/f4/1a/msv270.PMC4760081.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
Network was reconstructed using STRING database of known and predicted protein interactions ( http://string-db.org/ ; Szklarczyk et al.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
The presence ofconserved protein domains and motifs was veriﬁed using Conserved Domain Database (CDD; http://www.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
nih.gov/cdd ) and Conserved Domain Search Service (CD Search; http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
Other resources heavily used in the present study are: InBase—intein database ( http://tools.neb.com/inbase/ ; Perler 2002 ); European Nucleotide Archive (ENA: http:// www.ebi.ac.uk/ena/ ); Genome at NCBI ( http://www.ncbi.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
nlm.nih.gov/genome/ ); Basic Local Alignment Search Tool (BLAST) programs ( http://blast.ncbi.nlm.nih.gov/Blast.cgi ); “The All-Species Living Tree” Project ( http://www.arb-silva.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
COG annotation was performed using COG database ( http://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
The InterPro database was used in GO enrich- ment analysis ( http://www.ebi.ac.uk/interpro/ ).,OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
Supplementary Material Supplementary ﬁgures S1–S17 and tables S1–S7 are available atMolecular Biology and Evolution online ( http://www.mbe.,Non-OADS,/arxiv_data1/oa_pdf/45/ba/msv271.PMC4760082.pdf
"This is an Open Access article distributed under the terms o f the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use , distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/4f/c7/msv336.PMC4760084.pdf
Supplementary Material Supplementary ﬁgures S1–S3 and table S1 a r ea v a i l a b l ea t Molecular Biology and Evolution online ( http://www.mbe.,Non-OADS,/arxiv_data1/oa_pdf/4f/c7/msv336.PMC4760084.pdf
"Genomic DNA was prepared from isolated leukocytes using a standard procedure.14For mutation analysis, the extracted DNA was ampli ﬁed using PCR primer sets (Supplementary Table S1) for 13 exons of PAX6 (NCBI; M93650; http://www.ncbi.nlm.nih.gov/nuccore/189632/) under the PCR conditions previously described.16The PCR product was puri ﬁed and directly sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI 3100 autosequencer (Applied Biosystems, MA, USA), as previously described.17The sequences were compared with the reference in the database at the National Center for Biotechnology Information (NCBI;NC_000011.9; http://www.ncbi.nlm.nih.gov/nuccore/NC_000011.9).",OADS,/arxiv_data1/oa_pdf/43/be/hgv201552.PMC4760117.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplemental Information for this article can be found on the Human Genome Variation website (http://www.nature.com/hgv).Genotype –phenotype correlation in Aniridia T Yokoi et al 5 © 2016 The Japan Society of Human Genetics Human Genome Variation (2016) 15052",Non-OADS,/arxiv_data1/oa_pdf/43/be/hgv201552.PMC4760117.pdf
"Three variant reads were identi ﬁed in the mother out of a total read depth of 18 suggesting 17% mosaicism.Sanger sequence con ﬁrmation was performed as described with a reduced signal from the mutant allele supporting mosaicism.4 This novel splice site variant was not present in the Human GeneMutation Database (HGMD Version 2014.2) or in the ExomeVariant Server (Version ESP6500SI-V2, 6,503 individuals, Seattle,WA, USA; http://evs.gs.washington.edu/EVS).",Non-OADS,/arxiv_data1/oa_pdf/44/23/hgv201569.PMC4760119.pdf
"We look forward to future ascertainment of additional patients with this condition to lead to a more complete understanding of the clinical spectrum, facilitate its clinical recognition andappreciate the remarkable developmental pleiotropy of OFD1 dysfunction and phenotype.HGV DATABASE The relevant data from this Data Report are hosted at the Human Genome Variation Database at http://dx.doi.org/10.6084/ m9.ﬁgshare.hgv.768.",Non-OADS,/arxiv_data1/oa_pdf/44/23/hgv201569.PMC4760119.pdf
"Information on each variant was obtained from the UCSC Genome Browser (GRCh37/hg19 assembly) (http://genome.ucsc.edu/)9and the HapMap10database for the population of Han Chinese in Beijing, China (CHB).",OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
"Candidate variants located in the 3 ʹ-untranslated region (UTR) of genes were screened with two databases; microRNA.org —Targets and Expression (http://www.micro rna.org/microrna/home.do)13,14and miRDB (http://mirdb.org/miRDB/).15,16 This screening was used to determine whether the variants were located inpredicted microRNA-binding sites.",Non-OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
"In addition, variants were also examined to determine whether they were located withinDNaseI hypersensivity sites or gene regulatory sites (e.g., promoter regions) using HaploReg v2 (http://www.broadinstitute.org/mammals/haploreg/ haploreg.php) 17and to prioritize functionally interesting variants.",Non-OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
"Furthermore, investigations in the UCSC genome browser (http://genome.ucsc.edu/) Gene Sorter database 40revealed that expression of ITPA is high in peripheral blood CD4+ T cells and in the lungs.",OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
Available at http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf?ua = 1.,Non-OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information for this article can be found on the Human Genome Variation website (http://www.nature.com/hgv)New susceptibility variants for young-onset tuberculosis A Nakauchi et al 6 Human Genome Variation (2016) 15067 © 2016 The Japan Society of Human Genetics",Non-OADS,/arxiv_data1/oa_pdf/e4/0e/hgv201567.PMC4760120.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 335–340International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  335OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S9638 5Feasibility of spirometry in primary care to screen  for COPD: a pilot study Violaine giraud1,2 alain Beauchet3 Thierry gomis4 Thierry Chinet1,2 1aP-hP, Department of Pneumology  and Thoracic Oncology, ambroise- Paré hospital, 2UeFr Paris île- de-France Ouest, Versailles saint  Quentin-en-Yvelines University,   3Public health Department, Unité  de recherche Clinique, hôpitaux  Universitaires Paris Ile-de-France  Ouest, 4Boulogne-Billancourt, Paris,   FranceBackground:  COPD is a frequent but underdiagnosed disease whose diagnosis relies on the  spirometric demonstration of bronchial obstruction.",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"However, numerous arguments  support COPD screening, most notably because forced expiratory volume in 1 second  (FEV1) declines rapidly at the early stage,10,11 effective treatments exist to diminish  dyspnea and the frequency of exacerbations,12 and outcomes of attempts to quit smoking  might improve after diagnosis.13,14 In a Finnish global screening program, early COPD  management was able to lower the number of hospitalizations by ~40%.15 Furthermore, Correspondence: Violaine giraud service de Pneumologie et d’Oncologie  Thoracique, hôpital ambroise-Paré,  9 avenue Charles de gaulle, 92104  Boulogne-Billancourt, Paris, France Tel +33 01 4909 5802 Fax +33 01 4909 5806 email violaine.giraud@aphp.f r Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Giraud et al Running head recto: Primary-care spirometry screening for COPD DOI: http://dx.doi.org/10.2147/COPD.S96385",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
Available from: http://www.who.int/gard/publications/ chronic_respiratory_diseases.pdf .,Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
Available from: http://www.sante.,Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"Avail - able from: http://www.goldcopd.co m. Accessed January 5, 2016.",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"Available from:  http://www.drees.sante.gouv.fr/IMG/pdf/er481.pd f. Accessed January 5,   2016.",Non-OADS,/arxiv_data1/oa_pdf/91/24/copd-11-335.PMC4760207.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 327–334International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  327StuD y Pr OtOCO lopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/COPD.S10085 9Study protocol for a randomized controlled trial  of telephone-delivered cognitive behavior therapy  compared with befriending for treating depression  and anxiety in older adults with COPD Colleen Doyle,1 David  Dunt,2 David Ames,3 Marcia  Fearn,3 Emily (Chuanmei)  you,1 Sunil Bhar4 1Australian Catholic university,   Melbourne, VIC, Australia; 2Centre  for Health Policy, the university  of Melbourne, Melbourne, VIC,   Australia; 3National Ageing research  Institute, Melbourne, VIC, Australia;   4Department of Psychological  Sciences, Swinburne university of  technology, Hawthorn, VIC, AustraliaBackground:  COPD is an umbrella term to describe chronic lung diseases that cause limitations  in lung airflow, including emphysema and chronic bronchitis.",Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
"COPD has multiple comorbidities, and two of the most common and least-treated  comorbidities are depression and anxiety.2 There has been no consensus on the preva - lence of depression and anxiety in people with COPD, due in part to the variation in Correspondence: Colleen Doyle Villa Maria Catholic Homes, 6 Studley  Park rd, Kew, VIC 3101, Australia tel +61 4 0973 9136 Fax +61 3 9387 4030 Email colleen.doyle@acu.edu.a u Journal name: International Journal of COPD Article Designation: Study Protocol Y ear: 2016 Volume: 11 Running head verso: Doyle et al Running head recto: A study protocol for telephone support for patients with COPD DOI: http://dx.doi.org/10.2147/COPD.S100859 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
Or use: http://youtu.be/5gRNkXgLGk 0Video abstract,Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a3/40/copd-11-327.PMC4760208.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/22/92/ppa-10-153.PMC4760209.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 153–158Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  153OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S7547 7Priorities in the primary care of persons  experiencing homelessness: convergence and  divergence in the views of patients and provider/ experts Jocelyn steward,1 cheryl l  holt,2 David e Pollio,3 erika l  Austin,4,5 nancy Johnson,4 Adam  J gordon,6,7 stefan g Kertesz4,8 1Department of health care Management,   clayton state University, Morrow, gA,   2Department of Psychology, University of  Maryland, college Park, MD, 3Department  of social Work, University of Alabama at  Birmingham, 4Birmingham VA Medical center,   5Department of Biostatistics, University of  Alabama at Birmingham school of Public  health, Birmingham, Al, 6VA Pittsburgh health  care system, 7University of Pittsburgh school  of Medicine, Pittsburgh, PA, 8Department of  Medicine, University of Alabama at Birmingham  school of Medicine, Birmingham, Al, UsAPurpose:  Homeless individuals face unique challenges in health care.",Non-OADS,/arxiv_data1/oa_pdf/22/92/ppa-10-153.PMC4760209.pdf
"First, under new correspondence: stefan g Kertesz health services research and Development  Program, Birmingham VA Medical center, 700  south 19th street, Birmingham, Al 35233, UsA Tel +1 205 996 2866 Fax +1 205 439 7248 email skertesz@uabmc.ed u Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Steward et al Running head recto: Priorities in the primary care of persons experiencing homelessness DOI: http://dx.doi.org/10.2147/PPA.S75477 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/22/92/ppa-10-153.PMC4760209.pdf
Or use: http://youtu.be/Bd_nEPSBB7 wVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/22/92/ppa-10-153.PMC4760209.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/22/92/ppa-10-153.PMC4760209.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2016:11 341–349International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  341OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S8902 7COPD characteristics and socioeconomic burden  in hellenic correctional institutions eleni g Bania1 Zoe Daniil1 Chrysa hatzoglou1 evangelos C alexopoulos2 eirini Mitsiki3 Konstantinos I  gourgoulianis1 1respiratory Medicine Department,   University of Thessaly Medical school,   University hospital of larissa, larissa,   2Faculty of social sciences, hellenic  Open University, Patras, 3Medical  Department, novartis hellas, athens,   greeceBackground:  The high prevalence of smoking (80%) in Greek correctional institutions is  anticipated to result in high prevalence of COPD in such settings.",Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
"Among members of the European Union,  Greece has one of the highest consumption rates of tobacco products, with an estimated  average of 2,458 sticks per capita for 2010, equivalent to a total of 27.7 billion cigarettes Correspondence: eleni g Bania University of Thessaly Medical school,  Biopolis, larissa 41500, greece Tel +30 69 5800 8644 email bania.eleni@hotmail.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Bania et al Running head recto: COPD characteristics and burden in Greek correctional institutions DOI: http://dx.doi.org/10.2147/COPD.S89027",Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
"Available from:  http://www.who.int/respiratory/copd/burden/en/index.htm l. Accessed  December 22, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
Available from: http://who.int/ mediacentre/factsheets/fs310/en /.,OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
"Available at http://www.ministryofjustice.gr/ site/el/APXIKH.asp x. Accessed December 17, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5d/b9/copd-11-341.PMC4760210.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"Cipro ﬂoxacin's bactericidal action is due to interference with the enzyme DNA gyrase, which is needed for the synthesis ofContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/rinphsResults in Pharma Sciences http://dx.doi.org/10.1016/j.rinphs.2015.06.001 2211-2863/ &2016 Published by Elsevier B.V.",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"79 (2) (2011) 320 –327, http://dx.doi.org/10.1016/j.ejpb.2011.05.006 21641994 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"73 (6) (2011) 615 –620, http://dx.doi.org/ 10.4103/0250-474X.100234 23112394 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"Murthy, Thermoreversible-mu- coadhesive gel for nasal delivery of sumatriptan, AAPS PharmSciTech 7 (3) (2006) 67, http://dx.doi.org/10.1208/pt070367 17025248 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"315 (1–2) (2006) 12 –17,http://dx.doi.org/10.1016/j.ijpharm.2006.01.029 16616442 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"14 (3) (2013) 6499 –6515, http://dx.doi.org/10.3390/ijms14036499 23525047 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"9 (2) (2012) 197 –204, http://dx.doi.org/10.2174/ 156720112800234530 22283647 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"31 (3) (1998) 267 –285, http://dx.doi.org/10.1016/S0169-409X(97)00124-5 10837629 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"56 (11) (2008) 1596 –1599, http://dx.doi.org/10.1248/cpb.56.1596 18981612 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"4 (2012) S42 –S45, http://dx.doi.org/ 10.4103/0975-7406.94138 23066202 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"78 (4) (2010) 959 –976, http://dx.doi.org/10.3797/scipharm.1001-06 21179328 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"[21] Y. Liu, J. Liu, X. Zhang, R. Zhang, Y. Huang, C. Wu, In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery, Aaps PharmSciTech 11 (2) (2010) 610 –620, http://dx.doi.org/10.1208/s12249-010-9413-0 20354916 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"315 (1–2) (2006) 12 –17,http://dx.doi.org/10.1016/j.ijpharm.2006.01.029 16616442 .",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
"33 (5) (2008) 469 –475, http://dx.doi.org/10.1080/02713680802023104 18568884 .S.B.",Non-OADS,/arxiv_data1/oa_pdf/1d/a0/main.PMC4760229.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fb/57/main.PMC4760230.pdf
Due to theContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/mmcrMedical Mycology Case Reports http://dx.doi.org/10.1016/j.mmcr.2016.02.001 2211-7539/ &2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/fb/57/main.PMC4760230.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fb/57/main.PMC4760230.pdf
The ﬁnal se- quences were compared with others from the C. tropicalis MLST database ( http://pubmlst.org/ctropicalis/ ).,OADS,/arxiv_data1/oa_pdf/fb/57/main.PMC4760230.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine International Journal of Nanomedicine 2016:11 597–605Dove press submit your manuscript | www.dovepress.co m Dove press  OrIg INal researchopen access to scientific and medical research Open access Full T ext article 597 http: //dx.doi.org/10.2147/IJN.S9565 4cytoprotective effect of glutaraldehyde  erythropoietin on heK293 kidney cells  after silver nanoparticle exposure Kanidta sooklert1,2 supreecha chattong3 Krissanapong Manotham3 chawikan Boonwong1 I-yanut Klaharn1 Depicha Jindatip4 amornpun sereemaspun1,4 1Nanobiomedicine laboratory, Department  of anatomy, Faculty of Medicine,   2Inter-Department Program of Biomedical  sciences, Faculty of graduate school,   chulalongkorn University, 3renal Unit,   Department of Medicine, lerdsin general  hospital, 4Department of anatomy, Faculty  of Medicine, chulalongkorn University,   Bangkok,  ThailandAbstract:  The toxic effects from exposure to silver nanoparticles (AgNPs), which are broadly  present in many consumer products, have long raised concerns.",Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
"Previous studies have revealed that AgNPs can induce cel - lular apoptosis through the mitochondrial-dependent apoptosis pathway that involves  downregulation of the pro-survival protein Bcl2.4 Many reports show that the main  mechanism of AgNP-induced damage in mammalian cells is mediated by increases  in the level of intracellular reactive oxygen species (ROS) and oxidative stress.5,6 correspondence: amornpun sereemaspun Nanobiomedicine laboratory, Department of  anatomy, Faculty of Medicine, chulalongkorn  University, 1873 rama 4 road, Pathumwan,  Bangkok 10330, Thailand Tel +66 9 6569 8859 Fax +66 2 252 7028 email amornpun.s@chula.ac.t h Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Sooklert et al Running head recto: Glutaraldehyde-EPO prevents nanosilver-induced kidney injury DOI: http://dx.doi.org/10.2147/IJN.S95654 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
Or use: http://youtu.be/hzznwIxKBa UVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/a5/ijn-11-597.PMC4760275.pdf
"Our workalso demonstrated that IFN gcan induce the upregulation of B7-H4 in vitro , and © Ramtin Rahbar and Pamela S Ohashi *Correspondence to: Pamela S Ohashi; Email: pohashi@uhnres.utoronto.caSubmitted: 05/05/2015; Revised: 05/07/2015; Accepted: 05/08/2015 http://dx.doi.org/10.1080/2162402X.2015.1050575 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
Nat Rev Immunol 2008; 8:467-77; PMID:18500231; http://dx.doi.org/10.1038/nri2326 2.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
Cancer Immunol Res 2015; 3:184-95; PMID:25527357; http://dx.doi.org/10.1158/2326- 6066.CIR-14-0113 4.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
J Clinical Oncol 2015; 33(17):1974-82; PMID:25605845; http://dx.doi.org/JCO.2014.59.43585.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell inﬁltration.Gynecol Oncol 2007; 106:119-27; PMID:17509674; http://dx.doi.org/10.1016/j.ygyno.2007.03.039 6.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
Applied Immunohistochem Mol Morphol 2007; 15:363-70; PMID:18091377; http://dx.doi.org/ 10.1097/01.pai.0000213159.79557.71 7.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
Biochem Bio-physical Res Commun 2015; 459:277-83; PMID:25725157; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
Science Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/ scitranslmed.3003689 10.,Non-OADS,/arxiv_data1/oa_pdf/2e/9e/koni-05-01-1050575.PMC4760282.pdf
"© Mohammad A. Sayem, Yusuke Tomita, Akira Yuno, Masatoshi Hirayama, Atsushi Irie, Hirotake Tsukamoto, Satoru Senju, Eiji Yuba, Toshiaki Yoshikawa, Kenji Kono, Tetsuya Nakatsura, and Yasuharu Nishimura*Correspondence to: Yasuharu Nishimura; Email: mxnishim@gpo.kumamoto-u.ac.jpSubmitted: 04/13/2015; Revised: 06/01/2015; Accepted: 06/10/2015 http://dx.doi.org/10.1080/2162402X.2015.1062209 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
"44 Prediction and selection of possible promiscuous HLA class II-binding GPC3-LPs To predict possible promiscuous HLA class II-binding human GPC3-derived peptides, the amino acid sequence of the humanGPC3 protein was analyzed using a computer algorithm, http://tools.immuneepitope.org/mhcii/).",OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Hepatology 2011; 53:1020-2; PMID:21374666; http://dx.doi.org/10.1002/hep.24199 2.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/ NEJMoa0708857 3.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
J Hepatol 2014; 60:681; PMID:24216445; http://dx.doi.org/ 10.1016/j.jhep.2013.10.030 4.,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Hepatol Res 2011;41:296-302; PMID:21348907; http://dx.doi.org/ 10.1111/j.1872-034X.2011.00778.x 5.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx.doi.org/10.1016/S0006-291X(03)00908-2 7.,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Res 2005; 65:6245-54; PMID:16024626; http://dx.doi.org/10.1158/0008-5472.CAN-04-4244 8.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044 9.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Clin Cancer Res 2006; 12:2689-97; PMID:16675560; http://dx.doi.org/10.1158/1078- 0432.CCR-05-2267 10.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Eur J Immunol 1993; 23:1011-6; PMID:8386663; http://dx.doi.org/10.1002/eji.1830230504 13.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Nat Rev Immunol2003; 3:621-9; PMID:12974477; http://dx.doi.org/ 10.1038/nri1149 14.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
J Exp Med 2004; 200:701-12; PMID:15381726; http://dx.doi.org/10.1084/jem.20041270 17.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Res 2004; 64:386-90; PMID:14729649; http://dx.doi.org/10.1158/0008- 5472.CAN-03-2596 18.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Blood 2001; 97:192-7; PMID:11133760; http://dx.doi.org/ 10.1182/blood.V97.1.192 20.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-1322 21.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Nat Rev Cancer 2008; 8:351-60;PMID:18418403; http://dx.doi.org/10.1038/nrc2373 22.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
ClinCancer Res 2011; 17:6847-57; PMID:21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385 23.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Clin Cancer Res 2011; 17:4568- 80; PMID:21586625; http://dx.doi.org/10.1158/ 1078-0432.CCR-11-0184 24.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Tissue Antigens 2000; 56:522-9; PMID:11169242; http://dx.doi.org/10.1034/j.1399-0039.2000.560606.x 25.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Tissue Antigens 2000; 55:383-400; PMID:10885559; http://dx.doi.org/10.1034/j.1399- 0039.2000.550501.x 26.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Int J Cancer 2008; 123:2616-25; PMID:18770861;http://dx.doi.org/10.1002/ijc.2382327.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Sci 2011; 102:71-8; PMID:21087352; http://dx.doi.org/10.1111/j.1349- 7006.2010.01780.x 28.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Hum Vaccin Immunother 2013; 9:1228-33; PMID:23466818; http://dx.doi.org/10.4161/hv.24179 29.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Clin Cancer Res 2013; 19:4508-20; PMID:23714729; http://dx.doi.org/ 10.1158/1078-0432.CCR-13-0197 31.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Int J Cancer 2014; 134:352-66; PMID:24734272; http://dx.doi.org/10.1002/ijc.28376 32.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Sci 2015; 106 (5):505–11; PMID:25726868; http://dx.doi.org/10.111/cas.12650 33.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Oncoimmunology 2014; 3:e28100; PMID:25340007; http://dx.doi.org/10.4161/onci.28100 34.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Clin Cancer Res 2015; 21:312-21; PMID:25391695; http://dx.doi.org/10.1158/1078-0432.CCR-14-0202 35.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi.org/10.1056/ NEJMoa0810097 36.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/ nature11824 37.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Nat Rev Immunol 2002; 2:85-95; PMID:11910899; http://dx.doi.org/10.1038/nri724 38.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
PMID:23374704; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
J Immunother 2012; 35:78-88; PMID:22130163; http://dx.doi.org/10.1097/CJI.0b013e31823731a4 40.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Annu Rev Biochem 1988; 57:991-1028; PMID:3140715; http://dx.doi.org/10.1146/annurev.bi.57.070188.005015 41.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
J Clin Oncol 2011;29:610-8; PMID:21245428; http://dx.doi.org/ 10.1200/JCO.2010.30.5425 44.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Immunogenetics 2013; 65:357-70; PMID:23392739; http://dx.doi.org/10.1007/s00251-013-0684-y 45.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
BMC Bioinformatics 2010; 11:568; PMID:21092157; http://dx.doi.org/10.1186/ 1471-2105-11-568 46.,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Cancer Sci 2011; 102:697-705;PMID:21231984; http://dx.doi.org/10.1111/j.1349- 7006.2011.01865.x 47.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Biomaterials 2013; 34:5711-21;PMID:23639528; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Int J Cancer 2010; 127:1393-403; PMID:20063317; http://dx.doi.org/ 10.1002/ijc.25160 49.,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
Hum Immunol 1998; 59:549-60; PMID:9757911; http://dx.doi.org/10.1016/S0198- 8859(98)00050-0 5 0 .,OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
J Exp Med 1997; 185:2043-51; PMID:9182675; http://dx.doi.org/10.1084/jem.185.12.2043 e1062209-14 Volume 5 Issue 1 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/55/04/koni-05-01-1062209.PMC4760284.pdf
"1, e1069462 (3 pages)http://dx.doi.org/10.1080/2162402X.2015.1069462",Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
Cancer Res 2007;67:5479-88; PMID:17545630; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
J Immunol 2003; 170:3488-94; PMID:12646609;http://dx.doi.org/10.4049/jimmunol.170.7.3488 5.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
J Exp Med 2011; 208: 761-73; PMID:21444662; http://dx.doi.org/10.1084/jem.201019676.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
Front Immunol 2013; 4: 192; PMID:23874338;http://dx.doi.org/10.3389/ ﬁmmu.2013.00192 7.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
Immunol Cell Biol 2015;ePub Advance Online Publication 16 June 2015; PMID:26010746; http://dx.doi:10.1038/icb.2015.58 8.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
Int J Cancer 2014; 135:2868-77; PMID:24789737; http://dx.doi.org/10.1002/ijc.28945 10.,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
Cancer Cell 2014;26:623-37; PMID:25446896; http://dx.doi.org/10.1016/j.ccell.2014.09.006ONCOIMMUNOLOGY e1069462-3,Non-OADS,/arxiv_data1/oa_pdf/fa/b6/koni-05-01-1069462.PMC4760289.pdf
"1, e1104448 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1104448",Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Curr Opin Immunol 2013; 25:381-8;PMID:23582509; http://dx.doi.org/10.1016/j.coi.2013.03.003 2.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Eur J Immunol 2009; 39:902-11; PMID:19197939; http://dx.doi.org/10.1002/eji.200838780 3.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Immunol Rev 2009; 229:114-25; PMID:19426218; http://dx.doi.org/10.1111/j.1600-065X.2009.00767.x 4.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Immunity 1999; 11:141-51; PMID:10485649; http://dx.doi.org/10.1016/S1074-7613 (00)80089-8 5.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Science 2001; 291:319-22; PMID:11209085; http://dx.doi.org/10.1126/science.291.5502.3196.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Annu Rev Immunol 2008; 26:677-704;PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331 7.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
FEBS Lett 2004; 574:37-41; PMID:15358536; http://dx.doi.org/10.1016/j.febslet.2004.07.083 8.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c 9.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/10.4161/onci.21335 10.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792 11.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/10.1172/ JCI73639 12.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/ NEJMoa1305133 13.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Clin Oncol2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/ JCO.2013.53.0105 14.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
N Engl J Med 2013; 369:122- 33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369 15.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Clin Cancer Res 2014; 20:5064-74;PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271 16.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Nature2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954 17.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Clin Dev Immunol 2013; 2013:932318; PMID:24194775; http://dx.doi.org/10.1155/2013/932318 19.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Immunol 2013; 191:540-4; PMID:23772031; http://dx.doi.org/10.4049/jimmunol.1203161 22.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Immunity 2011; 35:400-12; PMID:21943489; http://dx.doi.org/10.1016/j.immuni.2011.06.015 2 3 .,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Cancer Immunol Immunother 2009; 58:553-66; PMID:18751701; http://dx.doi.org/10.1007/s00262-008-0578-2 24.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Eur J Immunol 2002; 32:3181-90; PMID:12555663; http://dx.doi.org/10.1002/1521-4141(200211)32:11%3c3181::AID- IMMU3181%3e3.0.CO;2-2 25.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Oncotarget 2015; 6:9612-26; PMID:25823822; http://dx.doi.org/10.18632/oncotarget.3324 26.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Immu- nity 2015; 42:265-78; PMID:25680272; http://dx.doi.org/10.1016/j.immuni.2015.01.00627.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Immunol 2008;181:4832-9; PMID:18802087; http://dx.doi.org/10.4049/jimmunol.181.7.4832 28.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Exp Med 2015; 212:1125-37; PMID: 26034050; http://dx.doi.org/10.1084/jem.20142237 29.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
J Exp Med 2000; 191:891-8; PMID:10704469; http://dx.doi.org/ 10.1084/jem.191.5.891 31.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
Int Immunol 2007; 19:1223-34; PMID:17898045; http://dx.doi.org/10.1093/intimm/dxm091 32.,Non-OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
JImmunother 2010; 33:956-64; PMID:20948441; http://dx.doi.org/ 10.1097/CJI.0b013e3181fad2b0 33.,OADS,/arxiv_data1/oa_pdf/33/4c/koni-05-01-1104448.PMC4760290.pdf
"2 NK cells-mediated innate immunity is proposed to play a pivotal role in host defense against cell malignancy transformation.3,4NK © Jian Gao, Zhaojun Duan, Ling Zhang, Xiangbo Huang, Lu Long, Jing Tu, Hua Liang, Yu Zhang, Tao Shen, and Fengmin Lu *Correspondence to: Tao Shen; Email: taoshen@hsc.pku.edu.cn; Fengmin Lu; Email: lu.fengmin@hsc.pku.edu.cn;Submitted: 03/10/2015; Revised: 04/29/2015; Accepted: 04/30/2015 http://dx.doi.org/10.1080/2162402X.2015.1048061 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
CA: a cancer journal for clinicians 2011; 61:69-90; PMID:21296855;http://dx.doi.org/10.3322/caac.20107 2.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Lancet 2003; 362:1907-17; PMID:14667750; http://dx.doi.org/10.1016/S0140-6736(03)14964-1 3.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J Immunol 2014; 193:2016-23; PMID:25015826; http://dx.doi.org/10.4049/ jimmunol.13023895.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/ 10.1038/ni1582 7.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Int J Cancer J Int du Cancer 2007; 120:2625-34; PMID:17294447; http://dx.doi.org/10.1002/ijc.22579 9.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Clin Cancer Res 2009; 15:6993-7002; PMID:19861434; http://dx.doi.org/10.1158/1078- 0432.CCR-09-0991 10.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Cell 2010; 142:847-56; PMID:20850008; http://dx.doi.org/10.1016/j.cell.2010.08.031 11.,OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Clin Immunol 2008; 129:428-37;PMID:18824414; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Hepatology 2011; 53:73-85; PMID:21254163; http://dx.doi.org/10.1002/hep.23977 e1048061-10 Volume 5 Issue 1 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Eur J Immunol 2010; 40:2289-95; PMID:20540115; http://dx.doi.org/10.1002/ eji.200939910 14.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
PLoS pathogens 2012; 8:e1002594; PMID:22438812; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J Hepatol 2005;43:1013-20; PMID:16168521; http://dx.doi.org/ 10.1016/j.jhep.2005.05.026 16.,OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Blood 2010; 115:5170-9;PMID:20393128; http://dx.doi.org/10.1182/blood- 2009-11-256479 17.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
AIDS 2002; 16:1251-6; PMID:12045490; http://dx.doi.org/ 10.1097/00002030-200206140-00007 1 9 .,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Blood 2011; 118:3321-30; PMID:21791421; http://dx.doi.org/10.1182/blood- 2011-04-347260 20.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Cell Death Dis 2014; 5:e1512; PMID:25375377; http://dx.doi.org/10.1038/ cddis.2014.470 21.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Cancer Res 2012; 72:5463-72; PMID:22915757; http://dx.doi.org/10.1158/0008-5472.CAN-11-267123.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Gastroen- terology 2010; 138:1931-42; PMID:20060829; http://dx.doi.org/10.1053/j.gastro.2009.12.051 25.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Clin Exp Med 2003;3:181-5; PMID:14648234; http://dx.doi.org/10.1007/ s10238-003-0023-y 26.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Hepatology 2013; 57:1654-62; PMID:23111952; http://dx.doi.org/10.1002/hep.26115 27.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Hepatology 2006; 43:362-72; PMID:16440347; http://dx.doi.org/10.1002/ hep.21035 28.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Hepatology 2009; 50:799-807; PMID:19551844; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J hepato-biliary-pancreat Surg 2008;15:515-21; PMID:18836806; http://dx.doi.org/ 10.1007/s00534-007-1293-7 30.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J Hepatol 2003; 38:200-7; PMID:12547409; http://dx.doi.org/ 10.1016/S0168-8278(02)00360-4 31.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Ann Surg Oncol 2014; 21:2429-35; PMID:24619495; http://dx.doi.org/ 10.1245/s10434-014-3621-x 32.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J Proteome Res 2014; 13:4847-58; PMID:24967658; http://dx.doi.org/10.1021/pr500262p 33.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Oncoimmunology 2013; 2: e26663; PMID:24498552; http://dx.doi.org/10.4161/ onci.26663 35.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/ onci.28147 36.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Oncoimmunology 2014; 3:e28582; PMID:25050222; http://dx.doi.org/10.4161/onci.28582 37.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Oncoimmunol- ogy 2013; 2:e25220; PMID:24167761; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Nat Rev Immunol 2003; 3:781-90; PMID:14523385; http://dx.doi.org/10.1038/nri1199 39.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Cancer Res 2013;73:1777-86; PMID:23302231; http://dx.doi.org/ 10.1158/0008-5472.CAN-12-3558 40.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
J Surg Oncol 2004; 85:36-41; PMID:14696085; http://dx.doi.org/10.1002/jso.10284 41.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Oncogene 2008; 27:5944-58;PMID:18836475; http://dx.doi.org/10.1038/ onc.2008.272 42.,OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Immunological Rev 2010; 235:267-85; PMID:20536569; http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x 43.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
O ncoimmunology 2014; 3: e28497; PMID:25050215; http://dx.doi.org/10.4161/onci.28497 44.,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
Lab Invest 2005; 85:285-96; PMID:15640833; http://dx.doi.org/10.1038/labinvest.3700219 www.tandfonline.com e1048061-11 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/7d/f4/koni-05-01-1048061.PMC4760296.pdf
"23-26 The insufﬁciency of NK cells in AML and the purported prognostic role of NK cells have inspired the design of NK cell-based immunotherapies, including the use of NK cell-activating © Anna Martner, Anna Rydstr €om, Rebecca E Riise, Johan Aurelius, Harald Anderson, Mats Brune, Robin Fo /C18a, Kristoffer Hellstrand, and Fredrik B Thor /C19en *Correspondence to: Kristoffer Hellstrand; Email: kristoffer.hellstrand@gu.seSubmitted: 02/05/2015; Revised: 04/07/2015; Accepted: 04/10/2015 http://dx.doi.org/10.1080/2162402X.2015.1041701 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
CA Cancer J Clin 2015; 65:5-29; PMID:25559415;http://dx.doi.org/10.3322/caac.21254 2.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Clin Oncol 2005; 23:1969-78; PMID:15632409; http://dx.doi.org/ 10.1200/JCO.2005.06.0273.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Clin Oncol 2013; 31:1293-301; PMID:23439754; http://dx.doi.org/10.1200/ JCO.2011.40.5977 4.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2005; 106:1154-63; PMID:15870183; http://dx.doi.org/10.1182/blood- 2005-01-01785.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2012;119:3890-9; PMID:22383796; http://dx.doi.org/ 10.1182/blood-2011-12-379008 6.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
PMID:11986221; http://dx.doi.org/10.1182/blood.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2007; 109:323-30; PMID:16940427; http://dx.doi.org/ 10.1182/blood-2005-08-027979 8.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Clin Exp Immunol 2001;126:403-11; PMID:11737054; http://dx.doi.org/ 10.1046/j.1365-2249.2001.01692.x 10.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Leuke- mia 2003; 17:716-30; PMID:12682629; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Leukemia 2012; 26:2019-26; PMID:22446501; http://dx.doi.org/10.1038/ leu.2012.87 13.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood Rev 2013; 27:209-16;PMID:23871358; http://dx.doi.org/10.1016/j.blre.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Cancer Immunol Immunother 2011; 60:1195-205; PMID:21644031; http://dx.doi.org/10.1007/s00262-011-1050-2 15.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.1068440 16.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2005; 105:4878-84; PMID:15731175; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2011; 117:764-71; PMID:20889923; http://dx.doi.org/10.1182/blood-2010-08-264085 18.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/ 10.1182/blood-2007-09-077438 20.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Immunol 2007; 179:89-94; PMID:17579025; http://dx.doi.org/10.4049/jimmunol.179.1.89 21.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Immunology 2009; 126:458-65; PMID:19278419; http://dx.doi.org/ 10.1111/j.1365-2567.2008.03027.x 22.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Immunol 2007; 178:4947-55; PMID:17404276; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/ 10.1146/annurev.immunol.23.021704.115526 25.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/ 10.1146/annurev-immunol-020711-075005 26.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Annu Rev Immunol 2001; 19:197-223; PMID:11244035; http://dx.doi.org/ 10.1146/annurev.immunol.19.1.197 27.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Immunotherapy 2011;3:1445-59; PMID:22091681; http://dx.doi.org/ 10.2217/imt.11.131 28.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2006;108:88-96; PMID:16556892; http://dx.doi.org/ 10.1182/blood-2005-10-4073 29.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2012; 119:5832-7; PMID:22550344; http://dx.doi.org/10.1182/blood-2011-11-391722 31.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Nature medicine 2011;17:537; PMID:21546964; http://dx.doi.org/10.1038/ nm0511-537a 35.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Cancer Invest 2011; 29:293-9; PMID:21469978; http://dx.doi.org/ 10.3109/07357907.2011.568563 37.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Am J Hematol 2011; 86:209-13; PMID:21264910; http://dx.doi.org/ 10.1002/ajh.21906 38.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Leuk Res 2014; 38:964- 9; PMID:24957413; http://dx.doi.org/10.1016/j.leukres.2014.05.014 39.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Eur J Haematol 2015; 94:279-80; PMID:25256820; http://dx.doi.org/10.1111/ejh.12454 40.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Clin Oncol 2008; 26:4934-9; PMID:18591543; http://dx.doi.org/10.1200/ JCO.2008.17.0472 41.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2008; 111:1044-53;PMID:18000167; http://dx.doi.org/10.1182/blood- 2007-04-084293 44.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Clin Oncol 2010; 28:808-14; PMID:20048183; http://dx.doi.org/10.1200/JCO.2009.23.2652 46.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Int Arch Allergy Appl Immunol 1990; 92:379-89; PMID:2150668; http://dx.doi.org/ 10.1159/000235169 49.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Br J Can- cer 2005; 93:757-62; PMID:16136045; http://dx.doi.org/10.1038/sj.bjc.6602768 50.,OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
J Clin Oncol 2002;20:125-33; PMID:11773161; http://dx.doi.org/ 10.1200/JCO.20.1.125 51.,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
Blood 2010; 115:453-74; PMID:19880497; http://dx.doi.org/10.1182/blood-2009-07-235358 www.tandfonline.com e1041701-11 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/79/09/koni-05-01-1041701.PMC4760300.pdf
"To characterize a protective inﬂammatory immune response mediated by tumor-speciﬁc Th1 cells, we have used myeloma- © Ole Audun Werner Haabeth, Kristina Berg Lorvik, Hideo Yagita, Bjarne Bogen, and Alexandre Corthay *Correspondence to: Ole Audun Werner Haabeth; Email: o.a.haabeth@medisin.uio.noSubmitted: 01/29/2015; Revised: 04/01/2015; Accepted: 04/06/2015 http://dx.doi.org/10.1080/2162402X.2015.1039763 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Immunity 2005; 22:371-83; PMID:15780993;http://dx.doi.org/10.1016/j.immuni.2005.02.003 2 .,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/ 10.1126/science.1129139 3.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Proc Natl Acad Sci U S A 2012; 109:2802-7; PMID:21908711; http://dx.doi.org/ 10.1073/pnas.1108781108 4.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Sci- ence 2014; 344:641-5; PMID:24812403; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Front Immunol 2014; 5:174; PMID:24782871; http://dx.doi.org/10.3389/ﬁmmu.2014.00174 6.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Front Immunol 2014; 5:197;PMID:24860567; http://dx.doi.org/10.3389/ﬁmmu.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471- 4906(02)02302-5 9.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Oncoimmunology 2012; 1:1146-55; PMID:23170261; http://dx.doi.org/10.4161/onci.21542 10.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature 07205 11.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227 13.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Eur J Immunol 1992; 22:703-9; PMID:1547816; http://dx.doi.org/10.1002/eji.1830220313 15.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Eur J Immunol 1995; 25:3079-86; PMID:7489746; http://dx.doi.org/ 10.1002/eji.1830251114 17.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Cancer research 2009; 69:5901-7; PMID:19567679; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4816 18.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nat Commun 2011; 2:240; PMID:21407206; http://dx.doi.org/10.1038/ncomms1239 19.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Blood 2012; 119:2176-7; PMID:22383793; http://dx.doi.org/ 10.1182/blood-2011-10-388892 20.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
OncoImmunology 2013; 2:e24383;PMID:23762808; http://dx.doi.org/10.4161/onci.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Int J Cancer 1981; 28:143- 52; PMID:6172388; http://dx.doi.org/10.1002/ijc.2910280206 22.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/ 35074122 23.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Proc Natl Acad Sci U S A 1998; 95:7556-61; PMID:9636188; http://dx.doi.org/ 10.1073/pnas.95.13.7556 24.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Proc Natl Acad Sci U S A 1975; 72:3666-70; PMID:1103152; http://dx.doi.org/ 10.1073/pnas.72.9.3666 25.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med 1999; 189:1343-54; PMID:10209050; http://dx.doi.org/10.1084/jem.189.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med 2000; 192:1373-80; PMID:11067885; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Scand J Immunol2000; 51:244-50; PMID:10736093; http://dx.doi.org/ 10.1046/j.1365-3083.2000.00671.x 28.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Cytokine 1992; 4:353-60; PMID:1420996; http://dx.doi.org/10.1016/1043-4666(92)90078-6 29.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med 1988; 168:2031-43; PMID:3143799; http://dx.doi.org/10.1084/jem.168.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Immu- nol 2003; 171:6448-56; PMID:14662844; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med 2003; 198:191-9; PMID:12860932; http://dx.doi.org/10.1084/jem.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med 1987;165:515-30; PMID:2950198; http://dx.doi.org/ 10.1084/jem.165.2.515 36.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Exp Med2013; 210:491-502; PMID:23460726; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nature 1983; 305:239-40; PMID:6412144; http://dx.doi.org/10.1038/305239a0 38.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Science 1998; 282:2085-8; PMID:9851930; http://dx.doi.org/ 10.1126/science.282.5396.2085 39.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Proc Natl Acad Sci U S A 1998; 95:588-93; PMID:9435236; http://dx.doi.org/ 10.1073/pnas.95.2.588 40.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Clin Oncol2012; 30:3396-401; PMID:22915661; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Oncoimmunology2013; 2:e24522; PMID:23894713; http://dx.doi.org/ 10.4161/onci.24522 44.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Immunother Cancer 2014; 2:2; PMID:24829759; http://dx.doi.org/10.1186/2051-1426-2-2 45.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Clin Cancer Res 2010; 16:4188-97; PMID:20587591; http://dx.doi.org/10.1158/1078-0432.CCR-10-0173 4 6 .,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Clin Cancer Res 2012; 18:1630-40; PMID:22383738; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2432 47.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Oncoimmunology 2013; 2:e25409; PMID:24083081; http://dx.doi.org/10.4161/onci.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Trends Immunol 2009; 30:227-33;PMID:19359217; http://dx.doi.org/10.1016/j.it.2009.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Cancer Res 2014; 74:1789-800; PMID:24448242; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Lancet 2001; 357:539-45;PMID:11229684; http://dx.doi.org/10.1016/S0140- 6736(00)04046-0 52.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025 54.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Gut 2001; 48:526-35; PMID:11247898; http://dx.doi.org/ 10.1136/gut.48.4.526 55.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nat Rev Cancer 2010; 10:403-14; PMID:20495574; http://dx.doi.org/10.1038/nrc2857 56.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Arthritis Rheum 2003; 48:963-70; PMID:12687538; http://dx.doi.org/ 10.1002/art.10939 57.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Ann Intern Med 1997; 127:186-94; PMID:9245223; http://dx.doi.org/ 10.7326/0003-4819-127-3-199708010-00002 59.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Cytokine 1999; 11:80-6; PMID:10080883; http://dx.doi.org/ 10.1006/cyto.1998.0398 60.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Natl Cancer Inst 1991; 83:119- 23; PMID:1988686; http://dx.doi.org/10.1093/jnci/ 83.2.119 61.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 66.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nat Med 2009;15:1170-8; PMID:19767732; http://dx.doi.org/ 10.1038/nm.2028 68.,OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Eur J Immunol 1990; 20:2359-62; PMID:1700755; http://dx.doi.org/ 10.1002/eji.1830201030 69.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Int Immunol 1996; 8:1001-8; PMID:8757945; http://dx.doi.org/10.1093/intimm/8.7.1001 70.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
Nat Med 2001; 7:94-100; PMID:11135622; http://dx.doi.org/ 10.1038/83416 72.,Non-OADS,/arxiv_data1/oa_pdf/a9/9b/koni-05-01-1039763.PMC4760324.pdf
"As normal or tumor inﬁltrating neutrophils are indistin-guishable by cell surface markers from g-MDSC, mechanistic © Yuhong Liu, Claire E. O ’Leary, Liang-Chuan S. Wang, Tricia R. Bhatti, Ning Dai, Veena Kapoor, Peihui Liu, Junjie Mei, Lei Guo, Paula M. Oliver, Steven M. Albelda, and G. Scott Worthen*Correspondence to: Yuhong Liu; Email: yuhongliu9@hotmail.com; and Dr. G. Scott Worthen; Email: worthen@email.chop.eduSubmitted: 02/13/2015; Revised: 06/06/2015; Accepted: 06/08/2015 http://dx.doi.org/10.1080/2162402X.2015.1061175 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/ 10.1126/science.1203486 2.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Semin Immunopathol 2013; 35(2):163-76; PMID:23007469; http://dx.doi.org/10.1007/s00281-012-0344-6 3.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-2583 4.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Carcinogenesis 2012; 33:949-55; PMID:22425643; http://dx.doi.org/10.1093/carcin/bgs123 7.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Cell 2011; 20:300-14; PMID:21907922; http://dx.doi.org/ 10.1016/j.ccr.2011.08.012 8.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer cell 2009;16:183-94; PMID:19732719; http://dx.doi.org/ 10.1016/j.ccr.2009.06.017 9.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Clin Cancer Res 2012; 18:5212-23; PMID:22837179; http://dx.doi.org/10.1158/1078-0432.CCR-12-1108 10.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
PLoS One 2012; 7:e40677; PMID:22815789; http://dx.doi.org/ 10.1371/journal.pone.0040677 11.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
PLoS One 2011; 6:e27690;PMID:22110722; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Res 2013; 73:6609-20;PMID:24085788; http://dx.doi.org/10.1158/0008- 5472.CAN-13-0987 13.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2004; 172:989-99; PMID:14707072; http://dx.doi.org/10.4049/jimmunol.172.2.989 14.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2011; 186:3197-205; PMID:21282514; http://dx.doi.org/ 10.4049/jimmunol.1002016 19.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Immunity 2005; 22:285-94; PMID:15780986; http://dx.doi.org/ 10.1016/j.immuni.2005.01.011 20.,OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Immunity 2008; 28:454-67; PMID:18400188; http://dx.doi.org/10.1016/j.immuni.2008.03.004 21.,OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Exp Med 2001; 194:519-27; PMID:11514607; http://dx.doi.org/10.1084/jem.194.4.519 22.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cell Immunol 2012; 272(2):166-74; http://dx.doi.org/ 10.1016/j.cellimm.2011.10.015 23.,OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Head Neck 2011;33:1301-8; PMID:21837700; http://dx.doi.org/ 10.1002/hed.21607 25.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Nat Commun 2011; 2:600; PMID:22186896; http://dx.doi.org/10.1038/ncomms1609 27.,OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Oncoimmunology 2012; 1:783-5; PMID:22934282; http://dx.doi.org/10.4161/ onci.19735 28.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2006; 177:8123-32; PMID:17114487; http://dx.doi.org/10.4049/ jimmunol.177.11.8123 29.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Res 2013; 73:3566-77; PMID:23576561; http://dx.doi.org/ 10.1158/0008-5472.CAN-12-3874 31.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer J 2010; 16:325-35; PMID:20693843; http://dx.doi.org/10.1097/ PPO.0b013e3181eb33bc 33.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Can- cer Res 2005; 65:11752-61; PMID:16357188; http://dx.doi.org/10.1158/0008-5472.CAN-05-1658 34.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2004; 172:2853-60; PMID:14978086; http://dx.doi.org/10.4049/jimmunol.172.5.2853 35.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
CXC chemokines in angiogenesis.Cytokine Growth Factor Rev 2005; 16:593-609; PMID:16046180; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Contrib Microbiol 2006; 13:118-37; PMID:16627962; http://dx.doi.org/10.1159/ 000092969 37.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Clin Cancer Res 2013; 19:3404-15; PMID:23653148; http://dx.doi.org/10.1158/1078-0432.CCR-13-0525 38.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Leukoc Biol 2009; 86:1065-73; PMID:19741157; http://dx.doi.org/10.1189/jlb.0609385 39.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Leukoc Biol 2008;84:623-30; PMID:18467655; http://dx.doi.org/ 10.1189/jlb.1107762 40.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Clin Oncol 2007; 25:1562-9; PMID:17443000; http://dx.doi.org/ 10.1200/JCO.2006.09.0274 41.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Res 2009; 69:7503-6; PMID:19752086; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-2152 42.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2011; 186:807-15; PMID:21148040; http://dx.doi.org/10.4049/ jimmunol.1001483 43.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Immunol 2012; 189:2191- 202; PMID:22815291; http://dx.doi.org/10.4049/jimmunol.1102729 44.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Oncoimmunology 2012; 1:1161-2; PMID:23170264; http://dx.doi.org/ 10.4161/onci.20928 45.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
J Clin Oncol 2009; 27:4709-17; PMID:19720929; http://dx.doi.org/10.1200/JCO.2008.18.9498 46.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Med Res Rev 2011; 31:311-63; PMID:19967776; http://dx.doi.org/ 10.1002/med.20185 47.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Crit Rev Oncol Hematol 2012; 82:296-309; PMID:21798756; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Immunol Immunother 2012; 61:1155-67;PMID:22692756; http://dx.doi.org/10.1007/ s00262-012-1294-5 49.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
PLoS One 2012; 7:e31524; PMID:22348096; http://dx.doi.org/ 10.1371/journal.pone.0031524 50.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Cancer Immunol Immunother 2013;62:1745-56; PMID:24092389; http://dx.doi.org/ 10.1007/s00262-013-1476-9 51.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506 52.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
Blood 2001; 97:339-45; PMID:11154206; http://dx.doi.org/ 10.1182/blood.V97.2.339 53.,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
PLoS One 2013;8:e53131; PMID:23372655; http://dx.doi.org/ 10.1371/journal.pone.0053131 www.tandfonline.com e1061175-13 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/b6/95/koni-05-01-1061175.PMC4760327.pdf
"16 © Marine M Leblond, Aur /C19elie N Gerault, Aur /C19elie Corroyer-Dulmont, Eric T MacKenzie, Edwige Petit, Myriam Bernaudin, and Samuel Valable *Correspondence to: Samuel Valable; Email: valable@cyceron.frSubmitted: 03/13/2015; Revised: 05/22/2015; Accepted: 05/24/2015 http://dx.doi.org/10.1080/2162402X.2015.1056442 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Image analysis Images were analyzed by in-house macros based on ImageJ software(http://imagej.nih.gov/ij/).,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330 2.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Glia 2011; 59:1169-80; PMID:21446047; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Neurooncol 2012; 106:493-504; PMID:21928115; http://dx.doi.org/10.1007/s11060-011-0701-7 4.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Eur J Nucl Med Mol Imaging 2012; 39:760-70; PMID:22307533; http://dx.doi.org/10.1007/s00259-011-2037-0 5.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Int J Radiat Oncol Biol Phys 1994; 29:427-31; PMID:8005794; http://dx.doi.org/ 10.1016/0360-3016(94)90432-4 6.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Clin Can- cer Res 2004; 10:8177-84; PMID:15623592; http://dx.doi.org/10.1158/1078-0432.CCR-04-1081 7.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Neuro Oncol 2005; 7:134-53; PMID:15831232; http://dx.doi.org/10.1215/S1152851704001115 8.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Metastasis Rev2007; 26:225-39; PMID:17440684; http://dx.doi.org/ 10.1007/s10555-007-9055-1 9.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Clin Cancer Res 2008; 14:2623-30; PMID:18451225; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4995 10.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Res 2006; 66:605-12; PMID:16423985; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005 11.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Science 2014; 344:921-5; PMID:24812208; http://dx.doi.org/10.1126/science.1252510 12.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Blood 2004; 104:2224-34; PMID:15231578; http://dx.doi.org/ 10.1182/blood-2004-03-1109 13.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Neurosurgery 2000; 46:957-62; PMID:10764271; http://dx.doi.org/10.1097/ 00006123-200004000-00035 14.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Neuro Oncol 2006; 8:261-79; PMID:16775224; http://dx.doi.org/10.1215/ 15228517-2006-008 16.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Neuro Oncol 2013; 15:1079-87;PMID:23828240; http://dx.doi.org/10.1093/neuonc/ not082 17.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471- 4906(02)02302-5 18.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Clin Invest 2012; 122:787-95;PMID:22378047; http://dx.doi.org/10.1172/JCI59643 20.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Immunol Res 2012; 53:11-24; PMID:22418728; http://dx.doi.org/10.1007/s12026-012-8291-9 21.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Immunol 2008;180:2011-7; PMID:18250403; http://dx.doi.org/ 10.4049/jimmunol.180.4.2011 22.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Cell2011; 19:1-2; PMID:21251607; http://dx.doi.org/ 10.1016/j.ccr.2011.01.005 23.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Clin Cancer Res 2013; 19:3776- 86; PMID:23741072; http://dx.doi.org/10.1158/1078-0432.CCR-12-1940 24.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Nat Med 2013; 19:1264-72; PMID:24056773;http://dx.doi.org/10.1038/nm.3337 25.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Am J Pathol 2005; 167:627-35; PMID:16127144; http://dx.doi.org/10.1016/S0002-9440(10)62038-X 26.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Res 2014; 74:24-30; PMID:24220244; http://dx.doi.org/10.1158/0008-5472.CAN-13-1196 27.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Neuroinﬂammation 2011;8:32; PMID:21489226; http://dx.doi.org/10.1186/ 1742-2094-8-32 29.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Nature 2014; 513:559-63; PMID:25043024; http://dx.doi.org/10.1038/nature13490 31.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Genes Dev 2010; 24:491- 501; PMID:20194441; http://dx.doi.org/10.1101/ gad.1881410 32.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Biol Chem 2013;394:529-39; PMID:23399636; http://dx.doi.org/ 10.1515/hsz-2012-0318 33.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Int J Cancer 2014; 136:1688-96; PMID:25111969; http://dx.doi.org/10.1002/ijc.29132 34.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Leukoc Biol 2004; 75:388-97; PMID:14612429; http://dx.doi.org/10.1189/jlb.0303114 35.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Am J Pathol 2008; 173:545-60; PMID:18599607; http://dx.doi.org/10.2353/ ajpath.2008.071197 37.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
EMBO J 2009; 28:2114-27; PMID:19536133; http://dx.doi.org/ 10.1038/emboj.2009.163 38.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Front Oncol 2012; 2:89; PMID:22888475; http://dx.doi.org/ 10.3389/fonc.2012.00089 40.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Pathol 2008; 216:15-24; PMID:18553315; http://dx.doi.org/ 10.1002/path.2370 41.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Res 2010; 70:5728-39;PMID:20570887; http://dx.doi.org/10.1158/0008- 5472.CAN-09-4672 e1056442-12 Volume 5 Issue 1 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Am J Pathol 2003; 163:1233-43; PMID:14507633;http://dx.doi.org/10.1016/S0002-9440(10)63483-9 44.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Blood 2009; 114:844-59; PMID:19454749; http://dx.doi.org/10.1182/blood- 2008-12-195941 45.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Res 2010; 70:7465-75; PMID:20841473; http://dx.doi.org/10.1158/0008- 5472.CAN-10-1439 46.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Trends Biochem Sci 2012; 37:364-72; PMID:22818162; http://dx.doi.org/10.1016/j.tibs.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Clin Invest 2008; 118:3930-42; PMID:19033663;http://dx.doi.org/10.1172/JCI3684348.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Neuro Oncol 2013; 15:172-88; PMID:23258846; http://dx.doi.org/10.1093/neuonc/ nos298 49.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Immunol 2005; 175:342-9; PMID:15972667; http://dx.doi.org/10.4049/jimmunol.175.1.342 50.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Leukoc Biol 2014; 95:129-37; PMID:24006507; http://dx.doi.org/10.1189/ jlb.0113045 51.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Environ Mol Mutagen 2004; 44:3-9; PMID:15199542; http://dx.doi.org/10.1002/em.20024 52.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Chemother Pharmacol 2011; 67:1211-24;PMID:21544630; http://dx.doi.org/10.1007/s00280- 011-1654-4 54.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Exp Med 2008; 205:1261-8;PMID:18490490; http://dx.doi.org/10.1084/ jem.20080108 55.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Immunology 2011; 132:226-39; PMID:21039467; http://dx.doi.org/10.1111/j.1365-2567.2010.03357.x 56.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Nat Med 2013; 19:1207-8; PMID:24100977; http://dx.doi.org/10.1038/nm.3355 57.,OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
Cancer Cell 2013; 24:589-602; PMID:24209604; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
J Neurooncol 2007; 85:191-202; PMID:17557137; http://dx.doi.org/10.1007/s11060- 007-9407-2 60.,Non-OADS,/arxiv_data1/oa_pdf/d5/18/koni-05-01-1056442.PMC4760330.pdf
"1, e1068493 (10 pages)http://dx.doi.org/10.1080/2162402X.2015.1068493",Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Cancer Lett 2012; 325:155-64;PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012 3.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Nat RevImmunol 2013; 13:101-17; PMID:23334244; http://dx.doi.org/10.1038/nri3369 4.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Immunotherapy 2014; 6:309-20; PMID:24762075;http://dx.doi.org/10.2217/imt.13.175 5.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Cancer ImmunolImmunother 2014; 63:199-213; PMID:24384834; http://dx.doi.org/10.1007/s00262-013-1509-4 6.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Exp Med 2004; 199:1607-18; PMID:15197224; http://dx.doi.org/10.1084/jem.200403177.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Immunol 2003; 171:5140-7; PMID:14607913; http://dx.doi.org/10.4049/jimmunol.171.10.5140 8.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Curr Opin Immunol 2008; 20:358-68; PMID:18501573; http://dx.doi.org/ 10.1016/j.coi.2008.03.018 9.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Exp Med 2003; 198:267-79; PMID:12874260; http://dx.doi.org/10.1084/jem.20030324 10.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Exp Med 2002; 195:617-24; PMID:11877484; http://dx.doi.org/10.1084/ jem.20011889 11.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Clin Invest 2004; 114:1800-11; PMID:15599405;http://dx.doi.org/10.1172/JCI200422046 12.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Immunol 2007; 178:2853-61; PMID:17312129; http://dx.doi.org/10.4049/ jimmunol.178.5.2853 14.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Exp Med 2003; 198:1631-41; PMID:14657217; http://dx.doi.org/10.1084/jem.20031192 15.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Blood 2002; 99:1259-66; PMID:11830474; http://dx.doi.org/10.1182/ blood.V99.4.1259 16.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Annu Rev Immunol 2014; 32:323-66; PMID:24499274; http://dx.doi.org/10.1146/annurev-immunol- 032713-120243 17.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Immunol Methods 2006; 312:34-9; PMID:16647712; http://dx.doi.org/10.1016/j.jim.2006.02.009 18.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Clin Cancer Res 2005; 11:1910-7; PMID:15756017; http://dx.doi.org/10.1158/1078-0432.CCR-04-1453 20.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Med 2005; 201:1503-17; PMID:15867097; http://dx.doi.org/10.1084/ jem.20042592 21.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Control Release 2012; 161:505-22; PMID:22353619; http://dx.doi.org/10.1016/j.jconrel.2012.01.043 23.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Control Release 2012; 157:354-65;PMID:21820024; http://dx.doi.org/10.1016/j.jconrel.2011.07.029 24.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Nat Immunol2010; 11:303-12; PMID:20228797; http://dx.doi.org/10.1038/ni.1853 25.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
EMBO J 2012; 31:2378-90; PMID:22505026;http://dx.doi.org/10.1038/emboj.2012.87 26.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Vaccine 2009; 27:3484-8; PMID:19200815; http://dx.doi.org/10.1016/ j.vaccine.2009.01.047 27.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Int J Pharm 2012; 423:45-54;PMID:21575695; http://dx.doi.org/10.1016/j.ijpharm.2011.04.068 28.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Immunol 2014; 193:961-9; PMID:24913977; http://dx.doi.org/10.4049/jimmunol.1303029 29.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Int Immunol 2010; 22:905- 13; PMID:21118907; http://dx.doi.org/10.1093/intimm/dxq444 30.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Drug Target 2003; 11:495- 507; PMID:15203918; http://dx.doi.org/10.1080/10611860410001670026 31.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Biomaterials 2011; 32:3666-78;PMID:21345488; http://dx.doi.org/10.1016/j.biomaterials.2011.01.067 32.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Vaccine 2008; 26:5046- 57; PMID:18680779; http://dx.doi.org/10.1016/j.vaccine.2008.07.035 33.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Control Release 2012; 159:338-45; PMID:22386518;http://dx.doi.org/10.1016/j.jconrel.2012.02.015 36.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Cancer Res 2013; 73:3865-76; PMID:23658368; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Vaccine 2008; 26:1626-37; PMID:18295941; http://dx.doi.org/10.1016/j.vaccine.2008.01.030 38.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Cell 2014; 158:506-21;PMID:25083866; http://dx.doi.org/10.1016/j.cell.2014.04.054 39.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Nat Immunol 2010; 11:313-20; PMID:20190758; http://dx.doi.org/10.1038/ni.1848 40.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Immune Netw 2011; 11:163-8; PMID:21860609; http://dx.doi.org/10.4110/in.2011.11.3.163 41.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
J Drug Target 2009; 17:652-61; PMID:19622019; http://dx.doi.org/10.1080/10611860903119656 42.,Non-OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
Eur J Pharm Biopharm 2013; 83:338-45; PMID:23201055; http://dx.doi.org/10.1016/j.ejpb.,OADS,/arxiv_data1/oa_pdf/db/75/koni-05-01-1068493.PMC4760331.pdf
"6They may also gain other tumor-derived fac- tors facilitating progression and metastasis.7,8 © Emilia Andersson, Isabel Poschke, Lisa Villabona, Joseph W Carlson, Andreas Lundqvist, Rolf Kiessling, Barbara Seliger, and Giuseppe V Masucci *Correspondence to: Giuseppe Valentino Masucci; Email: Giuseppe.Masucci@ki.seSubmitted: 04/01/2015; Revised: 05/11/2015; Accepted: 05/12/2015 http://dx.doi.org/10.1080/2162402X.2015.1052213 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cell 2006; 127:905-15; PMID:17129778;http://dx.doi.org/10.1016/j.cell.2006.09.042 2.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi.org/ 10.1146/annurev.immunol.22.012703.104803 3.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Nat Rev Cancer 2012; 12:210-9;PMID:22362216; http://dx.doi.org/10.1038/nrc3186 4.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancers 2011; 3:1672-90; PMID:24212778; http://dx.doi.org/10.3390/cancers3021672 5.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Clin Dev Immunol 2011; 2011:14; http://dx.doi.org/10.1155/ 2011/430394 6.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Int J Cancer 2003; 103:759-67; http://dx.doi.org/10.1002/ijc.10906 7.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Tissue Antigens 2008; 72:321-34; PMID:18700879; http://dx.doi.org/10.1111/j.1399- 0039.2008.01106.x 8.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Eur JImmunogenet 1997; 24:293-312; PMID:9306099;http://dx.doi.org/10.1111/j.1365-2370.1997.tb00025.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Scand J Immunol 2009; 70:516-25;PMID:19906192; http://dx.doi.org/10.1111/j.1365- 3083.2009.02326.x 10.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Int J Cancer2010; 127:249-56; PMID:20178101; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer Immunol Immunother 2008; 57:1719-26; PMID:18408926; http://dx.doi.org/10.1007/s00262-008-0515-4 12.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Adv Immunol 2006; 90:1-50;PMID:16730260; http://dx.doi.org/10.1016/S0065- 2776(06)90001-7 13.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Tissue Antigens 2007; 70:205-13; PMID:17661908; http://dx.doi.org/10.1111/j.1399-0039.2007.00875.x 14.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer Immunol Immunother 2009; 58:1599-608; PMID:19214504;http://dx.doi.org/10.1007/s00262-009-0669-815.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Med Oncol 2004; 21:49-52; PMID:15034213; http://dx.doi.org/ 10.1385/MO:21:1:49 16.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer Res 2006; 66:6387-94; PMID:16778217; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Mod Pathol 2014; 27:1296-305; PMID:24504073; http://dx.doi.org/10.1038/ modpathol.2013.210 18.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Lung Cancer 2001; 32:39-46; PMID:11282427; http://dx.doi.org/10.1016/S0169-5002(00)00204-X 19.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer 1977; 39:2345-7;PMID:872033; http://dx.doi.org/10.1002/1097-0142 (197706)39:6%3c2345::AID- CNCR2820390605%3e3.0.CO;2-W 20.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Laryngoscope 2002; 112:651-7; PMID:12150518; http://dx.doi.org/10.1097/00005537-200204000-00011 e1052213-8 Volume 5 Issue 1 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 2003; 64:315-26; PMID:12590976; http://dx.doi.org/10.1016/S0198- 8859(02)00821-2 22.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Immunol Res 2014; 2014:359748; PMID:24800261; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Exp Med 1997; 186:289-98; PMID:9221758; http://dx.doi.org/10.1084/jem.186.2.289 24.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 2003; 64:1039-44; PMID:14602233; http://dx.doi.org/ 10.1016/j.humimm.2003.08.346 25.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
"Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L. The class I HLA repertoire of pancreatic islets comprises the non- classical class Ib antigen HLA-G. Diabetes 2006; 55:1214-22; PMID:16644675; http://dx.doi.org/10.2337/db05-0731 26.",Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Blood 2004; 104:3153-60; PMID:15284117; http://dx.doi.org/10.1182/blood- 2004-03-0809 27.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Adv Immunol 2003; 81:199-252;PMID:14711057; http://dx.doi.org/10.1016/S0065- 2776(03)81006-4 28.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
SeminCancer Biol 2007; 17:413-21; PMID:17881247; http://dx.doi.org/10.1016/j.semcancer.2007.07.003 29.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Virchows Arch2006; 449:31-9; PMID:16541284; http://dx.doi.org/ 10.1007/s00428-005-0144-7 31.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer Res 2005; 65:10139-44; PMID:16287995; http://dx.doi.org/ 10.1158/0008-5472.CAN-05-0097 32.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Nat Immunol 2003; 4:815; PMID:12942076; http://dx.doi.org/10.1038/ni0903- 815 33.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Blood 2008; 111:4862-70; PMID:18334671; http://dx.doi.org/ 10.1182/blood-2007-12-12766234.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Science 2000; 287:1031; PMID:10669413; http://dx.doi.org/ 10.1126/science.287.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Proc Natl Acad Sci U S A 1998; 95:5199-204; PMID:9560253; http://dx.doi.org/10.1073/ pnas.95.9.5199 36.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 1990; 29:131-42; PMID:2249951; http://dx.doi.org/10.1016/0198-8859(90)90076-2 37.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Mol Biol 2008; 377:1297-303;PMID:18339401; http://dx.doi.org/10.1016/j.jmb.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
"HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; http://dx.doi.org/ 10.1038/35869 40.",Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Transl Med 2013; 11:247;PMID:24093459; http://dx.doi.org/10.1186/1479- 5876-11-247 42.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Cancer Immunol Immunother 2012; 61:1243- 53; PMID:22258792; http://dx.doi.org/10.1007/ s00262-012-1201-0 44.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Immunity2001; 15:213-24; PMID:11520457; http://dx.doi.org/ 10.1016/S1074-7613(01)00179-0 46.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 2004; 65:157-62; PMID:14969770; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 2003; 64:256-64;PMID:12559628; http://dx.doi.org/10.1016/S0198- 8859(02)00777-2 49.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Oncoimmunology 2013; 2: e26491; PMID:24482746; http://dx.doi.org/10.4161/ onci.26491 50.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Cell Mol Med 2010;14:2162-71; PMID:19799650; http://dx.doi.org/ 10.1111/j.1582-4934.2009.00917.x 51.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Immunol Res 2014; 2014:938561; PMID:24741633; http://dx.doi.org/10.1155/2014/ 938561 53.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Hum Immunol 2009; 70:1006-9;PMID:19660509; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
J Immunol 2003; 171:1918- 26; PMID:12902494; http://dx.doi.org/10.4049/ jimmunol.171.4.1918 56.,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
Clin Cancer Res 2008; 14:3372-9; PMID:18519766; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4433 www.tandfonline.com e1052213-9 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/de/74/koni-05-01-1052213.PMC4760332.pdf
"In the contextof B-cell lymphoma, type II anti-CD20antibodies such as tositumomab, are © Mireille Vankemmelbeke, Jia Xin Chua, and Lindy G. Durrant *Correspondence to: Lindy G Durrant; Email: lindy.durrant@nottingham.ac.ukSubmitted: 05/21/2015; Revised: 06/03/2015; Accepted: 06/05/2015 http://dx.doi.org/10.1080/2162402X.2015.1061177 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Science 2014; 343:1235681; PMID:24385630; http://dx.doi.org/ 10.1126/science.1235681 2.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Adv Cancer Res 2015; 126:1-10; PMID:25727144; http://dx.doi.org/10.1016/bs.acr.2014.12.0023.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Nat Rev Cancer2005; 5:526-42; PMID:16069816; http://dx.doi.org/ 10.1038/nrc1649 4.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Glycoconj J 2012; 29:565-6; PMID:22996057; http://dx.doi.org/10.1007/s10719-012-9448-4 5.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Clin Cancer Res 2015; 21(13):2963-74;http://dx.doi.org/10.1158/1078-0432.CCR-14-3030 7.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Blood 2011; 117:4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood- 2010-07-296913 9.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
Nat Rev Cancer 2012;12:860-75; PMID:23151605; http://dx.doi.org/ 10.1038/nrc3380 10.,Non-OADS,/arxiv_data1/oa_pdf/30/ad/koni-05-01-1061177.PMC4760334.pdf
"1, e1067745 (13 pages)http://dx.doi.org/10.1080/2162402X.2015.1067745",Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
"Data analysis and statistics Analysis and presentation of distributions was performed using SPICE version 5.3 (downloaded from http://exon.niaid.nih.gov), 39and PRISM for windows version 5.03 (GraphPad).",OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Science1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/ science.1840703 2.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Med 2000; 6:1018-23; PMID:10973322; http://dx.doi.org/10.1038/79526 3.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139 4.,OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Clin Oncol2012; 30:1835-41; PMID:22529253; http://dx.doi.org/10.1200/ JCO.2011.40.2271 5.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
N Eng J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 6.,OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Clin Oncol 2015; 33(17):1865-66; PMID:25667273; http://dx.doi.org/10.1200/JCO.2014.59.5041 8.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Clin Oncol2015; 33:1191-6; PMID:25713437; http://dx.doi.org/10.1200/ JCO.2014.56.6018 9.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Eur JImmunol 2008; 38:350-63; PMID:18200635; http://dx.doi.org/10.1002/eji.200737768 11.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http://dx.doi.org/10.1038/nri1961e1067745-12 F. WIMMERS ET AL.,OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nature 2013;494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824 15.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Rev Immunol 2008;8:247-58; PMID:18323851; http://dx.doi.org/10.1038/nri2274 16.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Immunol 2000; 1:311-6; PMID:11017102; http://dx.doi.org/10.1038/79758 17.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
"Cancer Immu-nol, Immunother 2006; 55:1142-50; PMID:16374636; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Curr Opin Immunol 2005;17:320-5; PMID:15886124; http://dx.doi.org/10.1016/j.coi.2005.03.002 20.,OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Exp Med 2007; 204:2473-85; PMID:17893201; http://dx.doi.org/10.1084/jem.20070784 2 2 .,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Science 1995; 270:1811-5; PMID:8525373; http://dx.doi.org/10.1126/science.270.5243.1811 23.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Exp Med 1997; 186:139-46; PMID:9207008; http://dx.doi.org/10.1084/jem.186.1.139 24.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Proc Natl AcadSci U S A 2000; 97:3388-93; PMID:10725362; http://dx.doi.org/ 10.1073/pnas.97.7.3388 26.,OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Exp Med 2006; 203:2865-77; PMID:17158960; http://dx.doi.org/10.1084/jem.20052246 27.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Exp Med1997; 186:757-66; PMID:9271591; http://dx.doi.org/10.1084/ jem.186.5.757 29.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Clin Invest 2014; 124:198-208; PMID:24292711; http://dx.doi.org/10.1172/JCI70510 30.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Virol 2003; 77:4911-27; PMID:12663797; http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003 31.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Med 2007;13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609 32.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506 33.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Immunol 2004; 172:989-99; PMID:14707072; http://dx.doi.org/10.4049/jimmunol.172.2.989 34.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
J Clin Oncol 2013; 31:2369-71; PMID:23715576; http://dx.doi.org/10.1200/JCO.2013.49.2157 35.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
"Cancer Immunol, Immunother 2011; 60:249-60; PMID:21069321; http://dx.doi.org/10.1007/s00262-010-0942-x 36.",Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Cancer Res 2013; 73:19-29;PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127 37.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368 38.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Cytometry A 2011; 79:167-74; PMID:21265010; http://dx.doi.org/10.1002/cyto.a.21015 40.,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
Cancer Res 2012; 72:6102-10; PMID:23010076; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479ONCOIMMUNOLOGY e1067745-13,Non-OADS,/arxiv_data1/oa_pdf/e0/44/koni-05-01-1067745.PMC4760336.pdf
"9 © Martina Schmittnaegel, Christian Klein, Victor Levitsky, and Hendrik Knoetgen *Correspondence to: Hendrik Knoetgen; Email: hendrik.knoetgen@roche.comSubmitted: 05/11/2015; Revised: 08/27/2015; Accepted: 05/14/2015 http://dx.doi.org/10.1080/2162402X.2015.1052930 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Int J Cancer 2010; 127:2209-21; PMID:20473913; http://dx.doi.org/10.1002/ijc.25423 2.,Non-OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Science 2008;321:974-7; PMID:18703743; http://dx.doi.org/ 10.1126/science.11585453.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Lancet Oncol 2015; 16:57-66; PMID:25524800; http://dx.doi.org/10.1016/S1470-2045(14)71170-2 4.,Non-OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Mol Immunol 2015; 67(2 Pt A): 95-106; PMID:25637431; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
NatRev Clin Oncol 2014; 11:630-2; PMID:25311350; http://dx.doi.org/10.1038/nrclinonc.2014.174 6.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222 7.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 8.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/ 10.1056/NEJMoa1406498 10.,OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
Cancer Immunol Res 2015; 3(7):764-76; PMID:25691327; http://dx.doi.org/10.1158/2326-6066 www.tandfonline.com e1052930-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/6c/a2/koni-05-01-1052930.PMC4760341.pdf
"1, e1062966 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1062966",Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Lancet 2014; 383:1490-502; PMID:24225001; http://dx.doi.org/10.1016/S0140-6736 (13)61649-9 2.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
The New England journal of medicine 1988; 319:525-32; PMID:2841597; http://dx.doi.org/10.1056/NEJM198809013190901 3.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Annu Rev Pathol 2011; 6:479-507; PMID:21090969; http://dx.doi.org/10.1146/annurev-pathol-011110-130235 4.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/ 10.1016/j.cell.2010.01.025 5.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
N Engl J Med 1990; 323:1228-33; PMID:2215606; http://dx.doi.org/10.1056/NEJM 199011013231802 6.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Am J Gastroenterol 2005; 100:2724-9;PMID:16393226; http://dx.doi.org/10.1111/j.1572-0241.2005.00287.x 7.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
In ﬂamm Bowel Dis 2007; 13:1016- 23; PMID:17476678; http://dx.doi.org/10.1002/ibd.20148 8.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Ann Surg Oncol 2000; 7:133-8; PMID:10761792; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139 10.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Gut 2013; 62:1714-23; PMID:23172891; http://dx.doi.org/10.1136/gutjnl-2011- 301785 11.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Immu- nol 2008; 180:2443-9; PMID:18250453; http://dx.doi.org/10.4049/ jimmunol.180.4.2443 12.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Nat Rev Immunol 2010; 10:103-10; PMID:20081870; http://dx.doi.org/10.1038/nri2692 13.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
JImmunol 2012; 188:3488-95; PMID:22371395; http://dx.doi.org/10.4049/jimmunol.1101977 14.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Gastroenterol 2010; 45:999- 1007; PMID:20405148; http://dx.doi.org/10.1007/s00535-010-0245-1 15.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Proc Natl Acad Sci U S A 2007; 104:282-7; PMID:17185418; http://dx.doi.org/ 10.1073/pnas.0606854104 16.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
ImmunolLett 2010; 128:80-5; PMID:19913053; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Am J Pathol 2010; 177:2804- 15; PMID:21037074; http://dx.doi.org/10.2353/ajpath.2010.100378 20.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Nat Protoc 2007; 2:1998-2004; PMID:17703211;http://dx.doi.org/10.1038/nprot.2007.279 23.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Carcinogenesis 2009; 30:183-96; PMID:19037092; http://dx.doi.org/10.1093/carcin/bgn26724.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Nat Med 2010; 16:708-12; PMID:20473304; http://dx.doi.org/10.1038/nm.2156 25.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Clin Invest 2012; 122:3127-44; PMID:22922255; http://dx.doi.org/10.1172/JCI61067 26.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Carcinogenesis 2013; 34:1861-9;PMID:23615396; http://dx.doi.org/10.1093/carcin/bgt135 27.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Cancer Cell 2009; 15:103-13;PMID:19185845; http://dx.doi.org/10.1016/j.ccr.2009.01.001 28.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Arterioscler Thromb Vasc Biol 2013; 33: e47-55; PMID:23162017; http://dx.doi.org/10.1161/ATVBAHA.112.253427 29.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Curr Cancer Drug Targets 2011; 11:451-64; PMID:21247378; http://dx.doi.org/ 10.2174/156800911795538066 32.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Immunol 2011; 187:1609-16; PMID:21734074; http://dx.doi.org/ 10.4049/jimmunol.1003080 33.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
The paracrine effect of cancer-associated ﬁbroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.J Pathol 2013; 231:180-9; PMID:23775566; http://dx.doi.org/10.1002/path.4226 34.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Asian Pac J CancerPrev 2013; 14:2563-6; PMID:23725175; http://dx.doi.org/10.7314/APJCP.2013.14.4.2563 35.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Dig Dis Sci 2011; 56:3596-601;PMID:21643739; http://dx.doi.org/10.1007/s10620-011-1760-5 36.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Biochem Biophys Res Commun 2014; 453(3):486-92; PMID:25280997; http://dx.doi.org/10.1016/j.bbrc.2014.09.106 37.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
"Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, Goll R, Florholmen J. Dynamics of the IL-33/ST2 network in the pro-gression of human colorectal adenoma to sporadic colorectal cancer.Cancer Immunol Immunother 2014; 64(2):181-90; PMID:25324197; http://dx.doi.org/10.1007/s00262-014-1624-x 3 8 .",OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Immunol 2014; 192:1972-81; PMID:24465013; http://dx.doi.org/10.4049/jimmunol.1302623e1062966-10 K. D. MERTZ ET AL.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Int J Can- cer 2014; 134:1669-82; PMID:24105680; http://dx.doi.org/10.1002/ ijc.28481 40.,OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Nature2014; 513(7519):564-8; PMID:25043027; http://dx.doi.org/10.1038/nature13577 41.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Int J Cancer 2010; 126:2635-43; PMID:19856313; http://dx.doi.org/10.1002/ijc.24989 42.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Virchows Arch 2013; 463:623-31; PMID:24085553; http://dx.doi.org/10.1007/s00428-013-1492-3 43.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
Nat Med 1998; 4:844-7; PMID:9662379; http://dx.doi.org/ 10.1038/nm0798-844 44.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Exp Med 2000; 191:1069-76; PMID:10727469; http://dx.doi.org/10.1084/ jem.191.6.1069 45.,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
J Carcinog 2011; 10:9; PMID:21483655; http://dx.doi.org/10.4103/1477-3163.78279ONCOIMMUNOLOGY e1062966-11,Non-OADS,/arxiv_data1/oa_pdf/0c/0a/koni-05-01-1062966.PMC4760343.pdf
"DOI: 10.6061/clinics/2016(02)03Copyright &2016 CLINICS –This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/ 4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
Available in: http://www.who.int/mediacentre/fact- sheets/fs282/en/ 3.,Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2013;24(5):415-20, http://dx.doi.org/10.1097/ ICU.0b013e3283641c56.",Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2011;15(5):476-9, http://dx.doi.org/10.1016/j.jaapos.2011.05.023.",OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2013;17(4):374-7, http://dx.doi.org/10.1016/j.jaapos.2013.05.006.",OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2010;14(6):472-7, http://dx.doi.org/10.1016/j.jaapos.2010.09.016.",OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"http://www.spotvision screening.com acessed August 25, 2014.",Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2001;27(1)129-42, http://dx.doi.org/10.1016/S0886-3350(00)00816-6.",OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2014; 18(2):169- 72, http://dx.doi.org/10.1016/j.jaapos.2013.11.019.",OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2014;51:1-7, http://dx.doi.org/10.3928/01913913-20131223-02.",Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
"2014;34(4):739-46, http://dx.doi.org/10.1007/s10792-013-9864-x.",Non-OADS,/arxiv_data1/oa_pdf/81/34/cln-71-02-069.PMC4760365.pdf
We reviewed the previous literature searching the term “Milia en plaque ”at PubMed (http://www.ncbi.nlm.nih.gov/ pubmed/).,Non-OADS,/arxiv_data1/oa_pdf/2d/fa/ajd-38-212.PMC4760378.pdf
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.115.012504,Non-OADS,/arxiv_data1/oa_pdf/15/5f/str-47-814.PMC4760382.pdf
"This is an Open Access article distributed under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/51/jiv522.PMC4760419.pdf
"This is an OpenAccess article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/ licenses/by-nc- nd/4.0/), which permits non-commercial reproduction and distribution of thework, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/02/8e/jiv543.PMC4760425.pdf
ethz.ch Supportin ginformation andORCID(s )from theauthor(s) forthis article areavailable ontheWWW under http://dx.doi.org/ 10.1002/ anie.201511 476.,Non-OADS,/arxiv_data1/oa_pdf/0c/5b/ANIE-55-3096.PMC4760428.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4e/a0/tcrm-12-209.PMC4760652.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 209–215Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  209Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S8203 4New combinations in the treatment of COPD:  rationale for aclidinium–formoterol Cristoforo incorvaia1 Marcello Montagni2 elena Makri1 erminia Ridolo2 1Allergy/Pulmonary Rehabilitation,   istituti Clinici di Perfezionamento  Hospital, Milan, 2Department of  Clinical and experimental Medicine,   University of Parma, Parma, italyAbstract:  The current guidelines on chronic obstructive pulmonary disease (COPD) recommend  the prominent use of bronchodilators, including long-acting β2-agonists (LABAs) and long- acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended  only in patients with severe disease or frequent exacerbations.",Non-OADS,/arxiv_data1/oa_pdf/4e/a0/tcrm-12-209.PMC4760652.pdf
"These include indacaterol, olodaterol, vilanterol  as a LABA, and glycopyrronium, aclidinium, and umeclidinium as LAMAs.5–8 Also,  LABA-LAMA combinations were introduced that make it easier to take the drugs Correspondence: Cristoforo incorvaia Allergy/Pulmonary Rehabilitation, istituti  Clinici di Perfezionamento Hospital, 1 via  Bignami, Milan 20100, italy Tel +39 02 5799 3289 Fax +39 02 5799 3579 email cristoforo.incorvaia@gmail.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Incorvaia et al Running head recto: New COPD-treatment combinations DOI: http://dx.doi.org/10.2147/TCRM.S82034",Non-OADS,/arxiv_data1/oa_pdf/4e/a0/tcrm-12-209.PMC4760652.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/4e/a0/tcrm-12-209.PMC4760652.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/a0/tcrm-12-209.PMC4760652.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 201–208Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  201Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S8244 9evaluation of a new tablet formulation of deferasirox  to reduce chronic iron overload after long-term  blood transfusions Anna w Chalmers Jamile M Shammo Department of internal Medicine,   Division of Hematology/Oncology,   Rush University Medical Center,   Chicago, iL, USAAbstract:  Transfusion-dependent anemia is a common feature in a wide array of hematological  disorders, including thalassemia, sickle cell disease, aplastic anemia, myelofibrosis, and myelo - dysplastic syndromes.",Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
"Each  unit of transfused red blood cells introduces 200–250 mg of elemental iron, with iron  overload occurring after approximately ten to 20 transfusions.3 Transfusional iron  overload occurs in patients with a wide array of hematological disorders including  thalassemia, sickle cell disease, aplastic anemia, myelofibrosis, and myelodysplastic Correspondence: Jamile Shammo Department of internal Medicine,  Division of Hematology/Oncology, Rush  University Medical Center, 1725 west  Harrison Street, Suite 809, Chicago, iL  60612, USA Tel +1 312 942 5157 Fax +1 312 563 4144 email jamile_shammo@rush.ed u Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Chalmers and Shammo Running head recto: Evaluation of a new tablet formulation of deferasirox DOI: http://dx.doi.org/10.2147/TCRM.S82449",Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
"Available  from: http://www.pharma.us.novartis.com/product/pi/pdf/jadenu.pd f.  Accessed January 7, 2016.",Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/7f/tcrm-12-201.PMC4760653.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3e/1a/tcrm-12-217.PMC4760654.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2016:12 217–223Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  217ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S9545 3Influence of MDR1 methylation on the curative  effect of interventional embolism chemotherapy  for cervical cancer Zhi huang1,* shuai Zhang2,* Yaping shen1 Weixin liu1 Jipu long1 shi Zhou1 1Department of Interventional  Radiology, The Affiliated Baiyun  Hospital of Guizhou Medical  University, Guizhou Medical  University, Guiyang, People’s  Republic of China; 2Department of  Interventional Radiology, Cancer  Hospital of Guizhou Medical  University, Guiyang, People's  Republic of China *These authors contributed equally   to this workBackground:  Multi-drug resistance (MDR) is the main cause of tumor failure to chemotherapy.",Non-OADS,/arxiv_data1/oa_pdf/3e/1a/tcrm-12-217.PMC4760654.pdf
"However, although surgical skills, radiotherapy  equipment, and technology update in recent decades, the therapeutic effect is not enhanced  and the 5-year survival rate is only 70%.1,2 Tumor local uncontrol and reoccurrence is the  main cause of treatment failure, followed by lymphatic metastasis and metastasis.Correspondence: shi Zhou Department of Interventional Radiology,  The Affiliated Baiyun Hospital of Guizhou  Medical University, Guizhou Medical  University, 28 Guiyang City Medical  Street, Guiyang 550002, People’s  Republic of China email zhousgz@yeah.ne t Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Huang et al Running head recto: MDR1 methylation correlates with cervical cancer chemotherapy DOI: http://dx.doi.org/10.2147/TCRM.S95453",Non-OADS,/arxiv_data1/oa_pdf/3e/1a/tcrm-12-217.PMC4760654.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/3e/1a/tcrm-12-217.PMC4760654.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3e/1a/tcrm-12-217.PMC4760654.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4b/1a/tcrm-12-189.PMC4760655.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 189–199Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  189Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S9998 5igG4-related disease: current challenges and  future prospects David Lang1 Jochen Zwerina2 Herwig Pieringer1,3 1Second Department of internal  Medicine, Kepler University Clinic,   Linz, 2First Department of internal  Medicine, Ludwig Boltzmann- institute  of Osteology, Hanusch Hospital,   vienna, 3Paracelsus Private Medical  University, Salzburg, AustriaAbstract:  Immunoglobulin G4-related disease (IgG4-RD) represents an immune-mediated  fibroinflammatory condition with a characteristic histopathological appearance that can affect  various organs.",Non-OADS,/arxiv_data1/oa_pdf/4b/1a/tcrm-12-189.PMC4760655.pdf
"Those epony - mous syndromes, such as Mikulicz’s disease, Riedel’s thyroiditis, Morbus Ormond,  or Küttner’s tumor, were believed to be rare, isolated disease entities.2 The first step  toward the discovery of IgG4-RD was the description of an autoimmune mediated,  steroid responsive form of pancreatitis, today known as IgG4-related disease or  type 1 autoimmune pancreatitis (AIP) in 1995.4 Subsequently, in 2001, Hamano et al  reported an elevation of serum IgG4 levels in patients with AIP5 and described also  the characteristic histopathological pattern in concomitant retroperitoneal fibrosis  (RPF),6 thus paving the way for the recognition of the truly multiorgan nature of  IgG4-RD.7 In 2012, a unified nomenclature of IgG4-RD was published, abandoning Correspondence: David Lang Kepler University Clinic, MedCampus iii.,  Krankenhausstraße 9, 4021 Linz, Austria Tel +43 732 7806 73797 Fax +43 732 7806 1325 email david_lang@aon.a t Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Lang et al Running head recto: IgG4-related disease DOI: http://dx.doi.org/10.2147/TCRM.S99985",Non-OADS,/arxiv_data1/oa_pdf/4b/1a/tcrm-12-189.PMC4760655.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/4b/1a/tcrm-12-189.PMC4760655.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/1a/tcrm-12-189.PMC4760655.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/14/15/opth-10-307.PMC4760656.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).clinical Ophthalmology 2016:10 307–312submit your manuscript | www.dovepress.co m Dove press  307 http: //dx.doi.org/10.2147/OPTH.S10021 3silent information regulator T1 in aqueous humor  of patients with cataract aki Kondo1 Mari goto2 Tatsuya Mimura1 Masao Matsubara1 1Department of Ophthalmology,   Tokyo  Women’s Medical University  Medical center east, 2Tokyo  Metropolitan cancer and infectious  Diseases center, Komagome hospital,   T okyo, JapanPurpose:  Silent information regulator T1 (SIRT1), a member of the sirtuin family, has a  preventive role in various ocular diseases.",Non-OADS,/arxiv_data1/oa_pdf/14/15/opth-10-307.PMC4760656.pdf
"Accordingly, this study was performed to measure the aqueous correspondence: aki Kondo Department of Ophthalmology, Tokyo  Women’s Medical University Medical  center east, 2-1-10 nishiogu, arakawa,  Tokyo 1168567, Japan Tel +81 3 3810 1111 Fax +81 3 3810 9817 email aki94088@hotmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Kondo et al Running head recto: Aqueous humor SIRT1 in cataract DOI: http://dx.doi.org/10.2147/OPTH.S100213",OADS,/arxiv_data1/oa_pdf/14/15/opth-10-307.PMC4760656.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/14/15/opth-10-307.PMC4760656.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/14/15/opth-10-307.PMC4760656.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/90/ac/ndt-12-339.PMC4760657.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 339–348submit your manuscript | www.dovepress.co m Dove press  339 http: //dx.doi.org/10.2147/NDT .S6910 5Dove press Reviewopen access to scientific and medical research Open Access Full T ext Article Traumatic brain injury-induced sleep disorders Mari viola-Saltzman Camelia Musleh Department of Neurology,   NorthShore University HealthSystem,   evanston, iL, USAAbstract:  Sleep disturbances are frequently identified following traumatic brain injury, affecting  30%–70% of persons, and often occur after mild head injury.",Non-OADS,/arxiv_data1/oa_pdf/90/ac/ndt-12-339.PMC4760657.pdf
"Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Viola-Saltzman and Musleh Running head recto: Traumatic brain injury-induced sleep disorders DOI: http://dx.doi.org/10.2147/NDT.S69105 Correspondence: Mari viola-Saltzman Department of Neurology, NorthShore  University HealthSystem, 2180 Pfingsten  Road, Glenview, iL 60026, USA Tel +1 847 663 8200 Fax +1 847 657 5767 email mviolasaltzman@northshore.or g",Non-OADS,/arxiv_data1/oa_pdf/90/ac/ndt-12-339.PMC4760657.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/90/ac/ndt-12-339.PMC4760657.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/90/ac/ndt-12-339.PMC4760657.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 641–660submit your manuscript | www.dovepress.co m Dove press  641 http: //dx.doi.org/10.2147/IJN.S9406 4Dove press OrIg INal researchopen access to scientific and medical research Open access Full T ext article gold nanoparticles enhance the effect of tyrosine  kinase inhibitors in acute myeloid leukemia therapy Bobe Petrushev,1,* sanda  Boca,2,* Timea simon,2  cristian Berce,3 Ioana  Frinc,4 Delia Dima,4 sonia  selicean,3 grigore- aristide  gafencu,3 alina Tanase,5  Mihnea Zdrenghea,4,6 adrian  Florea,7 sorina suarasan,2  liana Dima,8 raluca stanciu,3  ancuta Jurj,1 anca Buzoianu,9  andrei cucuianu,4,6,† simion  astilean,2,10 alexandru  Irimie,11,12 ciprian T omuleasa,1,4  Ioana Berindan-Neagoe1,13 1research center for Functional  genomics and Translational Medicine,   Iuliu hatieganu University of Medicine  and Pharmacy, 2Nanobiophotonics and  laser Microscopy center, Babes Bolyai  University, 3Department of Medicine, Iuliu  hatieganu University of Medicine and  Pharmacy, 4Department of hematology, Ion  chiricuta Oncology Institute, cluj-Napoca,   5Department of stem cell Transplantation,   Fundeni clinical Institute, Bucharest,   6Department of hematology, 7Department  of cell and Molecular Biology, 8school of  Dentistry, 9Department of Pharmacology,   Iuliu hatieganu University of Medicine and  Pharmacy, 10Faculty of Physics, Babes Bolyai  University, 11Department of surgery, Ion  chiricuta Oncology Institute, 12Department  of surgery, Iuliu hatieganu University of  Medicine and Pharmacy, cluj-Napoca,   romania; 13Department of experimental  Therapeutics, The University of T exas MD  anderson cancer center, houston, TX,   Usa *These authors contributed equally to this  work †This author passed away in February 2015Background and aims:  Every year, in Europe, acute myeloid leukemia (AML) is diagnosed in  thousands of adults.",Non-OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
"Various FLT3 inhibitors were approved for clinical use, although primary or  secondary resistance to TKI-based chemotherapy was also described.9,10 Primary correspondence: ciprian Tomuleasa research center for Functional genomics  and Translational Medicine, Iuliu hatieganu  University of Medicine and Pharmacy,  34 gheorghe Marinescu street, 400349 cluj- Napoca, romania Tel +40 741 337 480 email ciprian.tomuleasa@umfcluj.r oJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Petrushev et al Running head recto: Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in AML DOI: http://dx.doi.org/10.2147/IJN.S94064",Non-OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
Densitom - etry was performed on the Western blot figures by using the  J-Figure software ( http://rsbweb.nih.gov/ij /).,OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/ijn-11-641.PMC4760658.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c1/51/dddt-10-631.PMC4760659.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 631–647Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  631Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S9942 0epigallocatechin-3-gallate attenuates apoptosis  and  autophagy in concanavalin a-induced hepatitis by  inhibiting BniP3 sainan li Yujing Xia Kan chen Jingjing li T ong liu Fan Wang Jie lu Yingqun Zhou chuanyong guo Department of gastroenterology,   shanghai T enth People’s hospital,   T ongji University school of Medicine,   shanghai, People’s republic of chinaBackground:  Epigallocatechin-3-gallate (EGCG) is the most effective compound in green  tea, and possesses a wide range of beneficial effects, including anti-inflammatory, antioxidant,  antiobesity, and anticancer effects.",Non-OADS,/arxiv_data1/oa_pdf/c1/51/dddt-10-631.PMC4760659.pdf
"Keywords:  concanavalin A, hepatitis, EGCG, autophagy, apoptosis, BNIP3, STAT3, JAKs, IL-6 Introduction Autoimmune hepatitis (AIH) is a chronic disease closely related to abnormal immune  stimulation of liver cells, leading to liver cirrhosis, liver cancer, and even death.1 However,  the only available treatments for AIH are immunosuppressants and liver transplantation,  which is far from ideal.1–5 Therefore, determination of the pathogenesis of immune-related  liver disease and identification of a safe and effective therapy are urgently needed.6–8 Of the  animal models currently used, intravenous administration of the plant lectin concanavalin A   (ConA) is widely used to induce acute hepatitis in mice and has unique pathogenic features  and similarities in immune-mediated hepatitis to those seen in humans, such as in AIH,  acute viral hepatitis, and hepatitis caused by drug toxicity.5 ConA-induced liver injury is  mainly caused by abnormal immune response against liver cells and secretion of cytokines  such as tumor necrosis factor (TNF)- α, interleukin (IL)-6, interferon (IFN)- γ, and IL-1 β,  thus mediating liver damage.9–11 Of these cytokines, IL-6 is particularly significant due  to its multiple functions in the immune system and liver injury.12,13 Apoptosis, as a major constituent of programmed cell death, is choreographed by a set  of previously dormant proteases, the caspases,14 which can be triggered by both extrinsic  (the “death receptors”) and intrinsic (the “mitochondria”) pathways.15–23 The Bcl-2 fam - ily, including the BCL-2 homology (BH) 3-only proteins, contributes the procedure.24–26 correspondence: Yingqun Zhou;  chuanyong guo Department of gastroenterology,  shanghai Tenth People’s hospital, Tongji  University school of Medicine, shanghai  200072, People’s republic of china Tel +86 21 6630 2535 Fax +86 21 6630 3983 email yqzh02@163.co m;  guochuanyong@hotmail.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Li et al Running head recto: Epigallocatechin-3-gallate attenuates apoptosis and autophagy  DOI: http://dx.doi.org/10.2147/DDDT.S99420",Non-OADS,/arxiv_data1/oa_pdf/c1/51/dddt-10-631.PMC4760659.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/c1/51/dddt-10-631.PMC4760659.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/51/dddt-10-631.PMC4760659.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 661–673submit your manuscript | www.dovepress.co m Dove press  661 http: //dx.doi.org/10.2147/IJN.S9588 5Dove press OrIg INal researchopen access to scientific and medical research Open access Full T ext article Development of nanoantibiotic delivery system  using cockle shell-derived aragonite nanoparticles  for treatment of osteomyelitis lamin saidykhan1 Md Zuki Bin abu Bakar2 Yaya rukayadi1,3 aminu Umar Kura4 saiful Yazan latifah5 1Microbiology Unit, laboratory  of Natural Products, Institute of  Bioscience, 2laboratory of anatomy  and histology, Department of  Veterinary Preclinical sciences, Faculty  of Veterinary Medicine, 3Department  of Food science, Faculty of Food  science and T echnology, 4Vaccine and  Immunotherapeutics laboratory Unit,   Institute of Bioscience, 5Department  of Biomedical science, Faculty of  Medicine and health sciences,   Universiti Putra Malaysia, serdang,   selangor Darul ehsan, MalaysiaAbstract:  A local antibiotic delivery system (LADS) with biodegradable drug vehicles is  recognized as the most effective therapeutic approach for the treatment of osteomyelitis.",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
"The  conventional treatment of osteomyelitis involves the surgical removal of destroyed  bone tissues followed by intravenous supply of antimicrobials at a high concentra - tion for 4–6 weeks.3 However, the high concentration of intravenous antibiotics can correspondence: Md Zuki Bin abu Bakar laboratory of anatomy and histology,  Department of Veterinary Preclinical  sciences, Faculty of Veterinary Medicine,  Universiti Putra Malaysia, 43400 serdang,  selangor Darul ehsan, Malaysia Tel +60 3 8947 3405 Fax +60 3 8947 1971 email  mdzukiabubakar@gmail.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Saidykhan et al Running head recto: Development of nanoantibiotic delivery system DOI: http://dx.doi.org/10.2147/IJN.S95885",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
"Available from: http://emedicine.medscape.com/article/1348767- treatmen t. Accessed December 24, 2015.",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
"Avail - able from: https://cdn.shopify.com/s/files/1/0257/8237/files/nanoCom - posix_Guidelines_for_Zeta_Potential_Analysis_of_Nanoparticles.pd f.  Accessed December 1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/65/d1/ijn-11-661.PMC4760660.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/66/ed/ijgm-9-019.PMC4760661.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/66/ed/ijgm-9-019.PMC4760661.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/66/ed/ijgm-9-019.PMC4760661.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/ed/ijgm-9-019.PMC4760661.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f6/eb/dddt-10-697.PMC4760662.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 697Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/f6/eb/dddt-10-697.PMC4760662.pdf
"Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.Dove pres s 697CorrigenDumopen access to scientific and medical research open Access Full T ext Article http: //dx.doi.org/ 10.2147/DDDT .S10582 0Treatment of osteoporosis with eldecalcitol, a new vitamin D analog:  a comprehensive review and meta-analysis of randomized clinical trials  [Corrigendum] Xu Z, Fan C, Zhao X, Tao H. Drug Des Devel Ther .",Non-OADS,/arxiv_data1/oa_pdf/f6/eb/dddt-10-697.PMC4760662.pdf
"The article type should be  corrected as an “Original Research” paper.Journal name: Drug Design, Development and Therapy Article Designation: Corrigendum Y ear: 2016 Volume: 10 Running head verso: Xu et al Running head recto: Treatment of osteoporosis with eldecalcitol, a new vitamin D analog DOI: http://dx.doi.org/10.2147/DDDT.S105820",Non-OADS,/arxiv_data1/oa_pdf/f6/eb/dddt-10-697.PMC4760662.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3a/ef/cia-11-001.PMC4760663.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1–8Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S9759 3Physicians’ perspectives on the treatment of  osteoporosis patients with bisphosphonates Tao gu1 Debra F eisenberg  lawrence1 Judith J stephenson1 Jingbo Yu2 1healthCore, Wilmington, De,   2Merck & Co., Inc., Kenilworth,   nJ, UsABackground:  Noncompliance with bisphosphonate therapy among osteoporosis patients  attenuates the reduction of fracture risk.",Non-OADS,/arxiv_data1/oa_pdf/3a/ef/cia-11-001.PMC4760663.pdf
"National guidelines recommend pharmacological treatment for specific  groups of postmenopausal women at increased risk of fracture, including those with  low bone mineral density (BMD; defined as a T-score #-2.5).2–4 The recommended  first-line treatment, oral bisphosphonate therapy has been shown to decrease the risk  of vertebral and hip fractures.2 Bisphosphonate treatment should be long-term, ie, Correspondence: Tao gu healthCore, 123 Justison street, suite  200, Wilmington, De 19801, UsA Tel +1 302 230 2000 Fax +1 302 230 2020 email tgu@healthcore.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Gu et al Running head recto: Physicians’ perspectives on the treatment of osteoporosis patients DOI: http://dx.doi.org/10.2147/CIA.S97593",Non-OADS,/arxiv_data1/oa_pdf/3a/ef/cia-11-001.PMC4760663.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/3a/ef/cia-11-001.PMC4760663.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/3a/ef/cia-11-001.PMC4760663.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/91/cb/ppa-10-159.PMC4760664.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 159–169Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  159OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S9032 3Motivation of health workers and associated  factors in public hospitals of West Amhara,  northwest ethiopia Zemichael Weldegebriel1 Y ohannes ejigu2 Fitsum Weldegebreal3 Mirkuzie Woldie2 1Public Planning Department, Debark  hospital, Debark, north gondar,   Amhara region, 2Department of  health services Management, college  of Public health and Medical sciences,   Jimma University, Jimma, ethiopia;   3Department of Medical laboratory  science, college of health and  Medical science, haramaya University,   harar, ethiopiaBackground:  Health professionals’ motivation reflects the interaction between health  professionals and their work environment.",Non-OADS,/arxiv_data1/oa_pdf/91/cb/ppa-10-159.PMC4760664.pdf
"But it is the health workers’  motivation, manifested in their behavior in the workplace, that greatly affects the  outcome of the health system.3–5 Low morale among the workforce can undermine correspondence: Zemichael  Weldegebriel Debark hospital, lemalimo street,  Debark, north gondar, Amhara  region 33, ethiopia Tel +251 93 740 8660 email zemchuwg@gmail.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Weldegebriel et al Running head recto: Motivation of health workers in Ethiopian public hospitals DOI: http://dx.doi.org/10.2147/PPA.S90323",Non-OADS,/arxiv_data1/oa_pdf/91/cb/ppa-10-159.PMC4760664.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/91/cb/ppa-10-159.PMC4760664.pdf
Available from: http://hdl.handle.,Non-OADS,/arxiv_data1/oa_pdf/91/cb/ppa-10-159.PMC4760664.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e0/f8/ott-9-773.PMC4760665.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2016:9 773–780OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  773Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9197 7Phase ii trial of bevacizumab and erlotinib as a  second-line therapy for advanced hepatocellular  carcinoma ahmed O Kaseb1 Jeffrey s Morris2 Michiko iwasaki1 humaid O al-shamsi1 Kanwal Pratap singh  raghav1 lauren girard1 sheree cheung1 Van nguyen3 Khaled M elsayes4 lianchun Xiao2 reham abdel-Wahab1,5 ahmed s shalaby1 Manal hassan1 hesham M hassabo1 robert a Wolff1 James c Yao1 1Department of gastrointestinal  Medical Oncology, 2Department  of Biostatistics, 3Department of  Pharmacy, 4Department of Diagnostic  radiology, The University of T exas MD  anderson cancer center, houston,   TX, Usa; 5Department of clinical  Oncology, assiut University hospital,   assiut, egyptTrial registry:  Clinicaltrials.go v #NCT01180959.",Non-OADS,/arxiv_data1/oa_pdf/e0/f8/ott-9-773.PMC4760665.pdf
"Sorafenib is the only approved systemic  therapy for advanced HCC, but it has shown only modest activity in randomized Phase correspondence: ahmed Omar Kaseb Department of gastrointestinal Medical  Oncology, Unit 426, The University of  Texas MD anderson cancer center,  1515 holcombe Blvd, houston,  TX 77030, Usa Tel +1 713 792 2828 Fax +1 713 745 1163 email akaseb@mdanderson.or g Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Kaseb et al Running head recto: Bevacizumab and erlotinib in HCC DOI: http://dx.doi.org/10.2147/OTT.S91977",Non-OADS,/arxiv_data1/oa_pdf/e0/f8/ott-9-773.PMC4760665.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/e0/f8/ott-9-773.PMC4760665.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/f8/ott-9-773.PMC4760665.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2c/fc/dddt-10-699.PMC4760666.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 699–709Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  699Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S8525 3The clinicopathological significance and ethnic  difference of FHIT hypermethylation in non-small-cell  lung carcinoma: a meta-analysis and literature review Xiaoyu Wu1,* guannan Wu1,* Xuequan Yao1 gang hou2 Feng Jiang3 1Department of surgical Oncology,   affiliated hospital of nanjing  University of Traditional chinese  Medicine, nanjing, 2Department  of respiratory Medicine, The First  hospital of china Medical University,   shenyang, 3Department of Thoracic  surgery, Jiangsu cancer hospital, The  affiliated cancer hospital of nanjing  Medical University, nanjing, People’s  republic of china *These authors contributed equally  to this workAbstract:  Emerging evidence indicates that FHIT is a candidate tumor suppressor in many  types of tumors including non-small-cell lung carcinoma (NSCLC).",Non-OADS,/arxiv_data1/oa_pdf/2c/fc/dddt-10-699.PMC4760666.pdf
"Epigenetic alterations, particularly  aberrant DNA methylation, one of the best-characterized epigenetic modifications, correspondence: Feng Jiang Department of Thoracic surgery, Jiangsu  Cancer Hospital, The Affiliated Cancer  hospital of nanjing Medical University,  42 Baiziting, nanjing 210009, People’s  republic of china email fengjiang69@sina.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Wu et al Running head recto: FHIT  hypermethylation in NSCLC DOI: http://dx.doi.org/10.2147/DDDT.S85253",Non-OADS,/arxiv_data1/oa_pdf/2c/fc/dddt-10-699.PMC4760666.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/2c/fc/dddt-10-699.PMC4760666.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2c/fc/dddt-10-699.PMC4760666.pdf
a Search made with the online version of TBLASTX versus the nr/nt database with default parameters at NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=tblastx&PAGE_ TYPE=BlastSearch&LINK_LOC=blasthome).,OADS,/arxiv_data1/oa_pdf/3d/e5/apps.1500087.PMC4760746.pdf
"The seven loci tested in Dioon congeners were geno- typed in a separate run with an ABI 3730xl sequencer with GeneScan 500 LIZ size standard (Applied Biosystems/Thermo Fisher Scientific, Waltham, Mas-sachusetts, USA) and interpreted with Geneious version 8.1.3 software (Bio-matters, http://www.geneious.com/).",OADS,/arxiv_data1/oa_pdf/3d/e5/apps.1500087.PMC4760746.pdf
Website  http://www.jpnrdb.com/index.html   [accessed 1 February 2015] [in Japanese].,Non-OADS,/arxiv_data1/oa_pdf/ee/83/apps.1500096.PMC4760747.pdf
Web site  http://www.biodic.go.jp/rdb/rdb_f.html  [accessed 1 February 2015] [in Japanese].,OADS,/arxiv_data1/oa_pdf/ee/83/apps.1500096.PMC4760747.pdf
"Sequences  were visualized and edited using Geneious Pro version 5.3.4 (Biomatters, http://www.geneious.com/).",OADS,/arxiv_data1/oa_pdf/e8/57/apps.1500115.PMC4760751.pdf
"A search in the database PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) for all botanical investigations published between October 2012 and October 2015 that contain the term “ancestral charac - ter state reconstruction,” or any word combination thereof, in ei - ther the title, the key words, or the abstract, recovered a total of 27 publications (Table 1).",OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
An analogous search in the database ISI Web of Science (http://webofknowledge.com/) recovered a total of 93 publications.,OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
"To use WARACS, a user must have a Python interpreter as well as the Python packages DendroPy (https://pypi.python.org/pypi/DendroPy), NumPy (http://www.numpy.org), and six (https://pypi.python.org/pypi/six) installed.",OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
It is compatible with Python v.2.7 (https://www.python.org/download/releases/2.7/) as well as Python v.3.5 (https://www.python.org/downloads/release/python-350/).,OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
WARACS is available under a BSD open source license from a code-sharing repository at GitHub (https://github.com/michaelgruenstaeudl/WARACS).,OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
"In the absence of a user-defined color dictionary, WARACS employs a default color palette as specified by http://colorbrewer2.org for qualitative characters.",Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Website http://compbiolwiki.plos.org/wiki/Ancestral_reconstruction   [accessed 23 October 2015].,Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
"Mesquite: A modular  system for evolutionary analysis, version 3.04, August 2015, Website http://mesquiteproject.org [accessed 23 October 2015].",OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
"Zephyr: A Mesquite  package for interacting with external phylogeny inference programs, version 1.1, January 2015, Website https://mesquitezephyr.wikispaces.com   [accessed 23 October 2015].The script set WARACS enables several types of analyses  that are not or only partially available through the application  of Mesquite alone.",OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Website http://www.cladistics.com/aboutWinc.htm  [accessed 23 October 2015].,OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
"BayesTraits, version 2.0, September  2014, Website http://www.evolution.reading.ac.uk/BayesTraits.html   [accessed 23 October 2015].",Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Website http://www.python.org [accessed 23  October 2015].,Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Website http://www.R-project.org/ [accessed 23 October 2015].,Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Website   http://mnh.scu.edu.cn/soft/blog/RASP [accessed 23 October 2015].,Non-OADS,/arxiv_data1/oa_pdf/4f/4d/apps.1500120.PMC4760752.pdf
Keywords Sexual exploitation; Adolescents; Child Advocacy Centers; Forensic interviews with adolescents This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
http://dx.doi.org/10.1177/1077801210367643 .,Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
http://dx.doi.org/10.1542/peds.2013-1741 .,Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
"Retrieved from:  http://www.nursing.ubc.ca/PDFs/ItsNotWhatYouThink.pdf Saewyc, EM., Drozda, C., Rivers, R., MacKay, LJ., Peled, M. Which comes first: Sexual exploitation  or other risk exposures among street-involved youth?.",Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
"Available at:  http://www.hawaii.edu/hivandaids/Commercial%20Sexual%20Exploitation%20of%20Young %20People%20in%20New%20York%20City.pdf Stransky, M., Finkelhor, D. Crimes Against Children Research Center.",Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
"Available at: http://www.ohchr.org/en/professionalinterest/pages/crc.aspx Walsh WA, Cross TP, Jones LM, Simone M, Kolko DJ.",Non-OADS,/arxiv_data1/oa_pdf/9c/26/nihms5378.PMC4760762.pdf
Keywords Adolescents; Sexual abuse; Alcohol; Runaways; Multiple perpetrator rape; Gang rape This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
"Retrieved from ACOG website at: http://www.acog.org ATLAS.ti., Version 7.0.",Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
http://dx.doi.org/10.1542/peds.,Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
2014; 90  http://dx.doi.org/10.1136/sextrans-2013-051328  (in press).,Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
"http://tna.europarchive.org Lamb, ME., Hershkowitz, I., Orbach, Y ., Esplin, PW.",Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
"Retrieved  from: http://education.state.mn.us Moran PB, Vuchinich S, Hall NK.",Non-OADS,/arxiv_data1/oa_pdf/19/ce/nihms5374.PMC4760763.pdf
(http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1752-8062) Clinical and T ranslational Science,Non-OADS,/arxiv_data1/oa_pdf/43/2f/CTS-9-43.PMC4760886.pdf
(http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1752-8062) Clinical and T ranslational Science,Non-OADS,/arxiv_data1/oa_pdf/0f/01/CTS-9-36.PMC4760888.pdf
"Available at http://www.cdc.gov/homeandrecreational- safety/falls/adultfalls.html Accessed April 1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0e/e8/JGS-64-425.PMC4760892.pdf
"Available at http://www.nice.org.uk/CG161 Accessed April1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0e/e8/JGS-64-425.PMC4760892.pdf
"Available athttp://www.cdc.gov/HomeandRecreationalSafety/Falls/compendium.html Accessed June 1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0e/e8/JGS-64-425.PMC4760892.pdf
"Available at http://www.cdc.gov/homeandrecreationalsafety/Falls/steadi/index.html#offerAccessed June 1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0e/e8/JGS-64-425.PMC4760892.pdf
"Available at http://acl.gov/NewsRoom/Press_Re-leases/archive_ACL/2014/2014_09_25a.aspx Accessed April 12, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0e/e8/JGS-64-425.PMC4760892.pdf
"These data confirm our previous observation that the polymorphism frequenciesTable 2 Comparison of minor allele frequencies of studied polymorphisms in Egyptianscomparedwithpreviouslyreportedfrequenciesfromdifferentethnic populations Gene variant Genotype Egyptian African∗Asian∗European∗American∗ CYP2C19*2 G>A 0.126 0.169 0.334 0.148 0.115 CYP2C19*3 G>A 0.0025 0.004 0.051 0.000 0.000 CYP2C19*6 G>A 0.000 — — — — CYP2C19*8 C<T 0.000 0.004 — 0.003 — CYP2C19*10 C>T 0.000 — — — — CYP2C19*17 C>T 0.17 0.215 0.019 0.228 0.205 ABCB1*6 C>T 0.387 0.146 0.397 0.529 0.189 ABCB1*8 C>T 0.392 0.132 0.326 0.404 0.133 CES1 (G143E) G>A 0.01 0.040 0.000 0.024 0.016 ∗Information from 1,000 Genomes (http://browser.1000genomes.org/Homo_ sapiens/Info/Index).",Non-OADS,/arxiv_data1/oa_pdf/7c/1e/CTS-9-23.PMC4760893.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ annrheumdis-2015-207316).,OADS,/arxiv_data1/oa_pdf/9d/58/annrheumdis-2015-207316.PMC4760904.pdf
